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General introduction and aims of the studies 
Chapter 
1 
Pardy based on: "the use of arninoglycosides in ne\vbom infants". 
M. de Hoog,j.\V. Mouton,J.N. van den Anker, 
Paediatric and Perinatal Dmg Therapy, 1998: 48~56 
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1.1. Use of aminoglycosides in neonates 
1.1.1. General aspects of aminoglycosides 
Introduction 
Aminoglycosides, including tobramycin, have played a major role in anti.mi.crobial therapy 
since their discovery in the 1940's, now more than 50 years ago 1• Their bactericidal 
efficacy in gram-negative infections, synergism \vi.th B-lactam antibiotics, limited bacterial 
resistance and low cost have given these agents a finn place in antimicrobial treatment. 
However, the successful use of streptomycin (1944), gentamicin (1963), tobramycin 
(1967), amibtcin (1972) and netilmicin (1976) has been complicated by nephrotoxicity and 
ototoxicity in a significant number of treated patients. 
This revie\v summa.rizes the available data on aminoglycoside use in neonates. General 
aspects of aminoglycosides will be discussed, followed by a detailed description of specific 
aspects of aminoglycoside use in neonates. Pharmacokinetic parameters, drug resistance, 
toxicity and dosing schedules of the four commonly used aminoglycosides 'Will be 
revi.ewed. Special attention will be paid to recent insights into increasing dose and 
prolonging dosing interval in pretenn infants. 
Structure and chemical properties 
Figure 1: Basic structure if the main aminog(ycosides 
(.Adapted from: Mingeot-Leclerq et a/.)2 
Substituents on R-numbered spaces on basic aminocyclitol 
Alltilf()g/yto.iidt R, R, R, R, R, R, R, 
Tobr:unycin NH, H OH H NH~ H CH~OH 
Gcnt:l.IIJ.icin OH OH OH H NH~ H H 
Ncti.lm.icin CR H 
Amikacin OH OH OH H NH~ COR' CH~OH 
R.\' R, Rm 
OH H H 
CH; OH CH; 
CH, OH CH, 
OH H H 
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Figure 1 shows the basic structure of the main aminoglycosides. Aminoglycosides are 
comprised of t\VO or more amino sugars attached via glycosidic bonds to an aminocyclitol 
nucleus and have a molecular weight of 445 to 600 Dalton. This structure consists of a 
sL>:::-membered ring \Vi.th amino-group substituents, from which the term aminocyclitol is 
derived. To this central ring two or more amino-containing or non-amino-containing 
sugars are bound vi.a glycosidic bonds, which led to the term aminoglycosides for this 
group of antibiotics. The central aminocyclitol for most aminoglycosides, including 
tobramycin, is 2-deoxystreptam.ine. 
Arninoglycosides can be divided into chemical families "'ith related structures (table 1). 
Tobramycin belongs to the kanamycin family, derived from Sirep!Otl!JCes spp3• The 
kanamycin family is linked to m·o cyclic S%o-ats at positions 4 and 6 of 
2-dcoxystreptamine. Tobramycin is 3'-deo::-..ykanamycin. The relation bet\veen structure of 
am.i.noglycosides and activ--ity is incompletely understood. 
Table I: Families if aminogjycoside antibiotics_, divided in main gpJtfps and group members 
(adapted from Mande!!J' 
Family 
Streptomycin 
J(=unycin 
Gentarnicin 
Spccrinomycin"' (an aminocyclitol no glycosidic bond~) 
.tvfembcr 
Streptomycin 
1-Gmmycin A 
Kan::unycin B 
r\mikacin 
Tobr::unycin 
Dibekadn 
Gcntunicin C1, Cla., C2 
Sisomydn 
Nctilmicin 
Iscp:unicin 
Neomycin 
Paromomycin 
Aminoglycosides are \Vater soluble, cationic at normal pH, and distribute in plasma water. 
Protein binding is minimal. They have a stable structure over a \vi.de range of temperature 
and pHS. 6• Arninoglycosides are .inactivated in vitro by concomitant usc of ~-lactam 
antibiotics7-9. Tobramydn seems to be more easily inactivated than netilmicin, amik.acin or 
isepamlcin. 
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Method of action 
Aminoglycosides act by altering the integrity of the bacterial cell membrane in gro'\vi.ng 
bacteria by way of disturbing protein synthesis through binding to prokaryotic 
ribosomes10- 11 . These cationic antibiotics bind rapidly and passively to the negatively 
charged parts of phospholipids and other proteins in the bacterial cell membrane12. They 
can not pass through the porin channels because of their relatively large size13. They enter 
the bacterial cell by '\vay of a self promoted uptake process, described in detail below, 
wherein aminoglycosides displace Mg.:?:+ and Ca.:?:+ bond bettveen adjoining 
lipopolysaccharides in the bacterial cell membranc14· 15. This leads to a rearrangement of 
lipopolysaccharides, which creates transient holes making the outer membrane more 
permeable to the antibiotic16. This ionic binding of aminoglycosides to the cell membrane 
is follmved by a 2-staged energy dependent cellular uptakeiO. t7. 18. Phase I is slow, rate 
limiting, electron transport dependent and is termed energy dependent phase I (ED P-I). 
ED P-I precedes the loss of viabilit;.r and inhibition of protein synthesis12• It is related to 
the concentration of aminoglycoside and can be inhibited by low pH, anaerobic 
conditions and hyperosmolarity19, 20. Aminoglycosides themselves close the "holes" made 
in the cell membrane through decreasing transmembrane electrical potential, causing 
aminoglycosides to be trapped inside the bacteria21 resulting in far higher intracellular 
than extracellular concentrations. Phase II is characterized by an accelerated uptake of 
aminoglycoside in the cytosol and binding to the 30S subunit of ribosomes in a process 
utilizing energy from electron transport and ATP18- 22. 23. Specific binding may differ for 
different aminoglycosides2+-26. After binding to ribosomes, aminoglycosides disturb the 
proofreading process controlling the accuracy of proteins under construction. These 
aberrant proteins, when inserted in the cell membrane, lead to an increase of permeability 
and increased uptake of aminoglycosides27• In man, inhibition of protein synthesis can 
also occur at supratherapeutic concentrations, probably through non-specific binding to 
eukaryotic ribosomes28• Although inhibition of protein synthesis plays a major part in 
bacterial cell death, it is not the sole explanation for the bactericidal effect of 
aminoglycosides. Other antibiotics that inhibit protein synthesis, like chloramphenicol, are 
only bacteriostatic. Binding of aminoglycosides to the bacterial cell membrane itself may 
play a role in rapid bacterial cell death29. 
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Aminoglycoside antimicrobial activity 
In vitro activity 
r\m.inoglycosides have a concentration-dependent bactericidal spectrum encompassing 
aerobic and gram-negative bacteria like Enterobacteriacae, Escherichia coli, pseudomonas spp. 
and Haemophi!trs spp. Table 2 shows the in vitro spectrum of a.minoglycosides compared 
'Wi.th selected other antibiotics. 
Table 2: In vitro spectrum of actit/l!J of aminogfycosides against selected microorganisms. 
(Adaptedfrom Mandell}' 
.Aminoglycoside 
Organism. Gentamicin Tobramycin Amikacin Nctil:roicin 
Gram-negative 
Esch<.-richia coli + ~ + + 
l)roteus mirabilis + + + 
Kk·b.ridla sp. + + + 
Entcrobadrrsp. + + 
lvf.organdla sp. ~ + + 
Citro barter ~P- + + + + 
Serratia sp. + + + 
Salmonella sp. 
Protidmcia sp. + + + 
Adomonas sp. + + + 
Acim•t.obatft'Tsp. 0 ± 0 
Pseudomonas acruginosa + + + 
Bw:kholdcria ccpacia 0 0 0 0 
Stmotrophomonas !!laltophilia 0 0 0 0 
Nrissrria gonorhorm' 0 0 0 0 
Hatmophillfs inj!Hen:zae + + + + 
Yrr.rinia pestis 
Francist!!a t:darensis 
Gram-positive 
Stnptococcus pnmmoniac 0 0 0 0 
Stap/!Jiococms a/freus + + + + 
Stapl.[ylococms a/freus (J\1RSA) 0 0 0 0 
:vrRSA ::::: mcthicillin-rcsistlnt S. a:tmrs 
14 
The susceptibility of most gram-negative bacteria to gentamicin, tobramycin, netiJmicin 
and amikacin is relatively sirniiar3°. Although susceptibility to amikacin is three to fourfold 
less than the other aminoglycosides, this is compensated by its lower toxicity and 
therefore higher allowable dose. Gentamicin and tobramycin are comparable in activ--ity, 
although tobramycin is slighdy more active against P. aeruginosa. They are susceptible to 
the same modifying enzymes and resistance rates are therefore very similar. In contrast, 
a.r:nikacin is resistant to many of these enzymes and therefore often an alternative if strains 
are resistant to tobramycin or gentamicin. NetiJmicin susceptibility is comparable to that 
of gentamicin and tobramycin, although netiJmicin is resistant to some of the gentamicin 
inactivating enzyTileS and rhus in some cases a good altemativc.Antimicrobial activity of 
aminoglycosides has four distinct and clinically important aspects: 
I. Concentration-dependent killing 
II. Postantibiotic effect 
III. Adaptive resistance 
IV. Synergism 'W--ith other antibiotics 
Concentration-dependent killing 
In vivo and in v--itro studies have sho"rn that aminoglycoside induced rate of bacterial 
killing as well as induction of resistance is peak concentration dependent31-35• Thls is 
illustrated by figure 2. Other in v--itro investigations, mimicking in vivo fluctuations of 
drug concentrations, have shown a single bolus of aminoglycoside to be superior in rate 
and total amount of bacterial killing to the same dose in a multiple daily dosing regimen, 
in non-neutropenic animals36,37, 
Figure 2: killing ctmJes if tobramycin. Inocula if 5 x 105 ifu/ ml P. aerttginosa were incubated u-ith 
tobramycin for 24 hours in a range from 0.25-16 x MIC (Adapted from]. W. Moutonr 
0 2 4 6 24 
time (hours) 
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PrHtcmtibiotic effect 
Aminoglycosides are often reported to have a postantibiotic effect (P AE), meaning that 
there is suppression of bacterial gro\vt:h for several hours after antibiotic serum 
concentrations have dropped belo\v the J\1IC39-41. However, the PAE in these studies was 
not determined under conditions where decrease of concentrations was similar to that 
seen in patients. The PAE \vas most often determined by exposing bacteria to an 
antibiotic for limited a period of time, usually one hour, whereafter the drug is abruprly 
eliminated. Delay in resumption of gro\\!t:h is compared to a control curve. Recent in vitro 
pharmacokinetic models simulating the normal gradual decrease of serum concentrations 
in patients ho\vever, have failed to show ev--idence of a P.AE beyond the J\1IC, especially 
with longer serum half-lifes42. 43. In v--ivo experiments indicate that there is a PAE, which 
even increases with increasing serum half-life44. 45. The difference bet\veen in vivo and in 
vitro models is partly e::...-plained by the fact that in v--ivo regrowth of bacteria is determined 
at sub-~C concentrations42. Other host-related environmental factors may also play an 
important role. PAE should therefore be labeled as a postantibiotic sub-i\1IC effect. The 
clinical relevance is still unclear, and the emphasis on this effect in discussions on 
extending dose intervals of aminoglycosides is questionable. 
Adap!iJ)e resi.rtance 
Antimicrobial activity of aminoglycosides is associated with a temporary adaptive 
resistance46•47. It is a reversible form of resistance \Vhich develops within 1 to 2h of initial 
exposure to an aminoglycoside and disappears several hours after removal of the 
antibiotic. In this time period the bacterial population surv--iving the initial exposure are 
less susceptible to a renewed dose of aminoglycosides. 
Synerg;' with other an!ibiotics 
Synergy of aminoglycosides with other cell wall active antibiotics, like penic.ilJ.ID.s and 
cephalosporins has been established4. 4S. This synergy· is the basis of the clinical choice for 
combination therapy of aminoglycosides \v:ith penicillin or cephalospo:cins. 
Issues of toxicity, which 'Will be discussed later, concentration-dependent killing, 
postantibiotic effect (although doubtful), as well as adaptive resistance are the rationale 
for the change to extended intel\ral dosing of aminoglycosides over the last decade49•51 • 
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Drug resistance and susceptibility 
Resistance of aminoglycosides in the Kctherlands is defined according to national 
guidelines on susceptibility and is divided in three groups as sho\.VTI in table 3. 
Table 3: Susceptibili!J cnleria in mg/L according to the CRG 1 (Dutch COIJI!Jiittee 017 guidelines in 
sttsceptibili!J of microorganisms) compared JPith j'\.TCCLS gt~idelines 
Antibiotic CRG1 NCCLS' 
s R s I R 
<= >-<= > <= >=-<= >= 
Arnikacin 4 4..16 16 16 32 64 
Gentamicin 1-4 4 4 s 16 
::-Jetilmicin 2 2-8 8 s 16 32 
Tobrarnycin 1-4 4 4 s 16 
1 Cornmissie richtlijnen gevoeligheidsbepalingcn, ~ National Committee for the Clinic.:tl Laboratory Standards, 
S= susceptible, I=intermedi.ate resistance. R=resistant 
Resistance to aminoglycosides can occur by three mechanisms, ribosomal resistance, 
decreased uptake and/ or accumulation and enzymatic modification. Ribosomal resistance 
\v-ill not be discussed since it is only pertinent to streptomycin. 
1. Decreased uptake and/ or accumulation 
A decrease in drug uptake is a clinical significant aspect of aminoglycoside resistance. The 
underlying mechanism, though probably related to membrane impermeabilization, is not 
really k.no\Vn52. It pertains to all aminoglycosides and is a stable characteristic resulting in 
a moderate level of resistance2• Another important phenomenon in aerobic gram-negative 
bacteria is called adaptive resistance, defined as a reduced antimicrobial killing in originally 
susceptible bacterial populations after initial incubation with an aminoglycoside53_ It has 
clinical relevance especially for immunocompromised patients and in serious infections 
with gram-negative bacteria. Adaptive resistance is probably related to membrane protein 
changes and altered expression of regulatory genes of the anaerobic respiratory pathway54. 
It can be overcome by higher peak serum concentrations of aminoglycosides, \.Vhich 
underscores the need for extended dose intervals55. 
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2. Enzymatic modification 
Aminoglycosides can be modified with subsequent loss of antimicrobial activity by 
enzymes produced by bacterial pathogens4• The three major classes of enzymes are 
1\T-acetyltransferases, 0-nucleotidyltransferases and 0-phosphotransferases. The genetic 
code for these enzymes is largely contained in plasmids, thereby rendering the resistance 
easily transferable. In addition, it is important to realize that all susceptible positions in 
aminoglycosides can be modified by several enzymes and that several inactivating genes 
can easily develop from a common ancestor leading to the conclusion that it will be 
unlikely that making aminoglycosides resistant to inactivation by a specific enzyme '\vill be 
a worthwhile effort2. 
1.1.2. Specific aspects of aminoglycoside use in neonates 
General aspects in neonates 
Bacterial infections continue to be a major cause of morbidity and mortality in preterm 
infants admitted to neonatal intensive care units (.KICV's)56, though a decline in sepsis 
associated neonatal deaths has been reported57• The immunologically incompetent 
premature neonate is susceptible to invasive microbial infections through hospitalization, 
ventilation and invasive procedures, such as the introduction of central venous lines. 
Kosocomial infections in the neonatal period, including septicemia, meningitis, 
pneumonia or urinary tract infection occur in approximately 18% of very low birthweight 
(VLBW; <1500 g) infants58• Culture proven early onset sepsis, defined as within the first 
3-4 days of life, occurs in approximately 2% ofVLBW infants, but there are limitations to 
blood cultures in neonates and single blood cultures can be false negative59-61. 
Among major pathogens responsible for bacterial infections during the first month of life, 
Gram-negative bacteria like Escherichia coli, Klebsiella spp, Enterobacter spp and Pseudomonas 
spp, play an increasing role, possibly related to the increased prenatal administration of 
antibiotics and use of percutaneous central venous catheters in the Nrcuss, 62·64. 
Am.inoglycosides are effective against most nosocomial acquired gram-negative infections 
in term and preterm infants and are synergistic '\Vi.th ~-lactam antibiotics in treating group 
B streptococcal and coagulase-negative staphylococcal infections. They play an important 
role in the initial empiric treatment of neonatal septicemla65. After penicillins, 
aminoglycosides are the most commonly used drugs in the neonatal intensive care unit 
(NICLJ)". A MEDLIKE search shows that since 1966 more than 900 articles relating to 
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aminoglycoside use in neonates have been published. Despite this enormous amount of 
documentation, there is still much debate about the proper use of aminoglycosides in 
infants. 
Pharmacokinetics 
Aminoglycosides have a phannacokinetic profile consisting of a rapid distribution phase 
(tt/2r.~.), elimination phase (tl/2.3), and a second elimination phase (t1;2y). The gamma phase 
can only be determined after discontinuation of the drug. Distribution half-life is 
5-10 minutes in adults, but has never been measured in newborns. The gamma phase in 
infants is long. Nerilmicin was detectable in blood and urine 11 and 14 days after 
discontinuation, \Vi.th a tt/2y of 62.4h67, The tissue half-life in renal cortex is 4-5 days68. In 
most studies aminoglycosides are studied using a one-compartment open model \vi.th 
individual pharmacokinetic parameters esrim.ated by way of the method described by 
Sawchuk and Zaske69. In general, the serum concentrations and phannacokinetic data 
mentioned in most studies concern the elimination phase, which is adequately described 
by a one-compartment model. There are, however, some studies that have sho"'Wn a two 
compartment model to be supenor in predicting serum tt/2,3 and serum 
concentrations 70-72. 
Aminoglycosides are eliminated from the body by way of glomerular filtration; it is 
therefore predictable that a relation between glomerular filtration rate (GFR) and serum 
concentrations exists. The link bet\Veen GFR and arninoglycoside pharmacokinetics is 
often67. 73·79, but not consistendy71- 79-81 described in neonates. Brion et al_76 showed a 
linear relation bet\Veen GFR and gentamicin t112, but GFR was determined by serum 
creatinin. Some authors reported that serum creatinin measurements in newborns do not 
reliably predict GFR They hypothesized that serum creatinin concentrations in the initial 
days after birth were a reflection of maternal serum creatinin. However, it was recendy 
shown that the serum concentration is inversely related to gestational ageS2. If the serum 
creatinin concentration in the days after birth is indeed a reflection of maternal serum 
creatinin, the youngest infants should have had the lowest concentration because maternal 
serum creatinin is lowest at the beginning of the third trimester83. Therefore the elevated 
concentration of serum creatinin in these infants during the first postnatal days probably 
reflects the difficulty these children have to eliminate the excess creati.nin transferred from 
their mother. Furthermore in adults it has been shown that aminoglycoside 
concentrations can change \.Vi.thout concomitant change of serum creati.ninS+. 
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Table 4: Restr!ts ofpharmacokinetic studies if aminog!ycosides in neonates 
Reference N GA PNA Weight CL Vd tl/Z 
(weeks) (days) W="l (ml/min/kg) (L/kg-') (h) 
An1ik.acin 
Padovani, 32 32 ± 3.6 1740 = 810 1.08 ± 0.51 0.655 ± 0.414 7.6 ± 4.4 
1993 
Kenyon. 28 30.5 ± 2.86 1380 ::':: 170 0.83 ± 0.28 0.57±0.11 8.4 
1990 
Kenyon, 6 32-40 1-3 1500-3400 1.05 ± 0.30 0.70 ± 0.27 2 
1990 5 36-40 5-S 2100-3600 1.08 ± 0.42 0.49±0.11 5.6 
11 32-38 >8 1900-4600 1.78 ± 0.53 0.73 ± 0.13 5.1 
Gentamicin 
~akac, 1988 19 < 1500 0.75 ± 0.60 0.72 ± 0.45 13 
18 2: 1500 0.97 ± 0.23 0.78 ± 0.39 13.8 
20 4 < 1500 0.50 ± 0.18 0.60 ± 0.26 10.9 
28 4 2: 1500 0.72 ± 0.10 0.50 ± 0.18 8.1 
Kildoo, 1984 15 < 33 <7 < 1500 0.38 ± 0.15 0.53 ± 0.10 11.1 
15 < 33 8-30 < 1500 0.45 ± 0.17 0.50 ± 0.11 10.8 
6 < 33 > 31 < 1500 1.18 ± 0.45 0.50±0.11 4.4 
Koren, 1985 12 LS <1000 0.52 ± 0.08 0.35 ± 0.07 7.9 
36 1.8 2:1000 0.65 ± 0.13 0.38 ± 0.13 6.5 
20 ~ 30 LS 0.58 ± 0.12 7.4 
28 >30 1.8 0.63 ± 0.13 6.5 
hquicrdo, 11 28-33 2-30 1.00 0.597 6.53 
1992 31 35-38 2-30 1.22 0.538 4.95 
55 39-43 2-30 1.15 0.542 5.17 
Williams, 216 32.39 ± 2.83 1850 = 670 0.75 ± 0.25 0.54 ± 0.13 8.98 = 2.86 
1997 106(PDA) 29.02 ± 2.92 1160 = 530 0.67 ± 0.28 0.61 ± 0.15 12.24 ± 7.43 
Wattcrberg, 24 (PDA) < 1500 0.93 ± 0.33 0.64 ± 0.20 8.49 ± 2.69 
1987 16 < 1500 0.83 ± 0.4 0.41 ± 0.08 6.23 = 1.92 
Dahl, 1986 11 26-33 1-10 13 
6 34-40 1-10 6 
Iscmann, 
1996 16 30.6 ± 0.86 < 12h 1600 = 154 0.57 ± 0.03 10.2 ± 0.89 
18 29.2 ± 0.81 < 12h 1294 ± 145 0.58 ± 0.02 12.0 ± 0.84 
Abbreviations: n= number of patients in study, PDA= patent ductus :rrtcriosus, ECMO= C.""(tr.J.corporcal membr::me 
o:-.-ygetution, GA= gestational age, PKA= posmat:J.!. age, PCA= postconeeptio=l age, ASS= 5' apg:u: score, 
CL= tot:t.l. body cl=:mce, Vd= volume of distribution: t1 ;~= serum half-life 
20 
c~,'cl.i:,~ . 
Table 4 (contintted): Results ifpharmacokinetic stttdies if aminog!ycosides in neOJlates 
Reference N GA PNA Weight CL Vd 
'"' 
(week.'~) (days) (gram•) (ml/ min/kg) (L/kg"') (h) 
Gmta111ir:l1 (cMtimred) 
Southgate, 10 ECMO 36-43 <7 2.78 = 1.55 0.51 =0.11 9.55 ± 4.38 
1989 
TI1omson, 113 > 3-H .AS52:7 0-50 500-4500 0.88 0.47 
1988 :;34+AS5<7 0.73 
:;34-:-AS52:7 0.6 
Faur.:t. 1991 165 37 ± 4.5 7.8±11.7 2432 ± 952 0.64 ± 0.22 8.2 ± 4.8 
l)ons, 1988 15 < 37 0-2 1.03 ± 0.37 
27 :::: 37 0-2 1.40 ± 0.47 
s < 37 3-7 1.78 ± 0.63 
16 :::: 37 3-7 1.78 ± 0.38 
< 37 8-28 1.67 
14 2:37 8-28 1.97 = 0.43 
Nt"liil!licin 
Granati.. 1985 22 27-40 < 16 800-3400 1.07 ± 0.28 0.034 ± 0.11 9.6 
Kuhn.. 1986 12 28-33 < 28 770-2050 0.83 ± 0.27 0.63 ± 0.24 8.6 
Siegel. 1979 16 <7 < 2000 0.609 4.7 
s >=7 <::woo 0.599 4.1 
9 <7 > 2000 0.472 3.4 
23 <7 >::woo 0.617 4.4 
4 >=7 > 2000 0.510 3.8 
To/Jra!7()'cin 
Kahan. 1984 19 29-40 2-l 1000-3555 1.15 (0.70-1.83) 0.82 (0.54-1.76) 8.6(3.5-14.1) 
+-7 1000-3555 1.14 (0.62-1.56) 0.68 (0.40-1.06) 7.1(4.6-11.6) 
s 2-4 1000-1500 1.09 (0.74-1.15) 1.04 (0.64-1.36) 11.1(6.6-14.1) 
+-7 1000-1500 1.02 (0.62-1.55) 0.73 (0.46-1.06) 8.7 (5.7-11.6) 
Nahata, 1984 9 28-30 2-6 1.04 ± 0.22 0.84 ± 0.31 9.3 ± 2.8 
11 30-34 2-6 1.13 ± 0.35 0.81 ± 0.20 8.9 ± 3.0 
6 34-40 2-6 1.28 ± 0.31 0.61 ± 0.14 5.6 = 1.2 
7 2-6 1000-1250 1.05 ± 0.20 1.02 ± 0.27 11.3±3.0 
6 2-6 1260-1500 1.12 ± 0.39 0.74 ± 0.16 8.2 ± 2.0 
7 2-6 1500-2000 1.10 = 0.32 0.69 =0.16 7.5 ± 1.6 
6 2-6 2100-3500 1.28 = 0.31 0.61 ± 0.14 5.6 ± 1.2 
~:than, 1986 8 24-30 3-5 <1000 0.69:':0.10 0.59 ± 0.10 9.9 ± 1.5 
Abbreviations: n= number of p::tricnts in study, PDA= patent ductus :rrteriosus, ECMO= extracorporeal membmne 
oxygenation, GA= ):;<:Stacional a~;e, PJ'.,; . '\= posmatal age, PC:·\= postconcepti.onal age, ASS= s· apgar score, 
CL= total body cle::t.t:l.nee, Vd= volume of discriburion; t1;:= serum half-life 
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Keyes showed that serum trough concentrations could not be reliably predicted in 
newborns \\':ith serum creatininS0. In conclusion these studies suggest that, though there 
is a relation, serum creatinin .in the first week of life can not be accurately used to predict 
aminoglycoside clearance. 
Effect of gestational age and birthweight on pharmacokinetics 
The volume of distribution (V d) of most drugs is larger in neonates, especially in 
prematures, primarily due to a higher percentage of extracellular water85, 86. As can be seen 
.in table 4, this also holds true for aminoglycosides. There is a consistently higher V d for 
prematures, especially in the VLBW-group/ gestational age (GA) group below 30 weeks. 
:vfost authors have found birthweight (BW')7l, 77• 87-89 to be the best predictor of V d, some 
found Vd to be .independent of GA76· 90. In practice, this means that premarures \.vill end 
up having lo\.ver peak serum concentrations. The interpatient variability of V d .in these 
groups is greater and therefore serum concentrations are difficult to predict in the 
individual premature infant. Total body clearance (CL), associated with GA71. 78. 88 and 
BW7 1. 87-89, is lower and elimination half-life (tl/213) is longer .in preterm infants, leading to 
higher serum trough concentrations in this group. This can be explained by the significant 
increase of GFR with GA and BW" described in recent srudies91. 92• CL and t1;2 are also 
highly variable in the VLBW infants. Substantial effort has been put into developillg 
formulas, mostly based on population pharmacokinetic studies, which potentially \.villlead 
to better prediction of serum concentrations in the individual patientf6, 87.89_ Despite these 
efforts variability persists and therapeutic drug monitoring (TD_M) remains common 
practice ill all infants. 
Effect of postnatal age on pharmacokinetics 
Diminishing extracellular fluid .in the neonatal period93 leads to a corresponding decrease 
in V d "-;th increasing postnatal age (P'\iA), again especially in the VLBW group. In 
contrast, Faura et al.9-+ found no difference in Vd bet\veen 48h and 144h P~A, most likely 
e:-..-plained by the mean GA of 37 weeks in neonates included ill this study. Recent data 
have shown a significant postnatal .increase in GFR9t. 92_ A concomitant change in CL and 
tt/2 has been sho"'Wn for amikacin95, gentamicin76. 78, 79. 96, 97, netilrnicin67, 71 and 
tobramycin9S, but has been refuted by others77. 94. These data suggest that repeated TDM 
should be performed in the first week of life. 
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Effect of patent ductus arteriosus, indomethacin, extracorporeal membrane 
oxygenation (ECMO) and corticosteroids 
Patent ductus arteriosus (PDA) as well as postnatal exposure to indomethacin alter the 
rapid postnatal increase in GFR99, possibly through decreased renal blood flow, leading to 
an increase in V d and a reduction of CL. Increase in V d of gentamicin is found in infants 
with PDA90, too. In this patient group fluid overload is common. A recent study in 
premarures90 sho\ved that a gentamicin V d exceeding 0. 7 L/kg has 92% specificity for 
presence of a hemodynamically significant PDA. However, important deficiencies in the 
design of this study \vere reponed1D1• Closure of PDA leads to significant decrease in Vd 
of more than 30 %100- ro2. Dosage adjustments, based on TD_M, should be made in 
patients v.rith PDA. The effect of indomethacin, used for closure of PDA, as well as 
surgical closure itself necessitates TDM. Information on gentamicin disposition in infants 
on ECMO is scarce. T\vo small studies72. 103 showed Vd to be increased. Serum half-life in 
patients on EC:YIO was 9.55h and 9.24h respectively, and decreased to 3.87h in the same 
patients off ECMO in the study by Dodge et al103. Southgate et al. showed that serum 
creatinin is a significant predictor for t1;272. On the basis of these data, dosage adjust-
ments should be made in this group of infants. They advise an initial dose of 4.3 mg/kg, 
\Vi.th a maintenance dose of 3.7 mg/kg/18h103. Prenatal exposure to corticosteroids, 
which is seen increasingly in the VLB\V group, leads to increased intra-uterine maturation 
of kidney function, possibly through direct vasodilatation mediated by glucocorticoid 
receptors9t. Though this point has not been investigated yet, it might have a significant 
effect on pharmacokineric parameters in this group of infants. These studies indicate that 
extra therapeutic drug monitoring (TD:M) is ·warranted in patients who are either on 
ECMO, have an open ductus Botalli, or are exposed to indomethacin. 
Drug resistance and susceptibility 
Broad-spectrum antibiotics are generally used in NICU's as empiric treatment of 
(suspected) neonatal sepsis. Drug resistance in :::--JICU's is an important factor related to 
this empirical use. Over the years aminoglycosides remain antibiotics of first choice in the 
initial empirical treatment of neonatal septicemia, both because of their broad spectrum as 
well as their activiry..us. 
Since most serious infections in the NICU are caused by Enterobacteriaceae and 
coa.:,oulase negative staphylococci (CONS), these are the organisms that are now 
23 
considered \vi.th respect to emergence of resistance in the clinical setting. In one srody, a 
change from gentamicin to amikacin was initiated because of gentamicin resistant COKS. 
Although amlkacin resistance quickly emerged in the CO~S, the bacteria that caused the 
serious infections remained susceprible104• In another study, a change from gentamicin to 
amikacin because of the emergence of gentamicin resistant Enterobacteriaceae did not 
lead to an increase in am.i.kacin resistant strains. In contrast, there was a decrease in 
gentamicin resistance1D5. In a third study on a ~ICU, the change from gentamicin to 
amikacin led to an outbreak of amikacin resistant SetTatia spp, which remained susceptible 
to gentamicin1D6• However, this could have been due to the intrinsically higher activity of 
gentamicin against Serratia spp. In general, although the number of studies are limited, 
emergence of aminoglycoside resistant strains other than coagulase negative staphylococci 
is relatively slow1D7, which is a definite advantage over the third generation 
cephalosporins. The frequent use of these latter drugs has been shown to rapidly lead to a 
significant increase in the emergence of multiple drug resistant strains1D7·109• 
Toxicity 
The major specific side-effects of aminoglycosides are nephrotoxicity and ototoxicity. 
~eurotoxicity by way -of blockade of neuromuscular synapses \vith prolonged muscle 
weakness after the use of muscle rela.\:ants has not been described in infants. The delayed 
type hypersensitivity· reaction of the skin is mostly seen after use of topical application of 
neomycin or framycetin and has not been described in neonates. Kephro- and ototoxicity 
"ill be described in further detail. 
"l.'.Jephrotoxici!J 
Aminoglycoside nephrotoxicity is induced by 'l.vay of proximal tubular injury leading to 
cell necrosis. The mechanisms of toxicity have been mostly studied in animals. Less than 
5% of filtered aminoglycosides binds to the brush-border membrane of proximal tubular 
cells and is actively reabsorbed, finally causing cell death. Absorption through the 
basolateral surface has also been described68• Intracellular mechanisms resulting in cell 
death are formation of hydro:xyradicals, increase in phospholipidosis, inhibition of 
Na-K-ATPase, effects on microsomal protein synthesis, lysosomal and mitochondrial 
injury, increased tromboxane fu synthesis, and vascular factors like activated renin-
angiotensin system110• Because of the site specific damage, aminoglycoside nephrotoxicity 
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does not initially induce azotemia and decreased GFR, but leads to polyuric renal failure, 
defective unnary concentration ability, cylinduria, glucosuria, phosphaturia, 
aminoaciduria, rnicroproteinuria, enzy1:nuria and a slo\v rise in serum creatinin. High doses 
(> 40 mg/kg) are needed to create cortical necrosis and overt renal dysfunction111. 
Tubular cells undergo a proliferative response after treatment leading to repair. This 
response is diminished in ill patients112, which is a possible explanation as to why patients 
arc more sensitive to aminoglycosides. The degree of nephrotoxicity is determined by the 
quantity of aminoglycosidcs stored in the proximal rubular cell and the intrinsic potency 
of the drug to damage subcellular strucrures113. Aminoglycosides sho\v drug-specific 
saturable uptake into rubular cells in animalsll+ and humanstls. 116. Comparison bet\vcen 
once daily dosing (ODD) and multiple daily dosing (MDD) or continuous dosing for 
ami.kacin, tobramycin, gentamicin and netilmicin in adults showed considerably less renal 
accumulation for ODD in gentamicin, nctilmicin and amikacin. There \Vas no difference 
bet\veen dosage regimens for tobramycin, though the srudy group was small (n=18). In 
several large meta-analytical studies toxicity seems to be related to high trough 
concentrations, indicating that these concentrations are not lo\v long enough to prevent 
renal accumulation. l"ephrotoxicity related to ODD opposed to 01DD was found to be 
equal or less in these studies+9, so. 84- 117. ns_ A recent prospective study in adults sho\ved 
that both probability and time of occurrence of nephrotoxicity arc negatively influenced 
by multiple daily dosing119. There is no clear distinction in level of nephrotoxicity bet\veen 
the four aminoglycosides in studies in adults6S. 
The incidence of aminoglycoside nephrotoxicity in neonates is not well knO\vn, but seems 
to be considerably lower than in adults. Enduring glomerular flitration impairment has 
not been conclusively sho\vn in prospective studies. GFR \Vas not affected by tobramycin 
given for less than 6 days120_ The normal postnatal decline of plasma creatinin \vas 
temporarily decreased in preterm and term infants treated "\Vi.th amikacin, gentamicin or 
netilmicin. This diminished decline persisted for at least two days after discontinuation of 
therapy. After 10 days, these differences could no longer be detected, except for term 
infants treated "\Vi.th gentamicin 121 . Other studies sho\ved no difference in serum creatinin 
in treated patients versus controls122. 123. Ko difference in renal function \vas found 
bet\veen ODD and 01DD for amikacin and gentamicin123· 124. ;-.Jo relation bet\veen serum 
concentrations and GFR disturbances has been demonstrated in infants. 
Tubular dysfunction has been shO\vn in many studies involving neonatcst20-t2.2.125-129, and 
is more pronounced in term infants than in preterm newboms120. t23. 128, possibly 
explained by maturity dependent blood supply differences of the outer parts of the kidney 
and lower binding constants ID the immature kidncy13°. Several studies showed the 
dysfunction to be reversiblel21. 122. 125. One study showed enz~rmuria during treatment to 
be more pronounced "'With gentamicin than v.rith amikac.in in the low birthweight infant129. 
In ID.fants -wi.th a GA above 34 weeks no difference in proximal tubular damage was 
found betv.Tecn ODD and :MDD of amikacin123. A reversible increased loss of sodium, 
calcium and magnesium has been shown to exist during and just after treatment '\vith 
amikac.in, nerilmicin and gentamicin. "Crinary electrolyte loss is higher at peak serum 
concentrations121, 125. In the ill term and especially preterm infant, who is already at risk 
for electrolyte disturbances, the increased loss during aminoglycoside therapy might be 
clinically relevant. In summary aminoglycoside related loss of renal function 1s rare. 
Reversible tubular dysfunction is seen often and already occurs early in therapy. 
Ototoxicity 
Aminoglycosides are potentially cochleo- and vestibulotoxic. They accumulate in the 
lymphatic fluid of the inner ear from which they are only slowly eliminated (24-36h) 1". 
There is evidence for saturable uptake in animals132. Some authors suggest that ototoxic 
effect is only possible after conversion in serum of aminoglycosides to a cytotoxin 133. 134. 
Certain gene mutations lead to a familial increased risk of aminoglycoside induced 
sensorineural hearing loss135. Sequentially outer hair cells, inner hair cells and spiral 
ganglional neurons are damaged. Aminoglycosides seem to give a polyamine-like 
enhancement of glutamate N-methyl-D-aspartate (t'JMDA) receptor activity, resulting in 
excessive entry of sodium and calcium which leads to excitotoxic cell death. Protective 
trophic factors like platelet derived gro\.vth factor arc antagonized by aminoglycosides136. 
:-:-.JMDA receptor blockade has been shown to protect against aminoglycoside induced 
ototoxicity137. Hearing loss is usually bilateral, symmetrical and permanent131, and can also 
have a delayed onset of months131. Most authors suggest that ototoxicity is related to total 
dose and duration of therapy rather than to serum aminoglycoside concentrations, but the 
relation to aminoglycoside serum concentrations remains unclear. This form of toxicity 
usually occurs in patients who have received either long, or repeated, courses of 
aminoglycosides138. No difference in incidence bet\\reen ODD and :Y.fDD could be 
demonstrated11S, 119. In e.-...::perimental srudies amikacin appears to be more cochleoto:xic 
than gentamicin and tobramycin. Kerilmicin is probably the least ototoxic 
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aminoglycoside139 • .Although vestibulotoxicity is a disabling side effect in adults, it has not 
been shown .in neonates. 
There are many pitfalls in relating usc of aminoglycosides to loss of hearing in infants. 
Hearing loss .in neonates occurs .in 0.1-0.3% of casesWl. )-,Jumcrous risk factors for 
neonatal hearing loss have been identified. Perinatal infections, meningitis, prematurity, 
hyperbilirubinemia, birthwcight < 1500 grams, asphy-:da, respiratory distress syndrome, 
mechanical ventilation, antibiotics, and diuretics have all been .incriminated141 . Even 
though some studies show a relation to administration of aminoglycosides, it remains 
difficult to separate the effect of aminoglycoside use from concomitant factors140. 
Furthermore initial .investigations concerning hearing loss, before the .introduction of 
brain stem evoked response audiometry (BERA.), were hampered by the fact that 
conventional and behavioral audiometry were used, which arc not reliable under the age 
of 12-24 months. 
Table 5: Reported ototoxicity!![ aminog!ycosides in neonates 
Dru~ N 
and 
reference 
Amikacin 
Finitzo- 50 
Hieber, 1985 
Langhendries. 10 ODD 
1993 121:IDD 
Gentamicin 
Kohclet. 1990 7 
Tsai, 1992 17 
Beml.rd, 1981 26(6 to bra) 
Nt'1i1111icin 
Finitzo- 49 
Hieber, 1985 
GA PNA Duration 
of therapy 
28-41 0, before discharge, 5.3 ± 2.0 
follow up 
2:34 0,3,9 8.8 ± 1.8 
8.0 ± 2.4 
39.3 3 XA. 
3,10 K.A. 
37 5,10 8.7 ± 1.3 
27-41 0, before discharge, 5.2 ± 2.6 
follow up 
Total Serum Ototoxicity 
dose <:one. 
(mg/kg) 
< 403 Yes 2% (N.S.) 
N.A. Yes Xo 
~-A Yes Yes, prolonged 
breneies in the 
treated group 
K.A. Yes Yes, transient 
163 ± 81 Yes Yes 
< 129 Yes 2% (N".S.) 
X.A= not available, N.S.= not significant. GA= gcstarion:li age. PNA= posmatal age. cone. = concentrations 
(mg/L). v:liue. n =number of subjects, ODD= once daily dosing • .MDD= multiple daily dosing 
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Table 5 sho\vs the results of studies concemiDg aminoglycoside related ototoxicity. Of the 
many studies, only those using BERA -,;viJl be discussed belo\v. Ototoxicity is an 
infrequent occurrence in these studies. ~Iany studies did not flnd any aminoglycoside~ 
related toxicity. Cox et al.1 42 found that 14% of infants had abnormal latencies at 4 
months in a group of 43 infants \Vi.th multiple risk factors, but there were no controls. 
Interestingly, 3 infants had an initial normal BERA followed by an abnormal BERA at 
follow-up. This means that auditory· evaluation during, or just after discontinuing 
aminoglycosides, will not caprure all patients \vith induced hearing loss. In the other study 
-,;vi_th a high rate of ototoxicity, the 8 patients \vi.th abnormal BERA's and aminoglycoside 
treatment less than 10 days, also had another reason for hearing loss143. The best study so 
far, \vi.th a baseline value, follow-up and a control group, found 3 patients with hearing 
loss; 1 patient each treated \'Vi.th netihnicin or amikacin, and 1 controP44• Several studies 
found a transient hearing loss144.l+5. Some studies found a relation -,;vi_th duration14-t.t43 and 
total dose141. 1+6. :-Jo clear relation was found to peak and trough concentrations. 
Concomitant treaunent \vith furosemide and vancomycin was associated "vith hearing 
loss123, 139, 1+7. The results mentioned above lead us to conclude that aminoglycoside 
related hearing loss ID IDfants is IDfrequent, possibly transient and might be late ID 
appearing. 
Aminoglycoside therapeutic drug monitoring and dosing 
Dose and dosing interval are determined by the desired therapeutic range and 
phannacokinetic as well as pharmacodynamic properties of a drug. It is difficult to define 
the desired therapeutic range for aminoglycosides. Peak concentrations of> 4-5 mg/L are 
generally accepted as necessary for antibacterial efficacy when dosing thrice 
daily34. 84. 148. 149, but questions are being raised about the underlying basis of this 
assumption 138• \Vhat is known, is that efficacy of aminoglycosides is related to the ratio 
of peak serum concentration to the minimal IDhibitory· concentration (YJJC) of the 
infecting microorganism and the area under the time versus concentration curve (AUC). 
In vitro ratios of 10:1 prevent emergence of aminoglycoside-resistant pathogcns34· 35. In 
several large meta-analysis studies toxicity seems to be related to high pre-dose 
concentrations49.50. 84. 117. Commonly accepted trough concentration goals in adults are 
< 2 mg/L, but '\vhen dosiDg once a day most authors keep < 1 mg/L as a safe 
limit 51. 150. 151. As described before, neonatal data on nephro- and ototoxicity as well as 
efficacy, in relation to aminoglycoside serum concentrations are not available, and 
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therefore have to be extrapolated from adult and experimental models. Based on the 
aminoglycoside susceptibility of gram-negative pathogens involved in neonatal septicemia, 
a reasonable target range for neonates would therefore be peak serum concentrations of 
5-10 mg/L for gentamicin, nerilmicin and tobramycin and 15-30 mg/L for amikadn. 
Trough concentration goals are < 2 mg/L when dosiDg thrice daily and < 0.5-1.0 mg/L 
for ODD ID gentamicin, nerilmicin and tobramycin and 1.5-3 mg/L for amikacin. As 
described before, inves~aations concerning the pharmacokinetics of arninoglycosides and 
other drugs in neonates have sho\vn that elimination half-lives are longer in neonates, 
especially in preterms. This is primarily due to a higher percentage of extracellular water 
and thus a larger volume of distribution and reduced clearance. Most dosing schedules for 
preterm and term neonates take this into account. Currently recommended doses are 
2-2.5 mg/kg for gentamicin, nerilmicin and tobramycin and 7.5-10 mg/kg for amikacin, 
\Vith dosing intervals, dependent on gestational age (GA) and postnatal age (PKA), 
beNreen S and 24h. A critical look at the available data shows that required serum 
concentrations as mentioned above arc not reached \vith most of these dosing regimens, 
stressing the need for other dosing strategies. 
In larger studies, inadequate serum peak concentrations and elevated serum trough 
concentrations were found, especially in \TLB\V -infamsso, 152-155. It has to be noted that 
many studies used steady state peak serum concentrations after the fourth dose, which are 
often higher than initial peak serum concentrations. From the vie\V'Point of efficacy it is 
important to obtain an adequate peak serum concentration after tl1e first dose, which led 
several authors to advise a loading dose of aminoglycosides102, tso, 154- 156. It seems clear, 
that given the desired goals and the phannacokinetic properties, aminoglycoside dosing in 
newborns should be revised towards larger doses at extended intervals. Several studies to 
that effect have been published recently96.124. 
Due to the large interindividual variability of elimination half-life, especially in prcterms, 
dosing interval has to be individualized. Currently this is performed by taking blood 
samples in steady state, around the third or fourth dose. Antibiotic courses in neonates 
are often relatively short. Antibiotics arc initially starred in a large percentage of patients 
in the fl.rst 24h on clinical grounds. They are discontinued if cultures remain negative after 
2-3 days. Furthermore it is essential, when givlng aminoglycoside antibiotics, to obtain 
efficacious peak levels after the first dose. These arguments point to a need fo.r early 
TDM in neonates. A simple method for early TD:\1 might be obtaining t\vo serum 
samples lh and 6h after the first dose. Individual dosing interval is then determined by 
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the calculated t\;2, the target serum trough concentration being 0.5 mg/L. This method 
\vill have to be prospectively validated. 
In conclusion, on the basis of these recent data, dosing of aminoglycosidcs in newborns 
should be revised to higher doses per kg '\vi.th longer dosing intervals, as has been 
propagated in adults over the last few years. The rarity of aminoglycoside related toxicity 
in studies in infants, the paucity of case reports on this subject, the lack of evidence for 
relation to serum concentration, and the data in adults, justify starting infants on higher 
initial doses \'vith longer intervals and early TDM for clinical trials. 
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1.2 Use of vancomycin in neonates 
1.2.1. General aspects of vancomycin 
Introduction 
Vancomycin is an antibiotic first isolated from an Indonesian jungle soil sample in 1956 
and \Vas the first of the ne\v class of glycopeptide antibiotics. Irs initial clinical use in 1958 
\Vas facilitated by the emergence of penicillinase-producing staphylococci. It was largely 
supplanted by methicillin sodium, introduced in 1960, due to the frequent occurrence of 
side effects associated '.V'ith vancomycin use, including generalized skin eruptions, 
phlebitis, fever and more importantly deafness and renal failure157, 158. Several factors have 
contributed to the ''rediscovery" of vancomycin in the 70's. First, important changes in 
the preparation of vancomycin have led to a reduction of impurities present in the 
product and a concomitant decrease in incidence of side-cffects159-1G1. Second, d1e 
emergence of methicillin-resistant staphylococci has necessitated a change in antibiotic 
policy for these infections. 
Despite the emergence of vancomycin resistant enterococc~ vancomycin still is the most 
\Videly used glycopeptide antibiotic, and is a cornerstone in antibiotic treatment of gram-
positive infections in adults as well as neonates. 
Structure and chemical properties 
Vancomycin and teicoplanin comprise the commonly used glycopeptide antibiotics and 
are unrelated to other antibiotics. They are complex soluble glycopeptides, consisting of a 
seven-membered peptide chain, in the form of three large rings. Five of the seven amino 
acid residues arc common to all glycopeptidcs162·164-. A disaccharide, composed of glucose 
and vancosaminc, is also present but is not part of the cyclic structure. The molecular 
weight of vancomycin is 1,448 Dat65. 
Vancomycin is hydrophobic, but less so than teicoplanin163. It has a moderate protein 
binding (10-55%) and exerts its acti:viry over a \Vi.de pH range of 6.5-8 t66. 167. Vancomycin 
can be inactivated by heparin in high concenttations16S. 
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Method of action 
The bactericidal activity of vancomycin is based on the inhibition of bacterial cell '\vall 
synthesis. It complexes, by '\vay of hydrogen binding, to the D-alanyl-D-alanine portion of 
pcptides found only in bacterial cell walls. The binding of this large molecule to the 
peptide side chain shields the substrate from the enzy'IDe peptidoglycan synthetase169. This 
IDterferes with cross-linking of cell wall peptidoglycans and therefore bacterial cell wall 
rigidity can not be achleved163. I65, no. The mechanism of action implies that vancomycin 
can only exert its effect on gro'Wing bacteria. Other, less important modes of action are 
alteration of the permeability of cytoplasmic membranes and selective inhibition of RKA 
synthesis171, 172. 
Vancomycin antimicrobial activity 
Vancomycin is bactericidal for a host of aerobic and anaerobic gram-positive bacteria. 
Strains of Staphylococczrs epidermidis and Staphylococcm auretts are susceptible to vancomycin, 
although emergence of vancomycin intermediate resistant strains are a gro'\ving concern, 
'\vhich '\Vill be discussed later173. 
)Jormal minimum inhibitory concentrations (J\1IC's) are ID the range of 1-5 mcg/L 170. 
Vancomycin is bacteriostatic for enterococci167. 
Important aspects of antimicrobial activity of vancomycin for clinical practice are: 
I. Lack of concentration-dependent killing 
II. Postantibiotic effect 
III. Synergism 'W-i.th other antibiotics 
Lack of concentration-depmdent killing 
Several recent studies have shown that the extent of bacterial killing is not related to peak 
serum concentrations but to the time the antibiotic concentration is maintained above the 
11.IC174-176. This may however be dependent on rime of e::-..-position. An ID-vivo study 
sho'\ved that in the first 12h the 11IC '\vas the most important factor, '\Vhile for the total 
first 24h the ACC was more important177. There are conflicting conclusions in the 
translation of ID-vitro and in-vivo results to vancomyciD dosiDg. Most authors advocate 
12h IDteDrals ID adults. Some give continuous infusion and others dose once daily178-so. 
Treatment failures due to once daily dosing have been described1S1, 182. Continuous 
infusion of vancomyciD was proven to be as effective as IDtermittent dosing179. 
Postmt!ibiolic ejfea 
Vancomycin shows an in-v-i.tro postantibiocic effect (PAE) ~o-ainst S. aurms, S. epidem-;idis 
and enterococcal species, lasting 1-6h175. IS3-JS5. As \.vith aminoglycosides, PAE should be 
studied under conditions simulating time versus concentration curves seen in clinical 
practice The duration of PAE effect seems to be far longer when bacteria remain exposed 
to vancomycin concentrations of 0.1-0.3 mg/L, indicating a sub-MIC effectt 75. In vivo 
experiments relating PAE to vancomycin concentrations arc scarce. A definite conclusion 
on the clinical importance of the PAE of vancomycin can not be drawn. 
S_pmgy with other antibiotics 
Combination of vancomycin \.vi.th an aminoglycoside or rifampicin is synergistic for 
S. aureus (both methicillin-sensitive and medUcillin-resistant) and S. epidermidis and 
entcrococcal infections1SG, 187. In enterococcal infections synergy can be achieved in most 
cases by adding an aminoglycosidc as \VellJss. 
Drug resistance 
Clinically important resistance to vancomycin is seen in enterococci, S. a;Jre!JS and S. 
epidermidis. An unsettling increase of vancomycin-resistant enterococci has been noted in 
the l:nited States, related to selection pressure by indiscriminate use of vancomycin1S9. 190. 
Resistance in enterococci has been linJ.:ed to at least four genes and types of resistance, 
Van A, Van B, Van C and Van D. Van A and Van B resistance can be transferred by way 
of plasmid conj~oation to other cnterococci178- 191. Van A leads to vancomycin and 
tcicoplanin resistance, Van B resistance retains susceptibility to teicoplanin1G7. Van 
C phenotype sho\.V-s low level vancomycin resistance but remains susceptible to 
teicoplanin173• 192. 193. There are two alarming features to these resistance genes. First, a 
transfer of Van A resistant enterococci from poultry and domestic animals to humans has 
been noted, possibly as a result of avoparcin use as a growth promoter in animals194, 195. 
Second, transfer of vancomycin resistance from enterococci to S. cmretts has been 
demonstrated in the laboratory and an emergence of this phenomenon in the clinical 
situation is fearedl96• There arc an increasing number of reports on intermediate 
resistance in S. attreJts and S. epidermidis173. MIC's as high as 16 mg/L with minimal 
bactericidal concentrations (:VIBC's) of 64 mg/L have been reported for S. epidermidis, 
\.vi.th a concomitant resistance to teicoplanin197• After the first report in japan, a number 
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of papers have addressed the emergence of vancomycin intermediate resistant strains of 
S. atrreus (VIRSA) 173. 198. 199. Resistance seems to be related to thickened and aggregated 
cell walls, though the precise mechanism is not yet k..no\vn200. There is cross-resistance to 
teicoplanin. Infection with VIRSA is associated with treaanent failure of vancomycin2D1. 
An important mechanical factor in clinical resistance of S. epidermidi:S infections to 
vancomycin is the production of a biofilm by the bacteria, thereby shielding it from the 
antibiotic with a consequent reduction of antibiotic efficacy2D2. 203, Furthermore 
vancomycin is a large molecule, ·which inhibits diffusion into localized infection sites like 
endocarditis. 
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1.2.2. Specific aspects of vancomycin use in neonates 
General aspects in neonates 
The immunologically incompetent premature neonate is especially susceptible to invasive 
gram-positive infections through invasive procedures such as central venous lines. Late-
onset neonatal septicemia, defined as occurring after the first 4 days of life, is seen in up 
to 31% of very low birthweight (VLB\"V) infants20+. Stopi?Jiococros attre11s and coagulase-
negative staphylococci (CO~S) account for up to 55% of late onset nosocomial 
infections in ne'l-vbom infants2°~-20i. A substantial increase in the number of COKS 
infections rn neonatal units has been reported20s. 209. Especially VLB\V infants have 
sho\.vn an increase in this type of bloodstream infection, associated 'Wi.th length of stay, 
neonatal risk scores, increased usc of central venous lines and adm.inistration of parenteral 
nutrition21 0-212. Late-onset neonatal septicemia has significant impact on outcome and 
length of hospital smy. Length of stl.y is prolonged by nosocomial bacteremia by 
14-25 days20i, 21 0.213. Mortality in this group is at least twofold higher than in neonates 
\.vid1out late-onset sepsis and sepsis accounts for up to 45% of deaths occurring after t\.vo 
weeks of admission207. 
Vancomycin is '1-vi.dely used as empiric antibiotic for treatment of line-related infections in 
neonates. This glycopeptide antibiotic has been used in pediatric patients, including 
neonates, since the late 1950's214. As in adults, it has come into disuse in the 60's because 
of side effects. The resurge of interest in the SO's was instigated by the establishment of 
COKS as a clinical significant pathogen for neonatal septicemia and d1e emergence of 
methicillin resistant S. aure11s and S. epidermidis in neonatal intensive care units 
(NICU's) 2t5-2ts. With the increase of CONS as a cause of late-onset neonatal sepsis, the 
continuous use of low dose vancomycin or teicoplanin added to parenteral nutrition has 
been advocated 219-22+. Although a reduction in number of gram-positive infections in 
preterm infants has been shown, no decrease in mortality or length of stay has been 
provcn225. Given the concerns about development of resistance by overuse of 
vancomycin, routine prophyla.-xis '.Vi.th low-dose vancomycin should not be given225. 226. 
Frequent administration of vancomycin for intravenous catheter-related infections in 
neonates will remain necessary however, and knowledge about pharmacokinetic- and 
dynamic aspects of vancomycin use in neonates is needed to rationalize treatment. 
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Pharmacokinetics 
Vancomycin has a pharmacokinetic profile consisting of a distribution phase, \Vhich is 
longer than in aminoglycosides (tl/2:.:) and an elimination phase (tt/2,3). One, t\vo or three 
compartment models have been described in adults. It has been suggested that a 
triexponential model best describes vancomye1n disposition227_ Vancomycin 
pharmacokinetics in neonates has been described using a model independent2.2s, one180-208-
229-243 or n~.ro233. 238, 2-14-247 compartment model. A one compartment model seems to be a 
valid tool in predicting serum concentrations, as long as these are dra\vTI in the post-
distribution phase238_ Since most studies take peak serum concentrations 1h after a 1h 
infusion this is very likely the case. Earlier serum sampling might lead to an 
underestimation of the apparent volume of distribution at steady state rv~J­
Pharmacokinetic parameters of vancomycin in neonates are different from those in 
adults. These differences are largely determined by the change in amount of body \Vater 
and maturation of renal function, which takes place in term and preterm ne\vbom infants. 
These changes also result in higher inter-individual differences in neonates than in adults. 
Results of pharmacokinetic studies of vancomycin in neonates and infants are shown in 
table 6. 
Distribtrfion 
Vancomycin is only used intravenously in neonates. Distribution half-life (tt/2a) is 
approximately 0 . .5-1 hour in adults227. In neonates and infants it ranges from 0.05-0.49h, 
but has only been determined explicitly in one srudy245. Others have suggested that t112a 
might be longer, even up to four hours 238. 246. 247. Seay et al. calculated tt/2 a from 
population parameter values and found values between 2.8 and 3.7h depending on 
gestational age and dopamine as co-medication 238_ Volume of distribution in steady state 
(y,~) in neonates ranges from 0.38 to 1.06 L/kg, with the highest V~, described in patients 
on e.-xtracorporeal membrane oxygenation (EC::vfO). This is in the same range as 
described in adults227 . As mentioned by Rodvold248, volume of distribution studied after a 
single dose or calculated "\Vi.th the elimination tt/2~ was often larger than Vs,. 
Since meningitis often accompanies sepsis in neonates, penetration of vancomycin m 
cerebrospinal fluid (CSF) is of possible concern. Vancomycin dosing leads to CSF 
concentrations of7-21% of the serum concentration in adults 178_ 
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Table 6: Res!! lis of phar/J/acokimtic st11dies of 1/tlllCOit(Jcill in neo11ates 
N Subgroup/ 
Remark 
7 Do~c 10 mg/kg 
7 Dose 15 mg/kg 
7 Do~e 15 mg/kg 
Wcight 51 kg 
6 Weight> 1 kg 
11 :\:o mc:J.ns aYail"lblc 
14 PC\<41 
6 PCr\>43 
20 
PDJ\c+indomctbacin 
No PDA< concrob 
15 G"itst dose 
12 Steady st.l.tc 
13 
15 
1l 
+ Exposed to 
indometh:Ldn 
19 ~o i...'ldomerhacin 
29 
2 comp:w-.ment 
NO~.\iE.\.f•: 
1 compar.menr 
16 PCr\ 27-30 
15 PCA 31-36 
13 PCr\ 87 
15 Day 2 
15 Day 8 
12 ECl\.IO 
11 
15 EGdO 
15 No EClviO 
24 St:md.nd do~e 
GA 
32 
34 
40 
27-40 
26-40 
31 
26.5 
28.4 
29.8~ 
29.0 
29.3 
29.6 
27.6 
31.2 
26.6 
29.4 
35.9 
39 
30.8 
38.8 
39.7 
29.2 
29 Adjusted dose 30.5 
72 Development ..Ugorithm 29.4 
17 Testing ..Ugorithm 28.4 
59 NONMEM an.'llpis 29 
PNA PCA BW 
(d..1.ys) (wec:k) (gt;Un~) 
3.3 
30b 
32.7~ 
27 29-41 
8-66 32-41 
90-210 54.2 
7 
15 
30" 
29 
18 
34 
15 
16 
18 
18 
23 
24 
90 
90 
2' 
18 
13 
30 
24 
26 
39 
19 
29.0 
32.0 
36.4 
31.4 
38b 
33.2 
30.9 ~ 
28.5 
34.2 
33.4 
29.4 
32.9 
39.2 
33.4 
33.5 
33.9 
32.9 
32.0 
32 
1230 
1570 
3070 
830b 
13781' 
850--+380 
1300 
1069 
1375;, 
1297 
1262~ 
810 
1780 
1480 
1305 
1860 
972 
l379 
2616 
6400 
6400 
3300 
1186 
3100 
3400 
1500 
1800 
1520 
Vd (L/kg) 
0.736h 
0.706:, 
0.690:, 
0.970=0.426b 
0.647=0.3621> 
0.4-81±0.165 
0.377±0.036 
0.71±0.36 
0.+8±0.17 
0.693±0.149 
0.53±0.13 
0.52::::0.1 
0.4-7::::0.15~ 
0.48::::0.09 
0.51 =0.03 h,h 
0.57::':0.06 
0.52±0.08 
0.764::::54.1 '·tl< 
0.551±0.205 
0.55 ± 0.02 
0.56 ± 0.02 
0.57 ± 0.02 
0.81±0.6 
0.44±0.19 
1.06±0.45 
O.+S ± 0.13 
0.45±0.18 
0.39±0.12 
0.61±0.39 
0.65±0.34 
0.67±0.28 
0.669±18"'o' 
CL 
{ml/kg/min) (h) 
9.8 
27• 5.9 
30• 6.7 
1.099±0.293 9.92::::2.59 
1.030±0.223 5.35::::0.77 
3.5-9.6 
4.87 
3.04 
Rof 
245 
242 
247 
236 1.34::::0.46 
1.67=0.61 
0.38::0.15 
0.90±0.57 
24.6±12.4 249 
1.22±0.7J 
1.16±0.6J 
1.44±0.89 h 
1.07±0.34 
0.74±0.20 h 
0.6±0.17 
1.01=0.37 
1.00::::0.07 
1.17::::0.08 
1.33=0.08 
L5::o.5 
1.2±0.4 
0.78=0.19 
0.63=0.18 
0.65::::0.28 
0.79:':0.41 
1.19:':0.55 
0.99::0.41 
1.26±0.55 
1.40±0.67 
7.0±1.8 
6.0±2.0 
6.6±2.1 
5.1±3.0;, 
5.6±1.6 
8.5±2.8:, 
11.9±3.7 
229 
228 
230 
244 
232 
241 
241 
238 
237 
6.63=0.35 208 
5.59=0.36 
4.90::::0.39. 
231 5.3±3.2 
3.+±1.2 
16.9::9.5 250 
246 
8.29±2.23 240 
6.53±2.05 
6.9±4.5 
6.5±3.3 
180 
235 
233 
·'ml/min/1.7 m~. ~c:llcubtcd from individu.'ll v::J .. kes for ill p::tticnts mentioned in the :micle, cPopubtion me:m 
± interindiv'idu;:U v::tri::tbility, Jml/min. ~P::tten~ ductus ::t..""teriosu~. '::tgc \Vhen j)t:t on EC\fO, gPopubtion :uulysis, 
I'App:ll"ent volume of distribution of bct::t ph::tse, GA = gest:J.tional ::tge (wceb), PN1\ = po~tn::tul :tge, 
B\V' = birtl1\veight, 1\: =number of patients 
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C> ... 
In children Spears reported CSF concentrations of <0.8 mg/L in seven samples 1-12h 
after the vancomycin dose-~14• In infants the first report by Schaad et al. found CSF 
concentrations of 7-21% of the serum concentration in three patients24S. Later reports 
have mentioned CSF concentrations ranging from 0.2 to 17.3 mg/L, 'Wi.th vancomycin 
CSF penetration ranging from 7.1 to 68%251-254. ~o clear relation of CSF concentrations 
to serum concentrations was found. As in adults, there is a significant correlation bet\veen 
CSF concentration and markers for meningeal inflammation tG7, 253. Data on this subject 
are scarce, ho\vever, and vancomycin can not be relied upon to adequately treat gram-
positive meningitis \vhen given as the sole antibiotic. 
Excretion 
Vancomycin is eliminated from the body by way of glomerular filtration. After 24h 
80-90% of an administered dose can be recovered from urine in adults17s_ A small amount 
is eliminated by non-renal mechanisms of unkno\\rn orig1n2SS_ In neonates 44% of 
vancomycin \vas recovered unchanged after Sh228. Total body clearance (CL) in adults 
(0.71-1.31 ml/kg/min) is often higher than that reported in neonates and infants, 
although ranges arc similar2SG-.259. 
In neonates CL ranges from 0.63 to 1.5 ml/kg/min, depending on gestational age (GA) 
and/ or postconceptional age (PCA) (table 6). Lo\ver clearances \vere seen in special 
subpopulati.ons, \Vhich v.-ill be described later. Vancomycin tJ/.2.3 in adults ranges from 
4-Sh in patients with normal renal function. Mean t1;2~ in neonates of varying gestational 
and postconceptional ages ranges from 3.5-10h, \vi.th even longer half-lives in neonates 
exposed to indomethacin or ECMO rxeatment, which will be discussed in more detail 
below. 
Given the route of elimination, an association bet\veen glomerular filtration rate (GFR) 
and excretion is logical. In adults vancomycin clearance was directly related to renal 
function, \vith a vancomycin clearance of approximately 100 ml/ min in patients \vi.th 
normal renal function257- 260-263. In neonates this relation has been established as well. 
Serum creati.nin and creati.nin clearance have been correlated to clearance of vancomycin 
in several studies (table 7) 180- 229. 232-234. 237 • .239. 244. 247_ In term and preterm infants 
vancomycin clearance indexed for weight shows a negative correlation ,vith serum 
creati.nin 229 . .232 . .234-244-243. Pawlotsky et al. found vancomycin clearance (ml/kg/min) to be 
inversely related to serum creatinin, though the significance was lost in the multivariate 
analysis tso_ 
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Kildoo and co-workers found a difference in vancomycin clearance bet\veen patients 
with serum creatinin <53 ~Mol/L or 62-106 iJ-:Vlol./L; respectively 1.38±0.24 vs 
0.79±0.10 ml/kg/min 244. Schaible also found a negative correlation. In a study of 
11 infants vancomycin clearance (L/h) was best described by a combination of PCA and 
the reciprocal of serum creatinin (1/CrJ2+7. A recent study found a negative, but 
nonlinear relation in a population analysis of 59 neonates. Serum creatinin '\vas the sole 
covariate included in the final analysis, and dose reconunendations '\Vere purely based on 
this factor233. Rodvold et al. as '\Veil as Silva et al. showed a positive relation bet\veen 
creatinin clearance calculated according to Sch'\Vartz and vancomycin CL (ml/kg/ min) .239. 
248• 264. In the latter study the authors concluded that creatinin clearance was not an 
important covariate in explaining vancomycin clearance. 
Vancomycin t1;2~ displays a positive correlation '\virh serum creatinin229 . .232. The largest 
study to date, performed in 192 neonates, did not include creatinin or creatinin clearance 
as a covariate in the modeJ23S. Clearance found in dais study (0.29-0.98 ml/kg/min) was 
lower than reported in most studies, possibly due to the larger number of VLBW infants, 
sampling strategy or use of the KOI'\:.\tffi~ statistical approach. 
In the case of terminal renal failure, vancomycin clearance by way of hemodialysis and/ or 
peritoneal dialysis is slo'\v '\vi.rh doses of 15 rng/kg leading to trough serum concentrations 
of >4-5 rng/L after 7 days in adults 265. A significant increase of vancomycin clearance 
can be achieved '\vith continuous veno-venous hemodiafiltration 266. 
Taken togerher, the published evidence favors a clear relation between renal function in 
terms of serum creatinin or creatinin clearance and excretion of vancomycin. 
Effect of gestational age, postnatal age and postconceptional age on 
pharmacokineti.c parameters of vancomycin 
Gestational age, postnatal age and postconceptional age can all be expected to alter 
pharmacokinetics of vancomycin. As mentioned in the chapter about aminoglycosides, 
rhe volume of distribution (V d) of most drugs is larger in neonates, especially in 
prematures, primarily due to a higher percentage of extracellular water85• 86. Creatinin 
clearance (ml/min) sho'\vS a positive correlation \virh gestational age82• 267• On the basis of 
gestational age, premature neonates are expected to have a longer t11.2~. The postnatal 
increase in GFR seen in neonates as well as the reduction of extracellular fluid'>1-93 means 
rhat t1;.2p for vancomycin should decrease \vi.th increasing postnatal age. There is also a 
positive relation between postconceptional age and kidney function 267. 
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Table 7: Con-datiom beflPWl demographic variables and phamJacokinetic para!Jieters 
Correlation Coef. p-v::Uuc Ref Correlation Coef. p-valuc Ref 
EwrdiO!l (11&1 sla11dardi~;."d for ll"cigbt) Exm:lio11 (sla!ldardi~fd for IWigbt) 
CL (L/h) <:> GA 0.71 <0.0009 241 CL (ml/kg/min) <=> PC:\ 0.724 <0.005 234 
CL~"/h) ¢> GA 0.59 <0.01 237 CL (ml/min) <=> PCA 0.46 1 0.0002 180 
CL(L/h) <:> GA 0.48 <0.05 239 CL (ml/min) <=> PCt\ 0.741 0.0001 180 
CL(ml/min) ¢> GA 0.54 <0.05 244 CL (ml/ min) <=> PC.r\ + BW 0.521 0.0005 180 
CL(L/h) ¢:;:- P?\'i\ 0.54 <0.01 237 CL(L/kg/h) <:> PCA 0.62 <0.0005 241 
CL(ml/min) <=> BW 0.82 <0.05 244 CL(L/kg/h) <:> PN,\ 0.50 <0.008 241 
CL(rrJ/min) ¢:;:- BW 0.381 0.0013 180 CL(L/kg/h) ¢> PNA 0.46 <0.05 239 
CL(ml/min) ¢:;:- B\'\/ 0.671 0.0001 180 CL(ml/kg/h) <> BW 0.867 <0.00001 230 
CL(ml/min) ¢:;:- BW·' 0.83 <0.001 228 CL(ml/kg/h) <=> PC\ 0.863 <0.00002 230 
CL(mJ/ min) ¢:;:- BW" 0.89 <0.001 228 CL(rrJ/kg/h) ¢:;:- PCt\ 0.649 <0.001 236 
CL(L/h) ¢:> BW 0.85 <0.0001 241 CL(rrJ/kg/h) <=> P:\A 0.873 <0.00001 230 
CL(L/h) ¢:::- B\\l 0.90 <0.01 237 CL(ml/kg/ min) ¢:> B\\l 0.78 <0.001 229 
CL(L/h) ¢:::- B\\l 0.68 <0.05 239 CL(ml/kg/ min) ¢:> B\V' 0.62 <0.01 237 
k(1/h) ¢:> BW 0.464 <0.04 236 CL(ml/kg/ min) ¢> PC\ 0.8 <0.001 229 
PC:\ ¢:> B\\i' 0.89 233 CL(ml/kg/ min) ¢:> PCA 0.41 <0.05 244 
T1;~ <=> B\'\l -0.88 <0.0005 229 CL(mJ/kg/ min) <=> PCt\ 0.48 <0.005 208 
CL(mJ/min) <=> BS.:\·' 0.84 <0.001 228 CL(ml/kg/min) ¢:;:- PCt\ 0.271 0.0094 180 
CL(ml/min) <=> BS:\1' 0.89 <0.001 228 CL(mJ/kg/ min) ¢:> PC.r\ 0.221 0.01 180 
CL(ml/ miil) <=> PCA ...._ BW 0.7T 0.0001 180 CL(ml/kg/ min) <=> PCA 0.62 <0.01 237 
CL(ml/ min) <=> PC\ 0.88 <0.05 244 CL(ml/kg/min) ¢:> P::'\A 0.70 <0.01 237 
CL(ml/ min) <=> PCA 0.81 <0.00001 208 
CL(ml/min) <=> l)C\ 0.02 180 
CL(ml/ miil) <=> PCt\ 0.002 180 
CL(ml/min) <=> PCN 0.56 <0.05 228 
CL(m.l/min) <=> PCA" 0.62 <0.05 228 
CL(L/h) <=> PC\ 0.92 <0.0001 241 
CL(L/h) <=> PC\ 0.86 <0.01 237 
CL0"/h) ¢> PCA 0.57 <0.05 239 
CL(L/h) ¢:> PC.r\ 0.91 <0.0001 2+7 
T1;~ <=> PCA -0.91 <0.0001 229 
T1;~ <=> PCA -0.62.7 <0.01 234 
CL= v:mcomyci..'l. ck'2r.lrl.cc, PCA= postconcl-pcion::tl ::gc, B\V=body \Wight, Cr .. = serum crcatinin, ~=r' 
G.r\= gcsution;li :lgc. v" =volume of distribution in ste:ldy State, PNA = postn::tul :lge. CJ-'(;, = C!l-atinin dc:trmcc, 
K: = elimination ntc consmnt. BSA= body ~crfacc :trc:J.. ·'Brst dose, bsready stlte, cod.= correhtion coefficient 
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Table 7 (continued): ComlatioJls bet;nen demographic t'ariables and pharmacokillefic paratJJeters 
Correlation Cocf. p-value Ref Correlation Cocf. p-value Ref 
DistribtiliM (L) Rn1al jimrtio11 
V"(L) <:> BSA 0.93 <0.0001 241 V .• (L) ¢<> CL"(ml/kg/min) 0.70 <0.01 237 
V ... (L) <> BSA• 0.80 <0.001 228 CL(L/!1)¢>Cl.o-(ml/kg/min) 0.86 <0.01 
''" -0' 
V"(L) ¢:> BSN 0.89 <0.001 228 CL(L/h) <=> CL"(ml/kg/min) 0.27 <0.05 239 
V,.,(L) <=> B\\l 0.94 <0.0001 241 CL(ml/kg/ min)¢;> CLcc(ml/kg/ min) 0.59 <0.01 237 
V .. U-l "'BW 0.86 <0.05 244 CL(L/kg/h) ¢;> CLa(ml/kg/min) 0.31 <0.05 239 
V,_(L) <=> B\\/ 0.86 <0.01 237 V"(L/kg) <=> Cr. 0.47 <0.01 237 
V,(L) ¢<> BW 0.93 <0.05 239 V,-(L) <=> Cr, -0.40 <0.05 237 
V"(L) ¢:> B\V'" 0.77 <0.001 228 CL(L/h) <:> Cr, -0.65 <0.01 237 
V."'(L) ¢:> BW~> 0.89 <0.001 228 CL(ml/kg/min) ¢:> Cr, -0.74 <0.005 229 
V./L) <=> GA 0.84 <0.05 244 CL(ml/kg/min) ¢:> c,, -0.81 0.0027 232 
V.,..(L) ¢:> GA 0.61 <0.01 27>7 CL(ml/kg/rnin) <=> Cr, -0.82 <0.05 244 
V,(L) ¢:> GA 0.58 <0.05 239 CL(ml/kg/ min) ¢:> Cr, -0.64 <0.01 237 
V .. (L) <>PC\ 0.89 <0.0001 241 CL(ml/mi.n) <:>Cr .. -0.351 0.0165 180 
V"'(L) ¢:> PCA 0.67 <0.05 244 CL(ml/rnin) ¢:>Cr. -0.491 0.0001 180 
V ... (L) <> PCA 0.79 <0.00001 208 Tt;.c. <:::> Ct, 0.91 <0.0001 229 
V .. (L) ¢;> PC\ 0.80 <0.01 
, __ 
-0' T1;.c. <=>Cr .. 0.84 0.0012 232 
V,(L) <:::> PC\ 0.76 <0.05 239 T1t~ ¢:> Cr, 0.72.5 <0.01 23-t 
V ... (L) ¢:> PC\• 0.53 <0.05 228 Cr, <=> PC\ -0.62 <0.01 229 
V,(L) ¢<> PCA" 0.62 <0.05 228 CL(L/h) <=> B\\!..,...1/Cr .. 0.96 <0.01 247 
V"(L) <=> PNA 0.41 <0.05 237 
DisJrib11!iM (L! l::.gj 
V .. JL/kg) ¢:> GA 0.29 <0.05 239 
CL= vancomycin cl=cc. PC\= posrconccption:1l age, B\\l=body \vcight. Cr,= serum crcatinin, 1=r2 
G:\= gcst:rtion:li age, V, = volu.'Tle of distribution in steady state. P::\'A = posm:tt:li age, CL:r = cn:atinin clearance, 
K1 = elimination rate const:tnt, BSA= body surScc :J.te:L. ·'first dose. 0stt:ady state, cocf. =correlation coefficio:nt 
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AJl three factors have been related to vancomycin pharmacokinetics in neonates (table 7). 
A significant relation between unstandardized vancomycin CL (ml/ min or L/h) and 
gestational age has been noted, but in all of these studies significance disappears \.vhen 
clearance is normalized for body \.veight237-239• 244. The same studies have described Vs, in 
relation to gestational age and again significance disappears in all but one study \vhen V >s 
is described in L/kg 239. This implies that if weight is incorporated, GA is not an 
important determinant of vancomycin V,~ or CL. Several authors demonstrated the 
relation bet\veen P::--JA and standardized clearance (rnl/kg/min) or Vss (L) 230.237.239.241. 
Ko correlation \.Vas found by many others 20s. 228.232,236, 244.247. V~, (L) but not standardized 
Vs, (L/kg) has been related to PNA 237.244. Postconceptional age has been \.Vell described 
in relation to pharmacokinetic parameters for vancomycin. Unstandardized CL (rnl/min) 
180. 208. 228. 237. 239. 241. 244. 247 and standardized CL (rnl/kg/ min) 1so. 208. 229. 230, 234. 236. 237. 241. 244 
has been related to PCA. A concomitant change in t1;2~ has been noted as \vell 229. 234. As 
\.v-1th P~A, only unstandardized Vs, (L) has a significant correlation \.vith PCA20s. 228.237.241. 
244
. The dimi.nished influence of GA and P::--.JA can be explained by several factors. First 
the combined effects of GA and PNA are integrated in PCA. Although a stronger 
increase in renal function in term infants has been described earlier, the frequent prenatal 
exposure of neonates to corticosteroids seen over the last 5-10 years might mitigate the 
difference bet\veen term and preterm neonates, and therefore limit the effect of GA on 
clearance 91• Furthermore postnatal increase of GFR seems to be higher than intra-uterine 
increase 99. At the same PCA, this might imply that the effect of slower maruration of 
kidney function .in premarures is cancelled out by the difference in intra- and extrauterine 
development of GFR. A third and maybe more important factor is that vancomyc.in is 
seldom given in the first \Veek of life. Since a large increase of kidney function in neonates 
takes place in this period, the dynamics of these changes and their influence on 
vancomycin pharmacokinetics arc not seen .in the studies mentioned here. 
In most studies \vhere both the .influence of PCA as \Veil as PNA were studied 
significance of PCA out\Veighed that of PN"A 237. 239.241• These data suggest that clearance 
in relation to postconceptional age is the main determinant .in the pharmacokinetic profile 
of vancomyc.in in neonates. 
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Effect of patent ductus arteriosus, indomethacin and extracorporeal membrane 
ox-ygenation 
Prenatal as well as posmatal exposure to indomethacin has been sho\vn to negatively 
affect increase of kidney function in neonates 91, 268. 269. Open ductus Botalli can increase 
Vss and decrease CL in neonates99, 270. Several studies have addressed the effect of 
indomethacin treatment of open ductus Botalli on vancomycin pharmacokinetics in 
nc\vboms 239-241. 249. Asbury described 4 patients exposed to indomethacin and compared 
them to 19 \vith no exposure (table 6) 241 . Clearance was half that of the no indomethacin 
group, \vith a concomitant change in tuz~. The authors concluded however, that only in 
one patient the decrease of renal function could be attributed to indomethacin. Spivey et 
al. outlined a study in 11 neonates of whom 6 were exposed to indomethacin for closure 
of open ductus Botalli (table 6) 249. Volume of distribution was higher and clearance 
substantially lower in the indomethacin group resulting in a tt/.2~ of more than 24h. Ko 
specifics about peak sampling \vere given and the non-indomethacin group had 
substantially higher GA and PKA. Therefore a clear relation \vi.th indomethacin treatment 
could not be ascertained. Silva et al. outlined a study in 44 patients; 26 received 
concomitant treatment \vith indomed~acin and/ or mechanical ventilation 239• In these 26 
patients clearance was lower than in the other 18 (0.07 vs 0.086 L/kg/h). Although a 
definitive conclusion can not be made on the grounds of these data, they suggest that 
indomethacin treatment of open ductus Botalli leads to an increase of Vs, and a decrease 
of CL, warranting extra therapeutic drug monitoring in these patients. 
Hoie and od~ers were the first to describe vancomycin pharmacokinetics in 6 patients on 
EC:\£0271. Values for V, (0.68±0.12), CL (1.10±0.32 ml/kg/min) and elimination half-
life (7.71±2.61) '\verc not different from values in d~e literature for patients 'Without 
ECMO. Amaker and Bhatia studied 12 term neonates with a PNA of 0-6 days on ECMO. 
These patients had a CL of 0.78±0.19 ml/kg/min, a V, of 1.06±0.45 L/kg and a h/2' of 
16.9±9.5h. Clearance was lower than that seen in other groups of patients 'With a PCA>37 
\veeks and VS$ is higher zso. Creatinin in these patient was relatively high though \vith 
values ranging from 53 to 168 [J.mol/L. Bucket al. did a case-control study in 30 patients, 
of which 15 \Vere on EC:.\fQ240. Patients \Vere matched with historical controls for 
underl:ying disease and several other clinical factors. Renal function expressed in terms of 
serum creatinin was worse in the EC:'viO group (0.8±0.1 vs 0.6:!:0.2 flmol/L). Patients on 
ECMO had a mean GA of 38.8 weeks and a mean PNA of 12.7 days. ECMO patients 
had a slight, but significant higher half-life (8.29 vs 6.53h) and lower elimination rate 
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constant (K.:G 0.09 vs 0.12 h-1). Although these studies \vere relatively small and results 
\Vere some\vhat obscured by differences in renal function a longer half-life in vancomycin 
treated neonates on EC\10 is likely. 
J\ficrobiological and clinical susceptibility and efficacy 
Vancomycin is still \v-idcly used as the first-choice antibiotic for treatment of CONS 
infections in neonates. This choice is mostly based on the in-·vi.tro bactericidal activity of 
this antibiotic against gram-positive infections. A second reason is that emergence of 
vancomycin resistant pathogens in the )JICC is slo"\v in contrast to cephalosporin induced 
resistance108. Data on clinical efficacy in adults arc scarce. There is no correlation bet\veen 
serum vancomycin concentrations and clinical cure. Regimes associated 'vith peak and 
trough concentrations ranging from 18-47 ;;.g/mL and 2-13 ;;.g/ml, respectively, sho"\ved 
acceptable rates of effectiveness, but failures in these treatment groups had the same 
serum concentrations272. Serum bactericidal titers (SBT) of more than 1:8 arc related to 
rreatment success and high minimal bactericidal titers to :rviTC ratio's to treatment failure, 
but exact information pertaining to efficacy does not exist273. 274. Fi.-....::ed doses of 1g every 
12 hours or 7.5 mg/kg every 6 hours have been documented to be effective against 
staphylococcal and streptococcal infections265. Information in neonates is also difficult to 
find. The first study describing vancomycin use in 23 children, described 6 infants \vi.th 
staphylococcal infections, of whom 4 \Vere cured "\vith doses of 40-180 mg/kg/ day (i.v. or 
i.m.)214. An early study by Schaad et al. evaluated the susceptibility of 20 strains of S. 
aureus and 6 strains of S. epiderJJJidis from a group of 55 neonates, infants and children. 
Except for one tolerant strain of S. ourem: an SBT of 1:8 or greater \Vas observed \v-ith 
vancomycin concentrations of;::: 12 mg/L. 
A further study by the same authors detailed antibiotic treatment of 33 patients of whom 
10 were neonates and 11 were infants254. Indications for treatment were septicemia, shunt 
infections, pneumonia, abscesses, fasciitis and cellulitis. In 29 out of 33 patients S. o!frelfJ 
or S. epidermidis was cultured. Eleven of 33 patients received co-treatment "\v-ith another 
antibiotic. Serum concentrations were 18.4-57.1 mg/L (peak) and 3.1-18.8 mg/L (trough). 
The relation benveen these concentrations and antistaphylococcal activity were evaluated 
for 21 patients. In one patient 'l.v-ith recurrent septicemia by a tolerant strain of S. a!frms no 
bactericidal activity was seen, all other samples had bactericidal titers of 1:8-1:32 against 
the isolated pathogen. In all 19 patients who were re-cultured, the causative pathogen was 
eradicated. All but one of 33 patients improved clinically. This patient, a 12-year old girl, 
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had possible brucellosis. Ko details on which of these patients were neonates or infants 
\Vere given. In a smdy of 17 neonates and infants (14 patients '\Vith S. a!frms and 3 "'ri.th 
S. epidermidis infections), :.Jaqv'i et al. reported clinical success in 16/17 patients236. All 
patients had been pretreated \Vicl1 aminoglycosides. The one failure was a patient \vicl1 
recurrent endocarditis due to a vancomycin-tolerant S. al!retts. :\ican peak and trough 
serum concentrations in these patients ranged from 30.4- 57.8 mg/L and 9.5-15.1 mg/L, 
respectively. 
Lisby-Sutch and others described 11 patients in \vhom bactericidal titers were determined 
for infecting organisms23°. Serum inhibitory titers \Vere :;::.1:8 in 10/11 peak serum 
samples, \vith peaks ranging from approximately 10-45 mg/L. In the smdy by Reed et al., 
in \vhich infants were treated for S. epidermidis sepsis, 14 out of 15 patients sho'\ved clinical 
recovery, with initial peaks ranging from 18.8-73.3 mg/L and trough from 5.1-38 mg/L, 
respectively. No details about susceptibility were given and all patients were pretreated 
v.ith an arninoglycoside and a ,S-lactam antibiotic. Pa\vlotsky et al. showed dut continuous 
infusion of vancomycin was effective in 13 documented invasive infections v.ith 
concentrations ranging from 3-37.6 mg/LJSO. There are no definitive data relating serum 
concentrations to effect. These smdies, \v'i.th relative few numbers of patients, show clut a 
wide range of vancomycin peak and trough concentrations arc effective against gram-
positive infections in neonates and infants. But, on a critical note, these results do not 
validate the therapeutic range of peak concentrations of 20-40 mg/L and trough 
concentrations of 5-10 rng/L often mentioned in the literature. 
Choice of antibiotic and drug resistance 
Enterococci are a related genus of gram-positive catalase-negative cocci 275. They are a 
pathogen kno'\vn to cause outbreaks of disease in NICV's 276-278• Vancomycin resistant 
enterococci (VRE) infections in neonates can be accompanied \vith an increase of 
mortality279. Vancomycin use is a consistent risk factor for coloni2:ati.on and infection with 
vancomycin-resistant cnterococci2SO. Emergence of 'VRE has become a major infection 
control problem, especially in rl1e Lnited States. In the )Jed1erlands coloni2ation v.ith 
VRE ofhospi~ed patients seems to be relatively low 2s1. Vancomycin is mostly used in 
the setting of late onset (occurring after 3 days of age) sepsis. The choice is made on tl1.e 
basis rl1at CO:.JS are the most common pathogens in this period 282· 283. COKS is not 
however associated '\Vi.th fulminant late-onset septicemia in neonates. The mortality in 277 
neonates \vith late-onset CQ)JS septicemia \Vas 1% in contrast to late-onset gram negative 
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sepricernia, \.vhich had an associated mortality of up to 56% 282. This has implications for 
choices of empiric antibiotic treatment. Several authors have sho\.Vn prophylactic usc of 
lo\.v doses of vancomycin or teicoplanin to prevent late-onset septicemia in VL\W 
infants219-222, 224. 284. 2ss. An increase of VRE \.vas not reported, but the potential risk of 
development of vancomycin resistance in NICU's through injudicious usc of vancomycin 
has been pointed out22L 2ZU82. 286. Given the overall concern about vancomycin resistance, 
vancomycin prophyla..xis does not seem to be warranted at this time. Alternative 
antibiotics for empiric treatment are effective in the initial treatment of late-onset sepsis 
neonates. Cephalosporins and ~-lactam antibiotics have been effectively used as empiric 
treatment for gram-positive infections, \.vi:th a S'\vitch made to vancomycin when 
methicillin resistance was determined282. 287· 288. The postponed usc of vancomycin '\Vas 
not associated to treatment failure or increased mortality in these patients. 
A highly selective use of vancomycin seems to be justified by these studies. 
Toxicity 
Toxicity related to vancomyan usc has been the subject of numerous reports. 
Complications include Red man syndrome, neutropenia, thromboc:y"'topenia, eosinophilia, 
trombophlebitis, chills, fever, rash, nephrotoxicity and ototoxicity. Three cases of cardiac 
arrest (t\\ro fatal) associated "vith rapid infusion of vancomycin have been describcd214. 289, 
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. The most frequent problem encountered was the Red man syndrome, a histamine 
mediated rash of the face, neck, upper trunk, back and arms. This phenomenon, 
associated "vi.th pruritus, tingling flushing, tachycardia and shock, is related to the rate of 
infusion 170. It has been described in neonates and children, related to an infusion rate of 
< 1h by Schaad ct al., but also in 7 out of 20 patients '\v-ith infusion rates of 1h by 
Odio~45- 252. The incidence of most of these side effects has decreased enormously with 
the removal of impurities from early preparations in the 60's. ~ephro-and ototoxicity '\Vi.ll 
be described in more detail 
1:-lephroto:...,·ici!J' 
Vancomycin can cause reversible nephrotoxicity in man and has been studied extensively. 
Animal models have failed to demonstrate significant nephrotoxicity when vancomycin 
was given alonc29L292. Vancomycin can enhance aminoglycosidc ID.duced renal toxicity in 
animals and possibly ID humans161• 213. The incidence mentioned in adults varies. Some 
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studies did not detect any toxicity \.vith vancomycin monotherapy 294. In other studies in 
adults nephrotoxicity ranges from 5% in patients receiving vancomycin alone to 18% in 
patients \vi.thout control for other variables possibly influencing toxicity 272. 293. 295. It has 
been related to trough concentrations > 10 mg/L, but in most studies it remains unclear 
'\vhether elevated serum trough concentrations are the cause or consequence of renal 
failurc295. 296, Nephrotoxicity has been studied in several groups of neonates, though 
seldom explicitly. Many studies could not detect any nephrotoxicity 232. 236. 245. 247, 254. 297. 
These studies total 61 patients treated from 4 to 28 days, '\vi.th serum concentrations 
ranging from 1.9 to 92.5 mg/L. The earlier studies by Schaad and co-workers sho'\ved no 
difference between baseline and post-treatment serum urea and/or creatinin in 20 
neonates infants and children 245.254. Jarrett et al. did not find clinical or biochemical signs 
of renal failure in 11 patients in whom a baseline creatinin was determined 232• In another 
study 3 out of 12 VL \XIB infants had a rise of serum creatin.in of more than 0.3 mg/ dl 234. 
In 2 out of 3 patients serum creatinin normalized \vi.thin days of stopping treatment, the 
third patient died but obduction did not reveal renal abnormalities consistent with drug 
related nephrotoxicity. Gous et aL could not demonstrate a rise in mean serum creatin.in 
in lS infants bet\veen day 0,2 and 8 of treatment 231. Three of these patients had an 
increase of more than 50% of serum creatinin, but all three were also exposed to 
aminoglycosides, as was the patient described in a case-report 293. A case report sho'\ved 
that a vancomycin induced rise of serum creatinin in 2 children normalized after adjusting 
vancomycin concentrations to the therapeutic range. ::\faqvi and associates did not find 
ev-i.dence of renal toxicity in 17 neonates and infants treated for 10-42 days; all patients 
were also exposed to aminoglycosides236. T'\vent:y VLB\V infants displayed no change in 
serum creatinin or tubular function during vancomycin treatment (4-13 days)297. 
In a study using continuous infusion of vancomycin only one neonate out of 53 showed a 
reversible increase of serum creatinin 18°. The effect of simultaneous use of vancomycin 
and an aminoglycoside was prospectively evaluated in 61 infants299. ::\fo evidence of renal 
toxicity in terms of serum creatinin or urinalysis abnormalities was seen. Finally, Bhatt-
::\1ehta et al. looked at the effect of peak serum concentrations on renal function in 
neonates \vi.th a mean PCA of 32.4 wceks3°0. Patients were div-i.ded in two groups, 61 
patients \'Vi.th peak serum concentrations ::S 40 mg/L and 8 patients \'Vi.th peaks 
> 40 mg/L. ~ephrotoxicity was defined as a doubling of serum creatinin and was not 
seen in the group '\vi.th high peak serum concentrations. In the other 61 patients this was 
noted 6 times, but a doubling of serum creatinin to values of >53 flmol/L was only seen 
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in 3 patients. Interestingly, peak concentrations > 40 mg/L were only seen in neonates 
"\vi.th a baseline serum creatinin of >53 p..mol/L (0.6 mg/dl). This association was also 
found for trough concentrations > 10 mg/L. 
The overall conclusion from this information is that vancomycin induced nephrotoxicity 
.in neonates is rare, reversible, and there is no clear relation to serum concentrations. 
Ototoxicity 
Information on vancomyc.in ototoxicity is scarce. Vancomyc.in is said to be potentially 
vcstibulo- and cochlcotoxic3°1. T.innitus seems to precede hearing loss. As '\Vith 
aminoglycosides, hearing loss is more pronounced .in the high frequency range 
(8-16kHz) :m. There arc animal studies relating ototoxicity to vancomycin in comb.ination 
'\vith an aminoglycosidc, but little evidence for ototoxicity of vancomycin alonc302. 303. The 
first report of vancomycin related ototoxicity .in humans '\vas in 1958166 .• Reported 
incidence of ototoxicity .in adults is fc"\ver than 2% 272. Reports on ototoxicity are fraught 
with methodological problems. Most studies "\vere retrospective and included patients 
\vho had been exposed to other ototoxic medication, mainly aminoglycosidcs3ot. 
A relation bct\.vcen vancomycin related ototoxicity and serum concentrations could not be 
demonstrated from available literaturc293 . .t\ confounding factor, as in nephrotoxicity is, 
that the time of serum sampling .in relation to dose is not al"\vays mentioned, "\vhich douds 
.interpretation of these serum concentrations. Data on vancomycin ototoxicity in neonates 
arc almost non-existent. l"eonates born to mothers who received vancomycin .in the 
second or third trimester of pregnancy did not sho"\v hearing loss304. Brainstcm evoked 
response audiometry and behavioral audiometry did not demonstrate any ototoxicity in 12 
neonates and chilclrcn2s.+. One case report described a repeated accidental overdose .in a 
47 day old prcmature305. Although serum concentrations were in excess of 100 mg/L for 
4 days, no hearing loss "\vas found "\vi.th brainstem evoked response audiometry during 
follow-up. Hearing loss .in humans exposed to vancomycin is sporadic and no clear 
relation to serum concentrations or patterns of underlying illness can be detected . 
. Although the absence of case reports of vancomycin induced hearing loss .in neonates 
suggests that this is very uncommon, data in neonates are insufficient to form any 
conclusion on the relationship bet\veen vancomycin and ototoxicity. 
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Vancomycin dosing and dose interval 
As in other drugs, vancomycin dose and dosing interval are determined by its desired 
therapeutic range and pharmacokineric properties. Historically, vancomycin dosing has 
been titrated to obtain peak serum concentrations between 20-40 mg/L and serum trough 
concentrations of 5-10 mg/L. There is little scientific e\ridence for both ranges. The 
upper limit of 40 is based on the fact that the earliest study, describing ototoxicity \vid~ 
peak concentrations > 80 rng/L suggested that peaks should not exceed 50 mg/L166. As 
described before, there is no clear relation bettveen oto- or nephrotoxicity and serum 
concentrations. r\lso, there is no microbiological or clinical evidence for increased 
effectiveness of vancomycin at advised peak concentrations. The lo\ver limit of the range 
for trough concentrations seems to be reasonable. Susceptibility of most micro-organisms 
for which vancomycin is used is <1-2 mg/L. \V'ith a ma.:illnal protein binding of 50%, this 
means that vancomycin trough concentrations \\ill have to exceed 4 rng/L to stay above 
the 1viiC306. Although there are some reports relating nephrotoxicity to trough serum 
concentrations> 10 mg/L, there is insufficient ev1.dence to rigidly adhere to this goal295. 
Keverthcless, d~ese desired ranges of concentrations have been the goal of dosing 
regimens adv'ised in neonates and infants. The first report on vancomycin dosing in 
children used doses of 25-180 mg/kg/ day, \v'ith the highest dose used in an infant214. 
Following this first report many dosing regimens, related to PNA, PCA, body\\reight or 
serum creatinin, have been defined (table 8). The first dosing advice, based on 
pharmacokinetic studies in 21 infants, related dose to P::-JA245. The advise of 
10 mg/kg q 6h for infants older than 30 days "\vas evaluated by Gous et al231• Despite the 
large interinclividual differences most serum concentrations were '.vi. thin the desired range. 
Three out of 15 steady state trough concentrations were lower than 5 mg/L, though only 
one was below 4 mg/L. This study also demonstrated important changes in 
pharmacokinetic parameters between day 2 and 8 of treatment in the same patient, 
possibly related to a normalization of physiological changes occurring '.Vi.th septicemia. 
Alpert et aL stuclied vancomycin dosing in 44 infants and children and used doses of 10-
15 mg/kg '.Vi.th an interval of 6-12h243. Trough serum concentrations were relatively high, 
especially when using a 6h interval. The guidelines based on this paper, though not 
mentioned in the article itself, were evaluated in the same insri.ru:tion in a group of 11 
infants247• Results of this study suggested reducing vancomycin doses in the first 1:\vo 
months of life, though no specific advice is given by the authors. 
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Table 8: Recommended dosing regimens in neonates and infants 
PNA PCA BW Serum Target Dose Interval Reference 
(days) (weeks) (grnms) crcatinin peak/ (mg/kg) (h) 
(t=ol/L) trough 
<7 25-40/<10 15 12 Schaad, 1980245 
8-30 15 8 
> 30 10 6 
> 30 and CKS infection 15 6 
~14 29-35 <1000 25-40/2-12 25 LD, 15* 12 Gro$5, 1985242 
~14 29-35 >1000 25-40/2-12 12.5 LD. 10* 12 GrO$S, 1985242 
<41 25-30/<10 15 LD, 10"" 8 Kaqvi, 1986206 
>43 25-30/<10 15 LD, 10"' 6 Naqvi. 1986= 
< 27 <800 30/6 27 36 James, 1987:!:1~ 
27-30 800-1200 24 24 James. 1987229 
31-36 1200-2000 18-27 12-18 James, 1987m 
"?:.37 >2000 22.5 12 James, 1987= 
:::36 25-35/5-10 10 12 Reed, 198722~ 
30-34 <1200 25-35/5-10 10 12 Lisby-Sutch,19SS71 
30-34 >1200 25-35/5-10 10 8 
35-42 >1200 25-35/5-10 10 8 
>42 >1200 25-35/5-10 10 6 
25-32 < 1000 25-40/<10 15 24 Leonard, 1989234 
>14 >30 :::o.6 10 8 Kildoo, 1990244 
>14 >30 0.7-1.2 10 12 
~7 <30 20-40/<10 15 24 Gabriel, 1991 ~oa 
>7 <30 :::1.2 10 12 
:::; 14 30-36 10 12 
>14 30-36 ::;o.6 10 8 
>14 30-36 0.7-1.2 10 12 
9 >36 10 12 
>7 >36 :::o.6 10 8 
>7 >36 0.7-1.2 10 12 
<27 <800 25-35/5-10 18 36 McDougal19952"..a 
27-30 800-1200 18 24 
31-36 1200-2000 18 18 
>36 >2000 15 12 
PNA= posmat:tl age, PCA= postconceptional age, B\V' = body">vcight, LD= loading dose;• maimcn:mcc dose,*"' 
!T'.ai.ntenance dose P" day, 1Serum creati.nin in mg/dl, ~no indomethacin and/or mech=i.cal ventilation, 
3indomcthacin :md/ or mech=i.cal ventilation 
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Table 8 (continued): Recommended dosing regimens in neonates and infants 
PNA PCA BW Senun Target Dose Interval Reference 
(days) (weeks) (gmms) ercatinin peak/ (mg/kg) (h) 
(!=ol/L) trough 
532~ 12.5 12 Sih·a., 1998~J9 
5323 10 12 
>32~ 10 8 
>32:. 7.5 8 
7-30 <1000 10 18 Schaible, 1986247 
1000-2000 10 12 Alpert. 1983"43 
>2000 10 8 
31-60 10 6 
>60 10 6 
25-26 7 LD. 10*'" Continuous Pawlotsl.-y, 19981aa 
27-28 7 ill, 12** Continuous 
29-30 7 LD, 15** continuous 
31-32 7 LD. 18"* continuous 
33-34 7 LD, 20*A continuous 
35-36 7LD,23-~<* Continuous 
37-38 7 LD, 26** Continuous 
39-40 7 LD. 29** Continuous 
41-42 7LD,31~* Continuous 
43-44 7LD.34-"'" Continuous 
>45 7 LD. 40** Continuous 
20-29 20 8 Grimsley, 1999m 
30-39 20 12 
4{)-49 15 12 
50-59 12 12 
60-79 15 18 
80-1001 15 24 
>100 15 Depending 
on trough 
PKA- postnatal age, PCA- postconceptional :1gc, BW - bod)'\veight. LD- loading dose.* nuintcn:mcc dose,"* 
nuintenance dose pcr d::ty. 1Scrum crcatinin in mg/dl, 'no indomethacin :md/or mechanical ventilation, 
3indomethacin :.md/ or mcchanic:U ventihtion 
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Serum crearinin was higher than 53 t-tmol/L in 7 patients, which might have ske\ved 
results towards this conclusion. 
Gross et al. suggested a dosing regimen based on neonates \veighing either more or less 
than 1000 grams242. This advice was based on data in 9 prematures, of whom only 3 were 
< 1000 grams. One of these three had a high serum creati.nin of SO ~g/ml, so results for 
this group are doubtful. A loading dose of15 mg/kg followed by 10 mg/kgwith an PCA-
related interval based on average Vss and I<ci was advised by :-.Jaqv"i and co-workers 
folloVving a pharmacokinetic study in 20 neonates236. The group of patients \vith a PCA 
greater than 43 \Veeks comprised only 6 patients. James et al. proposed a very detailed 
PCA-defined dosing regimen, after finding an excellent correlation between tt/2.3 and PCA 
in 20 preterm infants229. Wben looking closely at the graphs, it is obvious that there \vere 
only t\vo patients each in the PCA groups of< 27 and> 37 weeks, which undermines the 
validity for these PCA groups. In a subsequent study by the same authors they showed 
that using their dose recommendation in preterms improved the chance of achieving 
serum concentrations within the therapeutic range over the dosiD.g regimen as proposed 
by Schaad et al245. 307. 
In a third study by the same group, the authors studied 12 infants weighing less than 
1000g and rev"ised the original adv"ise of James et al. to use vancomycin once daily in this 
group234• Vancomycin was given once daily to 10 of these infants and doses varied 
bet\veen 9.4 and 27.3 mg/kg. Peak concentrations were adequate (32.6±9.3 mg/L), but 
trough concentrations were low (5.7±4.5 mg/L). Both the original as well as the revised 
regimen by James, was tested in a later study in 44 neonates208• Individual Vd and!(.,] per 
patient were used to simulate the original and revised regimen by James. These results 
were compared to the dosing regimen as adv"ised by the authors and used in this study. 
On the basis of these simulations the authors concluded that their dose recommendations 
\Vere more precise in achieving adequate serum concentrations in premature neonates, 
although they did not present data in patients with a PCA < 27 weeks. Kildoo and others 
investigated 15 preterm neonates using an institutional PKA and BW vancomycin dosing 
algorithm244. The substantial differences in clearance bct\vcen patients due to renal 
function led to a proposed regimen based on serum creatin.in higher or lower than 
0.6 mg/ dl. They also estimated that using the dosing regimen of James would have led to 
peak serum concentrations e.>::ceeding 40 mg/L in 11 out of 15 cases. Reed also adv"ised 
an extended interval for neonates \vith a PCA :S 36 weeks22S. Doses in this study were 
9.8-17.8 mg/kg, with an interval of S hours in all but one of the 16 patients. 
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High steady state trough concentrations \Vere seen, ranging from 8.1-38 g/L, leading to 
the advice of a 12h interval. A confounding factor in the interpretation of thls study is the 
relatively high serum creatinin prior to therapy of up to 115 y.mol/L. Lisby-Sutch and 
~ahara developed a PCA and weight based regimen on grounds of a study in 13 
vancomycin treated infants230. There was a good correlation bet\veen daily vancomycin 
requirements and PCA, when 4 patients \v"'ith hepatic or renal disease ·were excluded. \\lith 
thls in mind, the subdivision into 4 groups in the dosage guideline has a very small basis. 
Asbury et al. studied pharn:ucokinetics of vancomycin in 19 neonates \vithout and 4 '.Vi.th 
indomethacin c_'(posure 241• The authors postulated that dose and dose interval in patients 
without indomethacin would lie in the range of 29.6 mg/kg/d vvith an interval of 6-!Sh. 
A limitation of this study \Vas that some of the peak serum concentrations as well as all of 
the steady state concentrations were calculated and not measured. The authors themselves 
do not advise to calculate vancomycin dosing according to their equations, until thls has 
been prospectively validated (table 9). Another study individualized dose and dosing 
interval on the basis of linear pharmacokinetic analysis on initial serum concentrations 
obtained after the initial dose of 15 mg/kg-232. Steady state peak and trough concentrations 
\Vere \vi.th.in the desired therapeutic range. Six out of eleven trough concentrations '\Vere 
lo'\ver than 5 mg/L ho\vevcr \vhich suggests an overestimation of t1;2~. 
Seay et al. studied 192 infants with a population pharmacokinetic model and found a 
relation bet\veen clearance and eA-posure to dopamine and/ or gestational age ::S32 weeks. 
Predictive performance of their dosing algorithm was prospectively validated in 30 
patients. Though the study results suggest using longer dosing intervals, no advice was 
made by the authors. 
Forty-four infants \Vere evaluated resulting in a dose recommendation depending on PCA 
and exposure to mechanical ventilation and/ or indomethacin239. Although the relation to 
indomethacin seems logical, effect of mechanical ventilation is harder to imagine. The 
authors described a relation between creatinin clearance and vancomycin clearance, but 
not with mechanical ventilation or indomethacin treatment alone. The clinical usefulness 
of the statistical relation to co-treatment found in thls study is doubtful. Pawlotsh.--y et al 
studied continuous administration of vancomycin after a loading dose in 29 
prematures 1so. PCA related dosing '\vas based on an evaluation of 24 other patients. This 
continuous dosing regimen led to steady state concentrations of 10-30 mg/L in 88%. As 
can be seen in table 8 the division in subgroups is very detailed and is, given the large 
inter-individual variation in pharmacokineti.c behavior bet\veen patients of the same PCA, 
S3 
probably not warranted. Grimsley and Thomson performed a population 
pharmacok.inetic analysis in 59 infants and based their dosing regimen on serum creatinin 
alone233. This regimen '.vas subsequently tested in 25 neonates and found to give more 
adequate trough serum concentrations. The number of patients \vith high serum creatinin 
in the prospective group was not mentioned. 
In conclusion, several dosing regimens in neonates have been proposed and tested. 
Studies based on PCA and/ or serum crearinin have shov.rn to achieve serum 
concentrations "'Within the therapeutic range20S. 231.234.238.3°7. Though an extension of dose 
interval to more than 8 hours has been suggested, especially .in VLBW infants, trough 
serum concentrations < 5 mg/L found in several studies should lead to caution in that 
aspecrzos. 230-234,307. 
Table 9. Formula's represmting dosing schedules 
Model 
1 compartment model 
1 compartment model 
1 compartment model 
2 compartiments model 
Formula 
CL (L/h):::0.0626xBW:x0.455"t:x0.6S6~-=-
vcl (L)=0.496 :x BW 
: CL(L/h)=0.007+6.875 X 10·5 X O.'i/ (g) 
Vd{L) = 0.034 + 4.991 x 10--tx CW(g) 
Vcl:::Q.562±15% L/kg (PC.r\::::32 weeks) 
Vcl= 0.498±16% L/kg (PCA>32 weeks) 
CL::: 0.07±41% L/kg/h (mdomcthacin ::r.nd/ or mechanical 
ventilation) 
! CL::: 0.086::!:35% L/kg/h (no indomethacin or mcclunical 
ventilation) 
CL(L/h)=0.0281:x PCA(weeks)-0.818 
Vcl(L)= 0.557:x BW'(kg)-0.051 
Vancomycin dosage (mg/kg/ d)=1.7835:xPCA(>vecks)-31.36551 
! V ancomvcin dos:1 e m k d'=1.5357:xPCArweeks -26.4576~ 
CL(L/h)=0.0224:xPCA-0.639 
CL(L/h) =0 .06xBW (kg) +0.09 5x(1/Scr)-0.141 
Vcl(L)=0.563xB\~'(kg)+0.052 
Author 
Scay, 19942~ 
Silva, 1998Zln 
i Asbury, 199Y41 
Sch:rible. 1986247 
CL= clearance. BW'= body,veighc. V" :::volume of distribution. PCA= postconceptional :1ge. Z1=1 if e::,:posed to 
dopamine. else 0, Z2=1 if G_,\.:::;32 weeks, else 0. 1Targcts= pe:tk 25-35, trough 5-10 mg/L. ~::r.rget = ste:ldy state 
concentration of 15 mg/L. 
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Therapeutic drug monitoring 
Therapeutic drug monitoring of vancomycin is mostly performed at steady state, '\\ti.th 
serum concentrations taken just before and lh after completion of the intravenous 
infusion. Target concentrations are peaks bet\'Veen 20-40 mg/L and troughs of 5-10 
mg/L. Peak serum concentrations depend on the timing of sampling and since there is a 
'\\ti.de variety in sampling time in relation to dose, this should be taken into account \vhen 
setting goals in therapy309, 310. Strangely enough, despite these differences in timing most 
authors adhere to the same peak level goals. 
In general, routine therapeutic drug monitoring is only rational \Vhen the drug has the 
follmving characteristics265. First a good correlation must exist between serum 
concentration and effect or toxicity. Second when this correlation exists, there must be 
large interindividual differences in pharmacokinetic beha"i.or bet\vcen patients. Third the 
clinical effect or toxicity of the drug must be hard to determine or have a delayed 
presentation, othenvi.se TDM \vill not influence treatment. Fourth a readily available assay 
\vith an adequate assay error must exist. Fifth use of TDM should appropriately predict 
subsequent serum concentrations in the same patient. 
In the case of vancomycin use in neonates the first condition is not met. As discussed 
before, neither efficacy nor toxicity show a clear relation to serum concentrations, and 
this is especially true for peak values. The second condition is true; there is a large inter-
indivi.dual variation bet\veen neonates and infants with different PCA's 'Wi.th a 
concomitant effect on obtained peak and trough serum concentrations. There is hO'wever 
no clear relation of peak concentration to toxicity and effect, so the clinical importance of 
this inter-individual variation is doubtfuL Furthermore it has been sho"\YTI in neonates and 
adults that peak serum concentrations >40 mg/L are seldom seen '\\ti.th trough 
concentrations below 10-15 mg/L 311-313. Given these considerations routine monitoring 
of peak serum concentrations is questionable. A case can be made for monitoring trough 
concentrations, although this is also debatable. Based on in-vitro studies, vancomycin 
trough concentrations should exceed 4-5 mg/L3°6. Acceptable cure rates "'Wi.th trough 
concentrations ranging from 2 to 18.8 have been described in neonates 230,236, 254. Except 
for endocarditis, there are no clinical studies in neonates, children or adults which have 
substantiated the clinical need for higher serum concentrations167, Several dosing 
regimens, which have been discussed before, especially those \vi.th dose intervals 
exceeding Sh, have sho'\\tn that trough serum concentrations can be lower than 5 mg/L, 
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indicating a need for trough level monitoring 208. 230-234-. 307. Trough level monitoring 
should thus be aimed at ascertaining that serum concentrations remain > 5 mg/L 
The third and fourth point of requirements for effective TDM are met by vancomycin. 
Pertaining to point five, several studies have investigated the predictive performance of 
TD)1 "\vith vancomycin in the neonatal setting232. 235.237.238,246.311.312.314. Controlling dose 
and/ or dose interval \v:ith TDM can be performed using first order elimination kinetics, 
as proposed by Sa'\vchuk and Zaske, or '\v:ith a Bayesian method69. In adults Bayesian 
feedback is associated with a better predictive performance than the method of Sa"\vchuk 
and Zaske315. Jarrett and associates obtained serum concentrations 2.7 and 12h after 
initiation of a 60-minute vancomycin infusion, and determined Vo and t112~ using first 
order elimination kinetics 232. :Aaintenance dose and dosing interval were calculated and 
results showed that 9 out of 11 infants had peak concentrations within the therapeutic 
range in steady state. All troughs were < 10 rng/L. They also concluded that using only 
the 2 and 12h serum concentration \Vorked as '\Veil as using all three. 
Two studies, using 132 routinely collected paired serum concentrations, demonstrated 
that, as long as there is no overt renal failure, serum trough concentrations < 10 mg/L are 
seldom accompanied by peak concentrations > 40 mg/L 311.312. One other study found 
no relation benveen pre-dose and post-dose concentrations in 100 paired samples, but 
only 3 patients had a high peak serum concentration associated \v-i.th a low trough value235. 
In a group of 74 :infants and children, including 30 neonates, therapy was optimized by 
using paired serum concentrations after the first dose314. TDM goals were peak and 
trough concentrations of 15-60 and> 4 mg/L, respectively. Standard vancomycin dosage 
guidelines, which were not specified, '\vere used. Initial trough serum concentrations were 
lo\v in 5 out of 30 neonates '\vi.th. After optimization, only 1 neonate had an insufficient 
trough concentration. The authors conclude that monitoring of vancomycin 
concentrations is essential to prevent underdosing. 
Burstein et al. studied pharmacokinetics in 11 neonates in a 2 compartment open model 
'\vi.th serum concentrations taken 3 and 9h after initiation of a 1h infusion of vancomycin. 
They calculated an optimal sampling strategy \vi.th 2, 3 or 4 serum samples, using 
population based optimal sampling strategies. These strategies were tested on 100 
simulated cases. All strategies underestimated actual distributional and total clearance 
(L/kg/h) as well as central compartment volume and Vd (L/kg). They concluded that no 
more than t\vo samples (0.5h after a 1h infusion and a trough concentration) are needed 
for clinical purposes. A lot of assumptions were made in calculating individual 
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pharmacokinetic parameters \virh only 2 serum concentrations, which somewhat clouds 
the results obtained in this srudy. The best srudy has been performed by Rodvold and co-
\Vorkers237. They developed a set of population based parameters (see table 9) based on 
data in 29 neonates. The precision of rhe dosing regimen based on rhese parameters \Vas 
tested in 18 neonates, \V-irh 35 courses of vancomycin, in \vhom more rhan 1 set of peak 
and trough concentrations \vas available. Prediction of subsequent paired serum 
concentrations was performed using eirher rhe population parameters alone or \V-irh 
Bayesian feedback of rhe first paired serum concentrations. The Bayesian method 
performed slightly better when subsequent serum concentrations \Vere taken \v-ithin 30 
days of the initial set. Bias and precision for this period were -1.62 and 4.72 mg/L (peak) 
vs 0.65 and 1.74 (trough). Population-based parameters were superior after 30 days, 
underscoring the potential change in individual pharmacokinetic parameters over time. 
The authors conclude rhat additional feedback concentrations are needed approximately 
every 14 days. These srudies indicate that TDM \V-irh use of 2 serum concentrations can 
predict subsequent serum levels reasonably well. Peak concentrations e~ceeding 40 mg/L 
are unlikely \v-irh trough concentrations< 10-15 mg/L. 
In conclusion, vancomycin has shown to be an effective and relatively safe antibiotic for 
treatment of gram-positive infections in rhe neonatal setting. Concerns about 
development of resistance warrants judicious use. Several dosing regimens were 
successful in aclUeving target serum concentrations. In rhe light of in-vitro and in-vivo 
studies of efficacy and toxicity it is unlikely that peak concentrations play a major role. 
TDM should therefore probably be aiming at producing trough concentrations 
> 5 mg/L, except for patients wirh certain specific illnesses like endocarditis. ::\feonates 
\V-ith renal failure should be monitored more closely. 
Further studies \ViJl have to determine dosing regimens adhering to this new target range. 
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1.3. Aims of the studies 
Chapter 1 sets out to rev-i_ew the literature pertaining to clinical, pharmacokineric and 
pharmacodynamic aspects of amlnoglycoside (including tobramycin) and vancomycin use 
in neonates. At the end it states the aims of the studies provided in this manuscript. 
Chapter 2 \V"ill describe the use of pharmacokinetic modeling of tobramycin antibiotics in 
neonates. Two methods of phannacokincric modeling, non linear mi'\.ed effects modeling 
(KO!\:;\iliYr) and non parametric expectation ma.x.imization (NPE:Yl), 'Will be compared 
in the setting of routine therapeutic drug monitoring in a neonatal intensive care unit 
(KICL~. 
Chapter 3 addresses the questions relating to pharmacokinetics and therapeutic drug 
monitoring of tobramycin in neonates. In chapter 3.1 a gestational age related tobramycin 
dosage regimen for neonates is developed and prospectively validated using routinely 
collected peak and trough serum concentrations. These data are analyzed in a population 
phannacokinetic model '\vi.th the follo\Ving questions: 
1. Is there a need for extended interval dosing of tobramycin in neonates ? 
2. Is there a relation bet\veen gestational age and dose or dosing interval ? 
3. Is there a need for a loading dose of tobramycin in neonates ? 
This proposed dosing reg1men is prospectively validated in a group of neonatal intensive 
care patients. In chapter 3.2 the use of early therapeutic drug monitoring is investigated. 
The follo\Vi.ng questions are adrcssed: 
1. \Vill the dosing reg1men mentioned in chapter 3.1 lead to effective peak serum 
concentrations after the first dose ? 
2. Is it possible to predict individual trough serum concentrations of tobramycin by t\vO 
serum samples taken 1 and 6 hours after the first dose ? 
3. \\!hat is the relation between individual dose intervals and gestational age of the 
patient? 
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Chapter 4 sets out to describe the pharmacokinetics of vancomycin in neonates. In 
chapter 4.1 a dosing regimen for vancomycin in neonates is developed. The following 
issues were studied: 
1. Is there a need for a gestational age dependent dosing regimen in neonates? 
2. Is there a need for the routine measurement of peak serum concentrations of 
vancomycin in neonates ? 
In Chapter 5 \Ve evaluate the relative risk of hearing loss in neonates exposed to 
tobramycin and/ or vancomycin. In chapter 5.1 \Ve designed a study using otoacoustic 
emissions to determine high frequency hear:ing loss in three year old children who have 
been treated on the neonatal intensive care unit. The purpose of this study is to: 
1. Determine whether high frequency hear:ing loss occurs in children \vho have been 
treated \vith tobramycin in the neonatal period. 
2. Relate hearing loss to serum concentrations and duration of therapy of tobramycin. 
In chapter 5.2 \Ve analyze results of routine neonatal hearing screening (A-ABR screening) 
performed in the NICU of the Sophia Children's Hospital. Screening results "ill be 
related to e."posure to tobramycin and/ or vancomycin. 
Chapter 6 is the concluding chapter in which the results of the previ.ous studies are 
discussed. Recommendations about dosing, dosing intenral and in&ddual therapeutic 
drug monitoring of tobramycin in neonates are made and suggestions for future research 
in this area are presented. 
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Chapter 
2 
Population modeling of tobramydn in nconates:a comparison ofKOK~M and NPE:.\12. 
M. de Hoog, R.C. Schoemaker, J. 1\i. van den Anker, AA Vinks 
S11bmitted 

SUMMARY 
::-.Jonlinear mixed effects modeling (NO::--.Jl\1E}.1) and nonparametric expectation 
rna..ximization (NPE~I2) have both been used in population modeling of tobramycin. We 
compared both methods for differences in population phannacokinetic parameters in 
relation to error models used. Predictive performance \Vas compared bet\veen models. 
A group of 470 neonates who had received tobrarnycin \vith a gestational age dependent 
dosing interval \vas analyzed according to a one-compartment model "vith NON.NIEM 
and NPE112. Additional models were made "vhere the assay error pattern in :\JPE:Yf2 
mimics :\JON11EM residual error and vice versa. Individual phannacokinetic parameter 
estimates were compared. Predictive performance was evaluated in a separate group of 61 
patients. Population estimates and variation coefficients (CV) for optimal models \Vere: 
NOK:'vffiYl K.; 0.071 h-1 (27%), v, 0.59 L/kg (9%), l\iPEM2, I<o, 0.079 h-1 (42%), 
V, 0.65 L/kg (48%). Forcing NO:\IMEM to use the :\IPEYI:2 error pattern as residual 
error or vice versa resulted in smaller differences in CV's of the estimates. ~O='J.01E:NI 
gave less bias (p<O.OS) than NPEM2 and comparable precision with this approach. In 
conclusion ~QN}..ffiM and ~PE:.\12 are dissimilar in population estimates. Differences in 
ranges of pharmacokinetic parameter estimates bet\veen ~ON.YIE:VI and KPEi\12 are 
largely determined by the method of incorporating error patterns in both programs. 
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INTRODUCTION 
Therapeutic drug monitoring plays an important role in the optimization of 
aminoglycoside dosing regim.es in neonates. Several nomograms and models 
incorporating gestational age, weight, postnatal age, co-meclication and other possible 
descriptive factors have been tested to define the optimal a priori dosing regimen for this 
v"Dlnerable population. However, due to the large inter-patient variability dose 
indiv-i_dualizarion based on serum concentration measurements early in therapy remains 
necessary. Bayesian feedback methods using population models have been sho'\VTI to be 
clinically superior and cost-effective in this respect1. l'onlinear mi:xed effects model 
(KOJ'.::Yffi:\,1) and the nonparametric expectation ma.'\lrnization (NPEM2) algorithm have 
been used for population pharmacokinetic modeling of aminoglycosides in neonates2•6. 
Both methodologies give an estimate of the interinclividual variability within a sample of 
subjects from the target population, given the data of past doses and responses (serum 
concentrations). Typically population phannacokinetic models are defined as the mean or 
median phannacokinetic parameter estimates \vi.th interpatient variability characterized by 
the standard deviation (SD) or coefficient of variation (CV). In addition, :\IPE:YI2 gives 
the full population probability distributions while KON:\1E:Vf provides estimates 
(standard errors) of the precision of its parameter estimates, including those describing 
variability. 
NO)-J::\-ffiYf assumes a unimodel normal or lognormal distribution of phannacokinetic 
parameters in the population under study. KPEM2 makes no assumption about the 
distribution other than a limitation to the possible values. Both methods have theoretical 
advantages for clinical use. ~PE:.\1.2 gives a graphic output of the probability distribution 
of a given combination of pharmacokinetic parameter estimates Goint density plot), and is 
able to discover and quantitatively describe unsuspected sub-populations that can give rise 
to multi-modal population distributions. \Vith KOJ'{~ .. ffi:\1 clinically important covariatcs 
can be easily analyzed and incorporated into the model. Maire et al. "verc the first to 
describe preliminary data on relative differences beNreen the modeling methods for 
amikacin in geriatric patients'.Recencly, NO:-..Jl\ffiM and ~PEM2 modeling has been 
compared describing flucytosine pharmacokineticss. 
To date, no study has addressed potential causes for differences found in population 
phannacokinetic estimates generated by either method. The residual error models used in 
::-..JON11EM and the assay error pattern plus additional environmental noise caprored by 
gamma used in :-..JPE~ play an important role in determining population parameters, 
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and changes in these parameters are likely to influence the flnal model. Clinlcally the most 
relevant question is '\vhich method gives the most useful model for capturing interpatient 
variability and for predicting (and therefore control) serum concentrations in any next 
patient. 
The aim of the present study was to compare results of population modeling '\Vi.th 
::'\JOK.MEM and the nonparamerric EM algorithm by re~analyzing tobramycin therapeutic 
drug monitoring data in a neonatal population as described recendy 3• The predictive 
performance of ~0::-.JivffiM and KPEN12 generated models '\Vas evaluated in a separate 
group of 61 neonates which was not part of the population modeling. 
PATIENTS AND METHODS 
Patients 
The patient population for this study consisted of two groups of neonates admitted to the 
neonatal intensive care unit of the Sophia Children's Hospital, Rotterdam empirically 
treated 'Wi.th tobramycin for suspected neonatal sepsis in the first '\veek of life. 
Data of the first group of 470 patients were used to develop population pharmacok.inetic 
models (model generation group). Tills group received the following tobramycin regimen 
in a 30~minute i.v. infusion: GA less than 28 weeks 3.5 mg/kg/24 hrs,28-36 weeks 
2.5 mg/kg/18 hrs, more than 36 '.veeks, 2.5 mg/kg/12 hrs. Drug administration times, 
dosing regimens, blood sampling times and demographic data were collected and have 
been published pre,~ously3. 
Data of a second group of 61 patients (validation group) were used to validate the 
population models developed "vith data of the model generation group. The validation 
group received 4 mg/kg/ dose of tobramycin with an interval of 48, 36 or 24 hours 
depending on their gestational age of < 32 weeks, 32-37 '\Veeks and > 37 weeks, 
respectively. Data collected in both studies included gestational age, birth weight, 5 minute 
Apgar score and e::-.:posurc to indomethacin and/ or corticosteroids. 
Tobramycin concentration monitoring 
Serum concentrations were d:ra"vn just before and 30 minutes after completion of the 
fourth dose in the model generation group. In the validation group TDM '\Vas performed 
3 and 8 hours after the first dose and just before d1e second dose. Concentrations of 
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tobramycin '\vere measured by a Fluorescence Polarization Immuno Assay (FPIA) using a 
TDxFLx (Abbott Diagnostic Division, Amstelveen, :\IL). The assay error pattern for the 
tobramycin assay was: SD (mg/L)= 0.0599 + 0.0126 C+0.00438 C2, where C is the 
measured serum concentration (mg/L). 
Population pharmacokinetic modeling 
Tobramyc.in data of the model generation group were analyzed according to a one-
compartment open model, assuming the data were attributable to the fourth dose after 
birth, using 1\iOJ\:MEM population pharmacokinetics software (NONME:\1: version V, 
J\:0:\1:\iE:\1: project group, University of California, San Francisco, CA) ' and the 
NPEM2 algorithm (l'-.'PEM2, USC*PACK collection of PC programs, version 10.7, 
LAPI(, Los Angeles CA)10. The model parameters were the elimination rate constant 
(Kd; h·') and volume of distribution (Vd; L/kg). For 1\iOI\i:\iE:\1: and NPEM2 individual 
empirical Bayes' estimates '\Vere generated for IZ:l and V d based on the population 
estimates. 
Nonlinear Mixed Effects Model (NONMEM) 
Data were analyzed using first order conditional estimation (FOCE). A constant 
coefficient of variation .intra- and .inter-indi-vidual error was assumed. 
Two models were parameterized: 
1. A model parameterized in terms ofi.C.,1 and Vd in a standard :\101\iMEM analysis. This 
standard model was defined as the optimal 1\iOJ\:MEM model and was compared to 
the optimal NPEM2 model in the validation group. 
2. A model parameterized in terms of Kd and V d and a fixed residual error of 0.0599 
plus a proportional error of 5%. In this way the input residual error in the ~ONlvfEM 
model is comparable to the assay error pattern in ~PEM2 model 1 over the 
concentration range studied. 
With each model individual empirical Bayes phannacokinetic parameter estimates were 
generated by ~ON:y(E:y£_ 
Non-Parametric Expectation Ma.ximization algorithm (NPEM2) 
With :\IPEM2 the joint probability density functions (PDFs), population means 
(± standard deviation), medians (± dispersion factor) and individual parameter estimates 
for IZ:l and V d \Vere estimated using the assay error pattern for the tobramycin assay as an 
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ex"Plicit measure for intra-individual error. In the NPE_;vf2 program this assay error 
pattern can also be multiplied by a factor (gamma) which can either be user defined or 
estimated by the program as a means to account for other environmental noise. A change 
of less than 0.001% in the likelihood function was taken as the convergence criterion for 
:\IPEM2. Calculations were based on 20.000 grid points. 
Three different )JFE_;vf2models were parameterized: 
1. A I<ei and V d model using the tobramycin assay error pattern and a fi;;:ed gamma of 
1.0. This is the most widely used method in )JPEY12 analysis. This model was 
compared to tbe optimal NOI'::\ffiYf model in tbe validation group. 
2. A I<ci and V d model using the assay error pattern multiplied by a gamma of 2.82 as 
detemtined by tbe program. This way of modeling has recently been described, and 
may be a better way to model total error with )JPE:y£2 11 . 
3. A I<cJ and Vdmodel using an error pattern that mimics the residual error of 21% found 
in tbe first :\101\MEY! analysis (SD (mg/L) = 0.21 C). By using this approach tbe 
NPEM2 error model becomes comparable to tbe residual error of tbe first 
1':0:\IMEM model. 
For each model ma.;;:imum a posteriori (JYIAP) Bayesian estimation was used to generate 
individual Bayesian posterior parameter estimates by using the 'population of one' utility 
in tbe KPEM2 program. 
Predictive performance evaluation: comparison ofNONMEM and NPEM2 
models in the validation group 
The relationship between the observed tobramycin concentrations and concentrations 
predicted by the population models was evaluated with data of the validation group. For 
thls purpose the mean population pharmacokinetic parameters and standard deviations of 
botb optimal models were defined in tbe MW\PHAR.'v! program (Yf\'7\PHARM, version 
3.15A, MecliWare; Groningen, The Netberlands) 12• Three and eight hour serum 
tobramycin concentrations were used as Bayesian feedback to the models. Next, predicted 
trough concentrations estimated by d~e :\!Iarquardt algorithm were compared '\v1.th the 
observed trough concentrations for each patient. 
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Statistical analysis 
Statistical analysis was performed using SPSS (SPSS for Windows V9.0, SPSS, Inc., 
Chicago, IL). 
Individual pharmacokinetic parameter estimates for both NOKMEY! and NPE:\12 
models were compared. The predictive performance of NOKMEY! and ]';PEM2 models 
'\vas evaluated by comparing predicted serum concentrations "vith observed serum 
concentrations according to the method of Shdner and Beal 13. Bias '\vas calculated as the 
mean prediction error (ME; mean difference betw'een measured and predicted 
concentration), and is a measure of the systematic error. Precision was calculated as the 
mean squared prediction error (mean of the sum of squared differences bettveen actual 
and predicted serum concentrations QY.[SE), and represents the accuracy of the systematic 
error. The root mean squared prediction error is the squared root of ::Y.£SE and converts 
the measure of precision back to concentration units. Relative predictive performance was 
determined by comparing differences and confidence intervals of differences of ~SE and 
:ME for models. 
Individual parameter estimates for comparable NOKMEM and :'-JPE:\12 models were 
analyzed using descriptive statistics. Bayesian parameter estimates for ~O~lv.ffiM and 
KPEi\12 were tested for significant differences 'W-ith the \Vilcoxon signed rank test. A 
significance level of p < 0.05 was accepted throughout. 
RESULTS 
Demographic parameters of both study groups are summarized in table 1. 
Table 1: De111ographics of botb stucfJ' grotrps 
Variable 
Gestational age 
(weeks) 
Birthweight (g) 
:\!ale/ female 
:\' .S., nor ~igr-..ificanr 
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Groupl 
(n=470) 
Median (range) 
31.6 (23.7-42.9) 
1530 (485-5245) 
267/203 
Group2 
(n=61) 
Median (range) Difference 
33.4 (25.7-41.4) N.S. 
2029 (765-4500) ::-:.s. 
34/27 ::-:.s. 
Data of 4 70 neonates in group I were used for the generation of population models. 
Population pharmacokinetic models were evaluated for predictive performance in the 
validation group consisting of 61 neonates. There '\Vere no significant differences in 
gestational age, '\veight or gender benveen groups. 
Figure 1 sho'\VS the error patterns used in J'\O~lvfEM and NPEiY12 expressed as the 
relation bet\veen the serum concentrations and the standard deviation of the 
concentration over the '\Vorking range. 
Figure 1: Relation between sertJI7l concentration and error pattem used in ]\TQ]\T]\1EM and l\PEM2 
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The line portraying the residual error estimated by J'\ONMEM (model 1) of 21% 
approximates the assay error pattern times the gamma of 2.82 found by )JPE:Y12 
(model2). If residuil error in NOK:\ffi:YI (NO:-liviEM model 2) is fi:-;ed like d>e assay 
error pattern in )JPE:yu (model 1), as described in the methods section, the lines 
representing assay error for both models are approximately the same over the 
concentration range in this patient group. 
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Table II:pop11lation pharmacokinetic parameters for NONMEM and I','PEM2 models 
K,, (h'') v, (L/kg) 
(CV%) (CV%) 
NO:-.:~M model! 0.0713 (27 %) 0.593 ( 9 %) 
:c-.:ONMEM model2 0.0695 (41 %) 0.568 (32 %) 
NPEM2 model 1 0.0789 (42 %) 0.646 (31 %) 
NPEM2 model2 0.0743 (42% 0.816 (36 %) 
:-.:PEM2 model 3 0.0783 (35 %) 0.647 (30 %) 
K.,1. elimination rate constmt; V J, distribution volume, CV%, coefficient of variation in % 
Population pharmacok.inetic parameter estimates for NPEJ\.12 and NON:MEM models are 
listed in table II. As can be seen population pharmacok.ineric parameter estimates from 
the ~'PEM2 analyses are higher in all models. For the two optimal models (NON~:VC 
model! and NPEM2 model 1), KPEM2 estimates are 11% higher for l<ci and 9% rugher 
for Vd. These differences remain largely the same when residual error in NO~:MEM is 
modeled according to the assay error pattern in NPEM2 (NO);J:MEM model 2 and 
~'PEM2 model 1) or ;~ce versa (NON~M model 1 and i'-'PEM2 model 3). The 
coefficient of variation is larger for NPEi\12 in the optimal models, 15% for~~ and 22% 
for V d· This difference decreases some'\vhat, to 8% and 21% respectively, when the 
NPE.:A.Z error pattern is modeled as ~ON~1EM residual error. \\!hen ~01"~:\1 
residual error is modeled to resemble the assay error pattern of NPEiv.!2 however, the 
difference in coefficient of variation is reduced to almost nothing (1 %). 
Table III: descripti;ie statistics of indh1tl:tal parameter e.rtimate.r with ]\,TQ]\,TMEM and l\'PEl\12 llJodels 
K,, (h'') K" (h'') v, (L/kg) v. (L/kg) 
Mean (SD) Median (range) Mean (SD) Median (range) 
NON11E:Y1 model1 0.073 (0.017) 0.071 (0.10) 0.59 (0.02) 0.59 (0.15) 
:\JONMEM model2 0.079 (0.030) 0.072 (0.19) 0.62 (0.23) 0.57 (1.71) 
NPEM2 model 1 0.076 (0.037) 0.069 (0.24) 0.82 (0.44) 0.73 (2.98) 
NPEfviZ model 2 0.075 (0.030) 0.067 (0.19) 0.80 (0.28) 0.76 (1.70) 
:-.:PEM2 model 3 0.078 (0.025) 0.069 (0.15) 0.63 (0.17) 0.60 (0.98) 
K:1. elimim.rion rate consunt: V 0, distribution volume 
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Table III and fig. 2-4 show descriptive statistics and histograms of indi;~dual Bayesian 
parameter estimates. The difference in means for I<eJ and V d be-rureen all comparable 
~OKMEM and NPEM2 models is statistically significant (p<0.001) except for I<.,t in 
KONMEM modell and ~PEM2 modell. 
As can be expected, ~PE112 and KONiv.IEM medians for Bayesian parameter estimates 
of K.; and vd follow the differences found in population estimates of both models. 
Medians for K.; arc higher for the NOKMEM models than for comparable ~PE~l2 
models, whereas Vci is consistently lower for :I:'\0:::--JN.l:EM than NPEM2. The changes in 
parameter estimates and ranges are illustrated in figures 2-4. The distribution for Ke1 and 
Vd (optimal models) is normal (Kologorov-Sm.i.rnov test) for ~ONMEM and neither 
normal nor lognormal for NPEM2. Standard deviation for both I<:ot and Vd arc higher for 
all :::--JPE~ models "\Vi.th a concomitant difference in distribution range. \Vhen 
NON11EM residual error mim.ics NPEl\12 assay error pattern, the differences in 
parameter ranges almost disappears (fig. 3, table III). These clifferences are reduced, but 
still large when :'-!PE:'v12 error pattern mintics NO~MEM residual error (fig. 4, table III). 
Table IV shows the predictive performance of both optimal KOJ\'~ffiYI: and NPEIV!2 
models. Bias for KOJ\'MEM and KPEM2 are -0.25 and -0.33 mg/L, respectively. The 
bias for the 1\'0~MEM model is significantly better than that for KPEM2 (p<0.05). 
Precision for the models is 0.44 mg/L for KOKME~I and 0.47 mg/L for ~EM2. 
Table IV: Prediaive peiformance of optima! NONMEM and 1'-iTEM2 models 
Bias" Precisiona 
Models used J\1can error Ratio" MSE' RootMSEl> 
(mg/L) (mg/L) 
NQ~:y[EM modell -0.25 0.08 (0.01-0.014)' 0.20 0.44 
NPEM2 model 1 -0.33 0.23 0.47 
' Datl points arc point cstinutes. \Vith 95% confidence intenr:lls in parentheses 
b :\1SE. mc:111 sq=cd error 
c Rcbtivc to KPE1:12 modcl1. ·, p<O.OS (\Vllcoxon) 
Ratio' 
(mg/L) 
-0.03 (-0.08-0.02) 
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F~ 2: Histograms for inditidtta! estimates ojKI and vd: optimal 1\TQl\TlvfEM and ~'PEJ.\12 models 
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Fzg 4: Histograms .for individzta! estimates ojK1 and Vd· l\.TPEl\12 assqy error pattern mimicking 
J\TOJ\.}l'\1EM residual error 
NPEM model3 NONMEM model1 
··-----------------------, •,-------~ 
Kel (0-1) Kol (h-11 
NPEM model3 NONMEM model1 
~----------------------, 
.•. 
I "'I m, 
I t ~~I 
Va(L/kg) W(~fxg) 
DISCUSSION 
Several population pharmacokinetic methods have been used in order to determine the 
optimal model for individualizing aminoglycoside therapy in adults14--16 and neonates of 
varying gestational ages2-s, 17 -18. The most \videly used methods for population modeling 
are nonlinear mi'(ed effects modeling (.KO:I'\.YIE::vr) and the non-parametric expectation 
ma.:'\.imization (KPEl\12) algorithm. Both methods can handle sparse data sets \vi.th 
varying amounts of information per subjcct19.20. 
~ONl\ffiM describes the data using a mi>:ture of fixed (e.g. time of measurement, dose) 
and random (variability '.Vi.thin or bet\:Veen subjects) effects. Besides population 
pharmacokinetic parameters the residual error is determined by the analysis. Thls residual 
error is the difference bet\veen predicted and obsenred concentrations and accounts for 
unexplainable variability like dosing error, assay error, model misspecification and errors 
in recorded timing of measurements. 
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:-.JPE~ describes the data using the assay error pattern of the drug as the predominant 
source of error. This assay error can be multiplied by gamma, as described in the methods 
section. Differences are to be expected bev,veen population pharmacokinetic estimates 
generated by these programs. To date, there are only a few studies comparing these 
methods :in the same patient group7· s. In the study by Vermes et al. various l"O='JivffiM 
and ='JPE1.12 models for flucytosine were compared using the population estimates as 
priors for :MAP Bayesian forecastingS. Predictive performance was evaluated using bias 
and precision. In their cohort of patients the NO)'JJ\1EM model had better predictive 
ability, although at closer inspection, there were no statistical differences in bias or 
precision bet\veen optimal :-.JQ)'Jj\.ffiM and NPEYL2 models. In the present study, using a 
comparable approach, '.Ve found the optimal :-.JONJ\ffiM model to have a significantly 
smaller bias. There '.Vas no significant difference in precision. The clinlcal relevance of this 
small, but significant difference in bias is unclear however. 
The intriguing question is why the population estimates, variation coefficients and 
individual Bayesian estimates differ between ::--lONMEM and ::--lPEY\2 . ::--lPEY\2 
calculates a higher v, and a slightly lower!(, than 1':0::--lMEM. The higher population v, 
is partly e::-..'Plained by more extreme outliers for individual estimates of V din NP£112; the 
difference in median of individual estimates for V a is 0.14 L/kg versus 0.23 L/kg for 
mean values. The difference in standard deviation for both models is even larger. This can 
be explained by t\vo reasons. First, :t'Q)-J:\{E:\1 assumes a normal or log-normal 
distribution and it \vill therefore tend to put less '.·veight on extreme outliers. The second 
important factor is that the assay error pattern used by NPEI\12 is appro:xirnatcly three 
times lower than the residual error in NO:-.J:\1EM. Because of this small bandwidth of 
error, :0-.TPEJ\.12 assumes serum concentrations lying outside of the e.'\pectcd range to be 
due to extreme pharmacokinetic parameters in the patient. These parameter estimates are 
incorporated in the expected distribution of parameters. NQ)J:MEM on the other hand 
does not :find a '.Vi.de distribution of pharmacokinetic parameters. This is mainly because 
extreme serum concentrations are considered to be a part of the residual (unexplained) 
error and are not ascribed to interindividual pharmacokinetic differences. This is 
illustrated by the histograms for indivi_dual parameter estimates. The initial differences in 
range decrease greatly when the assay error pattern in :-.JPE:J2 and residual error in 
NOJ-.;MEM are fi:<ed at the same level. 
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These results have implications for clinical use of these methods. As seen in this study, 
the use of gamma in NPEM2 may largely determine the difference between the final 
NOI\ME:YI and NPEM2 population estimates. 
This study as \veil as the study by Vermes suggest 0JOKlviEM to have a better predictive 
performance, when using population pharmacokinetic estimates as the basis for Bayesian 
feedbacks. This however does not mean that this \Vill hold true for every setting. Use of 
parametric methods like NOI\MEM still imply that all the information in the population 
is reduced to a mean or median \\tith a standard deviation or dispersion factor. This limits 
the ability to predict serum concentrations in ne\v patients. \Vith :t\PE:M2 an interesting 
new feature is under development; multiple modelingll. 21• \Vith this method proposed by 
Schumit7--ky and Jelliffe it is possible to retain all the information of the population and, 
using ::--JPErvr2, design an optimized regimen in which the weighted squared error in 
obtaining desired serum concentrations is minimized. It would be interesting to compare 
predictive performance of this method to ='!OKMEM. Furthermore, if the distribution of 
parameters in the actual population has discrete subpopulations, KOKMEM will not be 
able to detect these without further analysis, whereas ::-JPE::v.£.2 'W-ill. In this parricular 
setting predictive performance of KPE112 may be better. KO::-J1LEM on the other hand 
is able to integrate covariates in the analysis, which is a valuable feature for clinical 
application. We propose that both approaches have complementary strengths. KPEN.l2 is 
useful for obtaining the full joint density of pharmacokinetic parameter estimates and 
discrimination of clinically relevant subgroups. NOK~M is the robust method for 
obtaining estimates of residual error, parameter point estimates and population 
pharmacokinetic covariate models. 
In conclusion, this study sho\vs that tobramycin population modeling in neonates wi.th a 
parametric and nonparametric approach results in different indiv"i.dual parameter 
distributions. Differences in PK estimates can be largely e::-..-plained by differences in 
method of incorporating error patterns in ::-JOKlviEM and NPE112. 
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SUMMARY 
Objectiz..•e: Establish a tobramycin dosing schedule for neonates of various gestational ages. 
lVIethods: This \.Vas a retrospective study ""i:th prospective validation. A retrospective study 
in 470 neonates, \\r.ith suspected sepricemla in the first \.veek of life, was performed . .All 
patients received tobramycin according to the follo\.vi.ng scheme: infants "'Wi.th a gestational 
age (GA) of less than 28 weeks: 3.5 nag/kg/24 hrs, 28-36 weeks: 2.5 mg/kg/18 hrs, more 
than 36 weeks: 2.5 nag/kg/12 hrs. Trough and peak tobramycin serum levels were 
determined before and 30 minutes after the fourth dose. Tobramycin data were analysed 
according to a one-compartment open model using 1'\0N.MEM population phar-
macokineric sofuv·are. Individual empirical Bayes' estimates were generated based on the 
population estimates, and used to calculate predicted peak and trough levels for different 
dose and dosing intervals. To establish an opt:imal dosing regimen, target trough levels 
were set at below 2 mg/L and target peak levels above 5-10 mg/L. The dosing regimen 
was prospectively evaluated in 23 patients. 
&st~lts: Of the 470 patients 19.1 %of measured peak and 32.8% of measured trough to-
bramycin serum levels were outside the desired therapeutic range. 48.8% of infants \V-ith a 
GA of less than 28 weeks had an aberrant trough level. Using population estimates the 
follo\\ring dosing regimen was recommended: 
• GA < 32 weeks: 4 mg/kg/ 48 hrs 
• GA 32-36 weeks: 4 nag/kg/36 hrs 
• GA 2: 37 weeks: 4 mg/kg/24 hrs 
With this dosing schedule predicted peak levels were higher than 5 mg/L in 95.1% of 
cases. Predicted trough levels were higher than 2 mg/L in 1.9% and higher than 1 mg/L 
in 7.6%. Prospectively measured peak levels were higher than 5 mg/L in all but one. 
Measured trough levels were higher than 2 nag/L in three patients and marginally higher 
than 1 mg/L in four patients. 
Conclus-ions: With the use of this proposed schedule, taking into account differences in 
GAs, predicted peak levels "Will be therapeutic \.vhereas predicted trough levels "Will 
micimize toxicity. 
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INTRODUCTION 
During recent years there has been much debate about the optimal dosing interval and 
required serum concentrations of am.ID.oglycosides in adults, in order to ma.~c efficacy 
and minimize tox.icityl-5. Efficacy of aminoglycosides is related to the ratio of peak serum 
concentration to the minimal inhibitory concentration (NIIC) of the infecting micro-
organism and the area under the time versus concentration curve (AUC)L \ '.vhereas 
toxicity of these drugs seems to be related to high trough levels!. 5• Based on these 
pharmacodynamic characteristics and the results of clinical trials it was recently advocated 
in three meta-analytic studies2. 4. s to administer aminoglycosides in adults once daily. 
Aminoglycosides also play an important role in the initial empiric treatment of neonatal 
septicemia6• Various regimens for dose, dosing interval and monitoring have been 
suggested and implemented over the last two decades7•14• A significant relation bet\veen 
GA and the need for prolonged dosing intervals "\vas established, and the more recent 
dosing regimens propose· once daily dosing of aminoglycosides in very low birth weight 
infants11 -15. We, ho\vever, had the impression, that even "\·vith once daily adrnlnistration of 
aminoglycosides in these infants high trough levels were frequendy encountered. We 
therefore performed this study to investigate the results of the dosing schedule \Ve 
currendy use, in order to find a more appropriate dosing schedule to adrnlnister 
aminoglycosides to ne\vborns of different gestational ages during the first \Veek of life. 
"C sing population pharmacokinetics on our o"\vn data over the last few years we 
established a dosing regimen that combines optimal efficacy \vith minimal toxicity. To 
validate this regimen, we prospectively tested it in our patient group. 
PATIENS AND METHODS 
Patients 
This retrospective study \V-ith prospective validation comprised all neonates, in the first 
"\veek of life, who were treated "\vi.th tobramycin as part of their empiric treatment for 
suspected neonatal sepsis in the neonatal intensive care unit of the Sophia Children's 
Hospital between August 1992 and December 1994. Only infants whose paired peak and 
trough serum tobramycin levels were available were included. In the period bet\veen 
February and April 1997 additional patients were studied for validation. 
100 
Parameters 
All parameters were abstracted from the patient files. GA and birth\vcights \Vere 
recorded. GA \Vas determined on the basis of the mother's menstrual history, conftrmcd 
by early ultrasound examinations if available, and by physical examination \Yi.th the use of 
the criteria ofDubo\vitz ct all G. 
Administration and dosage regimen of tobramycin 
Tobramycin was given in combination '-Y-ith amoxicillin 50-100 mg/kg/day as empiric 
treatment for suspected neonatal sepsis. Patients wid1 documented invasive bacterial 
infection received at least 10 days of intravenous therapy. Patients '\vith sterile cultures and 
\v-ithout a focus of infection received a total of 72 h of therapy. Administration of 
tobramycin '\vas done in a 30 minute i.v. infusion with the following dosing regimen: GA 
less than 28 weeks 3.5 mg/kg/24 hrs, 28-36 weeks 2.5 mg/kg/18 hrs, more than 
36 weeks 2.5 mg/kg/12 hrs. All doses and times of administration were recorded 
routinely. Trough and peak blood samples were taken before and 30 minutes after the 
fourth dose. Dosage adjustments were made according to the outcome, wid1 d1e intention 
to keep trough levels bclo\V 2 mg/1 and peaks bet\veen 4 and 10 mg/1. 
Analytical Techniques 
Concentrations of tobramycin were measured by a Fluorescence Polarization Assay using 
a TDxFLx (Abbott Diagnostic Div--ision, Amstclveen, )JL). 
Data Analysis + Dosage recommendations and simulations 
Tobramycin data were analyzed according to a one-compartment open model, assuming 
the data were attributable to the fourth dose after birth, using :-.JON.LvffiM population 
pharmacokinetics soft\vare (NO:-.Jfv.ffiM version IV, )JON:MEM project group, 
University of California, San Francisco, CA). Based on the population estimates, 
individual empirical Bayes' estimates '\Vere generated. Scatterplots against weight and age 
indicated that both clearance and volume of distribution were related to age and weight. 
After estimation of clearance per kilogram birth weight, only a correlation between V d and 
age or weight remained (age and weight arc naturally highly correlated in this group). The 
empirical Bayes' estimates were used to calculate predicted peak and trough levels at 
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steady state for different dose and dose inter,ral combinations, and scatterplots against 
gestational age were constructed. 
Target serum to bramycin levels \.Vere set. The target trough level was below 2 mg/L 
(generally accepted as trough when dosing more than once daily) and preferably below 
1 mg/L 4• 17• Target peak levels \.Vere set at a minimum of 5 mg/L daily18-21 and preferably 
ten times the !v:1IC of the :infecting micro-organism because of the possibility of 
emergence of aminoglycoside-resistant pathogens at lower ratios21, 22. The rv.o:c of the 
most important gram-negative pathogen, Escherichia coli, is 1 mg/L in the Dutch 
popularion23, so target peak levels \vere 5-10 mg/L 
Prospective study: 
The predictive performance of the dosing regimen \vas evaluated prospectively :in patients 
receiving tobramycin according to the dosing recommendation mentioned in the results: 
• Gestational age S 32 weeks: 4 mg/kg every 48 hours 
• Gestational age> 32 but <37 weeks: 4 mg/kg every 36 hours 
• Gestational age ~ 37 \.Veeks: 4 mg/kg every 24 hours 
Tobramycin peak and trough serum levels were determined 30 minutes after the first dose 
and just before the second dose, and analyzed as described :in the retrospective study. 
RESULTS 
Retrospective study: 
Table I.lvf.eas!lred tobra»rycin concentrations in retrospectiv·e stuc!J' 
Gestational age group (weeks) 
Tobramycin (mg/L) GA<28 28:SGA<32 32,SGA<37 GA;;::37 TOTAL 
trough S2 42 (51.3) 103 (61.7) 104 (81.2) 67 (72.1) 316 (67.2) 
trough> 2 40 (48.8) 64 (38.3) 24 (18.8) 26 (28.0) 154 (32.8) 
peak< 5 4 ( 4.9) 37 (22.2) 32 (25.0) 17 (18.3) 90 (19.1) 
5:Speak:S10 75 (91.5) 128 (76.6) 96 [15.0) 74 [19.6) 373 (79.4) 
peak> 10 3 (3.7) 2 (1.2) 0 (0) 2 (2.2) 7 (1.5) 
TOTAL 82 (17.4) 167 (35.5) 128 (27.2) 93 (19.8) 470 (100.0) 
:!:'\;umbers an: number of patients. numbers in p::trenthe~c~ ::tre percentages of tot:ll in group. G.\:::::ge~t:ttional age 
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Four hundred and seventy neonates were enrolled in the study. Their gestational ages 
(GA) and birthweigths (B\V) ranged from 23 to 42 weeks (median 31.5 weeks) and from 
485 grams to 5245 grams (median 1530 grams), respectively. Table I summarizes the 
results of robramycin peak and trough concentrations for the different GA-groups. As 
can be observed 19.1 % of peak and 32.8% of trough levels \Vere outside d~e desired 
therapeutic range. In the GA groups belo\.v 28 weeks and bet\veen 28 and 32 \Veeks ilie 
percentage of aberrant trough levels was particularly high, 48.8% and 38.3% respectively. 
On the basis of ilie scatterplots and set target serum tobramycin levels d1e dosing is 
recommended at 4 mg/kg \viili the follo\V"ing dosing intervals: 
• GA < 32 \Veeks: 4 mg/kg every 48 hours 
• 32:S GA <37 weeks: 4 mg/kg every 36 hours 
• GA ~ 37 weeks: 4 mg/kg every 24 hours 
For illustrative purposes, the curves predicted using the advised dosing regimen and the 
empirical Bayes' estimates were constructed and concentrations corresponding to the 5d~, 
50th and 95th percentile computed for the three dosing intervals-age groups (Fig. 1). 
Calculations were performed using SPSS for Windows (V6.1.2). Fig. 2 and Table II show 
the predicted peak and trough levels \vith d~ese recommendations. 
Table II. Predicted tobramycin concentrations 11.ring revised do.ring recommendatioll 
Gestational age groups (weeks) 
Tobramycin (mg/L) Gi\<28 28:S_GA <32 32::SGA<37 GA 2:37 
trough :S 1 75 (91.5) 161 (96.4) 116 (90.6) 82 
1 < trough :S 2 6 (J.3) 5 (3.0) 9 (7.0) 7 
trough> 2 1 (1.2) (0.6) 3 (2.3) 4 
peak< 5 11 (13.4) 10 (6.0) 2 (1.6) 0 
5 :Speak :S 10 69 (84.1) 149 (89.2) 92 (71.9) 6 
peak> 10 2 (2.4) 8 (4.8) 34 (26.6) 87 
TOTAL 82 (17.4) 167 (35.5) 128 (27.2) 93 
numbers arc number of patients, numbers in parentheses arc percentages of total in group. 
GA = gcstario112.l age 
(88.2) 
(7.5) 
(4.3) 
(0.0) 
(6.5) 
(93.5) 
(19.8) 
TOTAL 
434 (92.3) 
27 (5.7) 
9 (1.9) 
23 (4.9) 
316 (67.2) 
131 (27.9) 
470 (100.0) 
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Figure 1. Predicted tobramycin concentration curoes ttsing re1Jised dosing recommendation. A, 4 mg/ kg 
eVeJ)' 24 brs. B, 4 mg/ kg evel)' 36 brs. C, 4 mg/ kg eve!]' 48 hrs. Cttmes are 95tb,50th and 
5th percentiles. 
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Fig. 2 clearly sho\.VS that predicted peak levels rise \vith gestational age. Predicted peak 
levels range from 2.9 to 18.7 mg/L, 'Wi..th a median of 8.0 mg/L. Predicted peak levels 
\.vere below 5 mg/L in 4.9% of the newborns and above 10 mg/L in 27.9 % of the 
nc\vborns. Median peak levels in the GA-groups were 6.1 mg/L < 28 \.Veeks, 7.3 mg/L 
bet\veen 28 and 32 weeks, 8.7 mg/L bet\veen 32 and 37 \.veeks and 13.2 in the term 
group. Insufficient peak levels are found in 11 of 82 (13.4 %) of neonates \.vi.th a GA < 28 
weeks. Of these 11 newborns, 10 had predicted peak levels between 4 and 5 mg/L. 
Predicted trough levels tanged from 0.01 to 8.1 mg/L (median 0.36 mg/L).Trough levels 
\.vere above 2 mg/L in 1.9% of all cases and bet\veen 1 and 2 mg/L in 5.7 %. As Fig. 2 
shows, there was no relation between GA and trough levels. Figure 1 shows the predicted 
serum levels over time for the dtree GA-groups. The 50th percentile line of tobramycin 
serum levels dropped below 1 mg/L at approximately 18, 24 and 32 hours in the once 
every 24, 36 and 48 hour group respectively. 
Fig11re 2. Predicted lobra/J()'ciJJ peak (sqNare.s) and trough (circles) levels with revised dosing 
recommendation 
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Prospective study 
Prospective evaluation was performed in 23 neonates. Their GA ranged from 24.4 to 42.1 
"\vccks (median 32.5). Table III summarizes the results of observ~ed tobramydn peak and 
trough concentrations for the different GA~groups using the recommended dosing 
regimen. Peak levels ranged from 2.9 to 13.5 mg/L >vith a median of 7.9 mg/L. Only one 
peak level is below 5 mg/L. .'Vledian peak levels in the GA-groups were 6.9 mg/L < 32 
"\vceks, 7.3 mg/L between 32 and 37 weeks and 9.0 in the term group. Trough levels were 
between 0.1 and 5.7 mg/L (median 0.7 mg/L). Trough levels exceeding 1 mg/L were 
found in 7 cases. Of these, three patients had trough levels of 1.2 mg/L and one patient 
had a trough level of 1.3 mg/L. .'Vfedian trough levels in the GA-groups were 0.7 mg/L 
below 32 "\Veeks, 0.65 mg/L bet\veen 32 and 37 "\Vecks and 0.95 rng/L in the term group. 
Table III.lvfea.mred tobraiJI)'cin concmtrations 11sing rni.red dosing rr:co!!lltlendation 
Gestational age groups (weeks) 
Tobramycin mg/L) GA<32 32:SGA<37 GA237 TOTAL 
trough.$. 1 6 (85.7) 5 (62.5) 5 (62.5) 16 (69.6) 
1 <trough .S. 2 2 (25.0) 2 (25.0) 4 (17 .4) 
trough> 2 (14.3) 1 (12.5) 1 (12.5) 3 (13.0) 
pcak<5 1 (14.3) 1 (4.3) 
5.$. peak .$.1 0 6 (85.7) 7 (87.5) 6 (75.0) 19 (82.6) 
peak> 10 1 (12.5) 2 (25.0) 3 (13.0) 
TOTAL 7 (3D.4) 8 (34.8) 8 (34.8) ?' _, (100.0) 
Numbers arc nu:nbcr of p:1cicnt~. numbcn in parentheses arc perccnmgcs of total in group 
GA=gcstacion:ll age 
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DISCUSSION 
Earlier inves~o-ations concerning the pharmacokinetics of aminoglycosides and other 
drugs in neonates have shown that elimination half lives are longer in neonates, especially 
in preterm neonates8·11 , 24• This is primarily the result of a higher percentage of body water 
and thus a larger volume of distribution and reduced clearance25. 26• Most dosing 
schedules for preterm and term neonates take dUs into account?-12. 14. \Ve had the clinical 
impression that our use of GA-related dosing still led to serum concentrations which 
\vere frequendy outside the desired range. The inventory of our O'\VTI results over d1e past 
fe\v years sho\ved that about one third of the initial trough serum levels were too high, 
particularly in premature neonates, and that in v'iew of these results a more appropriate 
dosing schedule should be found. 
The limitation of dosing aminoglycosides in neonates lies in the long elimination half life, 
and therefore the only way to effectively reduce trough serum levels "\v"ithout 
compromising adequate peak levels is by further increasing the dosing interval. It is 
difficult to define the desired therapeutic range for aminoglycosides. Peak levels of >4 to 
5 mg/L arc generally accepted as necessary for antibacterial efficacy whith administration 
three times a daylS-21; however questions arc being raised about the underlying fundament 
of this assumption3. \'lhat is k.no\.Vn, is that efficacy of aminoglycosides is related to peak 
levcl/fviTC ratio and AUC1. 21, and that in -vitro ratios of 10:1 prevent emergence of 
aminoglycoside-resistant pad1ogcns22• In the first week of life, d1e pathogens for which 
tobramycin is indicated as therapy are mainly acquired trough the birth passage. By far the 
most common pathogen in this group of gram-negative bacteria is E. Cofi27_ In a recent 
survey of the Dutch population, the .MIC;o for E. Coli was found to be 1 mg/L23, and 
although in theory a peak serum concentration of 10 mg/L would be optimal, a 
pcak/.MIC ratio of 5 can be considered to be effective. 
The effect of serum concentrations on toxicity is even harder ro quantify. High ami-
noglycosidc peak levels do not increase nephrotoxicity because of drug-specific sarurable 
uptakc2S-30_ In several large meta-analytical studies toxicity seems to be related to high pre-
dose levels, indicating that trough levels are not low long enough to prevent renal 
accumulation1. 2, s. t<J_ Commonly accepted trough level goals arc < 2 mg/L, but for once-
a-day administration most authors keep 1 mg/L as a safe limit+- 17_ Another point in the 
discussion is that renal toxicity is mosdy reversible, whereas ototoxicity is usually 
irreversible. Most authors suggest that ototoxicity is related to total dose and duration of 
therapy rather than to serum aminoglycosidc levels, but the relation to aminoglycoside 
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serum levels remains unclear. This form of toxicity usually occurs in patients \.vho have 
received either long, or repeated, courses of aminoglycosides3.Reports about ototoxicity 
in neonates are contradictory. Some authors report no relation31 -33, \.vhereas others did 
find a higher incidcnce34--36_ Until conclusive evidence is given, it seems prudent to keep 
duration of tobramycin therapy as short as possible. 
On the grounds of a peak/MIC ratio above 10 and the MICoo of E. Coli in our population 
a peak tobramycin serum concentration as high as 10 mg/L is desirable from the efficacy 
point of vie\v. A trough level belo\v 1 mg/L --will have to suffice until better data about 
toxicity are available. 
Using population pharmacokinetics, \VC established a better dosing scheme to meet these 
criteria. This resulted in the follo\.ving GA-rclatcd regimen: 
• Gestational age $ 32 \Veeks: 4 mg/kg/ 48 hours 
• Gestational age > 32 \.veeks but< 37 \veeks: 4 mg/kg/36 hours 
• Gestational age::=: 37 \Veeks: 4 mg/kg/24 hours 
\Vith this regimen most predicted peak levels are in the required range in neonates with a 
GA above 32 weeks, \vith acceptable predcited trough values for almost all (see table II). 
In the GA-group below 28 \Veeks, predicted peak serum levels arc arguably too lo\.v ill 12 
of 82 patients, but still 11 of these are bet\vcen 4-5 mg/L The prospective evaluation 
sho\ved that serum peak levels are in the desired therapeutic range in all but one patients 
(see table III). Yrcasured trough levels were mildly elevated in four patients and clearly too 
high in three, so there is a definite need for measuring trough serum levels before the 
second dose. This dosing regimen also makes redundant the need for a loacling dose of 
aminoglycosides in prematures, as suggested by some1L 17- 37 because high enough peak 
levels are achieved at the first dose. In addition, the practical advantage of this proposed 
schedule is a fixed starting dose per kilogram body"\veight, irrespective of GA. 
A possible problem in the once every 48 h group is that tobramyc:in levels might be 
subtherapeutic for too long. Serum levels at 24h in this group (figure 1) sho\v that most 
neonates arc around 2 mg/L, which is still higher than the l\1IC of relevant micro-
organisms, but drops belo\v 1 mg/L after approximately 32 hours. In the prospective 
group of 23 patients serum trough levels did not fall too low. Furthermore tobramycin is 
al\.vays given in combination with amoxicillin in this group and the post-antibiotic effect, 
or post-antibiotic leukocyte enhancement effect, or sub-~C effect, which will prevent 
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regrm:vth of bacteria at sub-lvilC levels of tobramycin for another period of at least 
hours33-40, so \Ve consider this a safe dosing intenral. 
In conclusion, the information that we presented sho\VS that acceptable therapeutic 
tobramycin peak and trough concentrations can be reached \Vith a simple dosing schedule 
for three separate GA-groups in the first \Vcek of life. Trough levels according to our 
scheme arc not toxic and probably not long enough bclo\v 1 mg /L to permit bacterial 
regro\V"i:h. 
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SUMMARY 
0/jective: To individualize tob.ramycin dosing regimens in neonates of various gestational 
ages using early therapeutic drug monitoring. 
Methods: This study was performed in neonatal patients \vith suspected septicemia in the 
first week of life. All patients received tobramycin in a dose of 4 mg/kg/ dose, as a 30' 
I.V. infusion, with a gestational age (GA) related initial interval of 48 hours (<32 weeks), 
36 hours (32-36 weeks) and 24 hours (2: 37 weeks). The target serum peak and trough 
serum concentrations were 5-10 mg/L and 0.5 mg/L, respectively. Serum trough samples 
as well as 1 and 6 hour samples were taken after the first dose. T obramycin 
concentrations were used to obtain gestational age dependent population models '.Vi.th 
NPE~ soft\vare. To investigate the effect of timing of sampling in a second group of 
patients, serum trough samples as well as 3 and 8 hour samples were taken after the first 
dose of tobramycin was administered. Serum trough concentrations were predicted using 
linear phannacokinetics in both groups and by using the population models with Bayesian 
feedback of one or two serum concentrations in the second group. These predicted 
concentrations were compared to actual serum trough concentrations. The predictive 
performance of the 1-Gh and 3-8h models and the population models were compared to a 
gestational age related model \.Vlthout therapeutic drug monitoring (fDJ\1). 
Results: A total of 247 patients were analyzed, 206 with 1-Gh serum samples and 41 with 
3-Sh serum samples. Peak serum concentrations were above 5 mg/L in 90.8 °/o and 
trough serum concentrations above 1 rng/L in 25.5% of cases. The 3-8h linear model had 
a bias of -0.31 mg/L and a precision of 0.48 mg/L and performed significantly better 
than the 1-6h model. The best KPEM model had a bias of -0.11 mg/L and a precision of 
0.45 mg/L. Kone of the models yielded a significant improvement of predictive 
performance over the model w-ithout TDM. 
Conclusion: Routine early therapeutic drug monitoring does not improve the model based 
prediction of initial tobrarnycin dosing intervals in neonates in the first week of life. 
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INTRODUCTION 
Neonatal sepsis is an important health care problem, especially in developing countries, 
with an estimated world\Vi.de mortality of 1.5-2 million per year 1. 
Although a trend for a decline in sepsis associated neonatal deaths in neonatal intensive 
care units (1'\ICD's) has been reported, treatment of (suspected) neonatal sepsis remains a 
cornerstone in neonatal intensive care practice 2• In recent years there is an increase 
towards gram-negative infections in the NICU3. 4• Culture proven early onset sepsis 
(occurring within 72 hours of birth) in very low birthweight infants (VLBW) is reported 
to occur in 1.9% of cases, but this does not reflect the need for antibiotic treatment in 
this patient group'. Diagnosing sepsis in these vulnerable patients is difficult. ]';;either 
blood culture, nor leukocyte count or CRP give conclusive evidenceS, 6. In many VLB\V 
infants early-onset sepsis is suspected on clinical grounds and antibiotic therapy is started 
and continued for 3-7 days. Initial empiric treatment with a combination of an 
ami.noglycoside with penicillin, amoxicillin or a cephalosporin is common practice7• 
Optimization of ami.noglycoside use in neonates warrants therapeutic drug monitoring 
(TD:tvl) for both efficacy and toxicity reasons. Aminoglycoside efficacy is related to the 
ratio of peak serum concentration to the minimal inhibitory concentration CMJC) of the 
infecting microorganism and the area under the rime versus concentration curve (A e C) s. 
If a peak we ratio of >10 is taken as essential, this means that adequate initial peak 
serum concentrations of 5-10 mg/L are warranted9. Toxicity is related to high pre-dose 
concentrations and serum trough concentrations should be in the range of 0.5-2 mg/L 
depending on the dosing IDterval7· 10. 11. Traditionally TDM for ami.noglycosides is 
performed in steady state around the fourth dose. For several reasons this is not useful in 
neonates in the first week of life. Antibiotic courses in neonates are often discontinued 
after a few days when blood cultures and other tests remain negative. Because of 
prolonged half-life and reduced clearance in prematurcs IDtervals of 24-48 hours arc 
advised in this patient group9· 12. 13. Large inter-individual differences remain and 
predictive performance of these proposed regimens might be improved by TDM. 
Traditional therapeutic TDM in this setting would not be performed in time to be of use. 
Early TD:vf direcdy after the first dose may improve treatment for the individual patient. 
There are two commonly used approaches to TDM in this setting. The first method is to 
take t\VO serum samples in the elimination phase after the first dose and calculate the 
individual dose interval by using first order elimination kinetics. The timing of the first 
sample is normally 1h after start of infusion, but it has been suggested that this is too 
116 
early 14• The second method is determining the individual intenral using a population 
pharmacokinetic model \Yi.th Bayesian feedback of one or t\vo serum sample. The aim of 
our study "\vas to explore the possibility of individualizing dosing interval in neonates of 
varying GA's during the first week of life. Both TDM strategies were analyzed. 
Furthermore the influence of timing of serum samples was studied. The predictive 
performance of these strategies was compared to our standard GA-related dosing 
regimen previously published9. 
PATIENTS AND METHODS 
Patients 
All neonates, in the first week of life, who \vere treated \Yi.th tobramycin as part of their 
empiric treatment for suspected neonatal sepsis in the neonatal intensive care unit of the 
Sophia Children's Hospital between December 1996 and June 2000 were eligible for this 
retrospective study. Only infants whose paired 1-6 hour or 3-8 hour and trough serum to-
bramycin levels were available were included. Furthermore the trough serum 
concentration had to be sampled within one hour of the advi.sed GA-related dosing 
interval of our previ.ous study9. 
Parameters 
GA, b.i.rtlT\veight, Apgar scores and medication '\vere noted in the patient files as a routine 
procedure. GA was determined on the basis of the mother's menstrual history, confirmed 
by early ultrasound examinations if available, and by physical examination '\Vi.th the use of 
the criteria ofDubowitz et al15. 
Administration and dosage regimen of tobramycin 
Tobramycin was given in combination with penicillin G as empiric treatment for 
suspected neonatal sepsis. Patients '\Vi.th documented invasive bacterial infection received 
intravenous therapy as considered appropriate by the attending physician, usually at least 
7 days. Treatment '\Vas discontinued after 72 h in patients with sterile cultures and '\Vi.thout 
a focus of infection. Administration of tobramycin was performed in a 30-minute 
intravenous infusion in a dose of 4 mg/kg. The initial dosing interval was 48, 36 or 24 
hours in neonates "\vi.th a GA of <32 weeks, 32-36 weeks and 2:: 37 '\Veeks, respectively 9. 
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Therapy adjustments were made at the discretion of the attending physician. All doses 
and times of administration were recorded routinely. Tobramycin serum samples were 
taken as part of routine therapeutic drug monitoring 1 and 6 hours after the first dose and 
just before the second dose. 
After analysis of this patient group (1-6h group) serum sampling was changed to 3 and 8 
hours (3-Sh group) after the first dose and just before the second dose to investigate the 
effect of sample timing on serum trough concentration prediction. 
Analytical Techniques 
Concentrations of tobramycin \Vere measured by a Fluorescence Polarization Assay using 
a TDxFLx (Abbott Diagnostic Dh~sion, Amstclveen, ::-.lL). 
The coefficient of variation for this test in our laboratory is 8% at 0.3 mg/L and <5% 
from 1-20 mg/L. 
Population modeling 
Data from the 1-6 h group of patients were used to obtain a population model by way of 
a nonparametric C..."'\:pectation ma..'\..llnizarion algorithm developed by Schumitzky (NPEM 
program, USC*PACK clinical collection version 10.7, LAPK, Los Angeles, CA) 
employing all 3 available data points (lh, 6h and trough concentration) per patient. A total 
of three models \vere made, one for each different gestational age group (GA-group): <32 
weeks, 32-36 weeks1 ?:.37 weeks. :vfodels were described in terms of volume of 
distribution (V d, L/kg) and elimination constant (Ke1, h-1). Serum concentrations were 
'\veighted by the reciprocal of its variance, fitted by the following equation: 
SD= 0.0599 + 0.0126C + 0.00438 U, where SD is the standard de>~tion of the assay 
and C represents the measured tobramycin serum concentration. 
The population models \vere achieved in 2 steps. The front part of the :t'-..1?EM program 
calculated individual parameter estimates for Ke1 and V d ill a one-compartment model by 
the iterative 2-stage Bayesian (IT2B) modeling approach. Parameter value boundaries 
used as priors for this step were arbitrarily set at 0 to 0.4 h-1 for K:1 and 0.2 to 3 l/kg 
forVd. 
The parameter estimates were then used as input for the actual :::--JPE:y£ program resulting 
in mean population parameter estimates and SD's. 
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Data Analysis 
The follo"v-1ng tobramyc.in TDM strategies \.Vere compared for predictive performance 
1. Linear pharmacokinetics (1 ~6h group and 3-8h group) 
Tobramycin data were analyzed according to a one-compartment open model for the 
1-6h group and the 3-Sh group. Analysis for the 1-6h group will be described in detail. 
Analysis for the 3-Sh group was similar. Based on the assumption that one and si' hour as 
'\Veil as the trough serum concentrations were determined in the elimination phase of the 
drug, serum concentrations were used to calculate the elimination constant (Ket), the 
elimination half-life (tv£) and the time to reacb a serum concentration of 0.5 mg/L (t""'") 
ln(c6)-ln(cl) . 
as follo\VS: I<eJ == _ , where C6 and Ct are serum concentrao.ons (mg/L) at t6 
0 
. , -!n( 05 ) 
and t 1 respecnvely, ! 1/.£ = 0.69.,/I<eJ, tUrgct = T + 1. 
The interval between the start of infusion and trough sampling [interval(h)] was 
determined. 
The predicted serum trough concentration (Cprcd) was calculated as follows: 
Cprcd== Ct.e·Kd.(intcrv:U-1) 
2. Pop:tfation model and Bqyesian fledback 
The GA-related population model '\vas used in conjunction '\v'i.th Bayesian feedback of 
either or both of the 3h and Sh serum concentrations to predict individual serum trough 
concentrations of the 3-Sh group by way of the :'.1\V\Pharm software package 
GY!W\PHAR..'Y!, version 3.30, YlecliWare; Groningen, The Netherlands). Tobramycin 
trough serum concentrations were predicted in this way and compared using either or 
both of the 3h and Sh serum concentrations as feedback. The same procedure was not 
performed in the 1-6h group because population parameters were based on this group. 
Validation in the same patient group could lead to a false favorable performance16. 
3. GA6rrro:tp model witho:lt TDlvl (no TD}Ilgrolfp) 
In our previous study we concluded that the initial tobramycin dosing interval in neonates 
in the first week of life would be optimal \vith 48, 36 or 24h in GA-groups <32, 32-36 
and ;;::37 ·weeks, respectively 9. This '\vas based on a desired trough serum concentration of 
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0.5 mg/L. If the actual trough serum concentration in the present study was taken v.1:r.hin 
1 hour of this GA-rclated interval, the predicted trough serum concentration was then 
defined as 0.5 mg/L. In this model no individual TD.\1: information was used to predict 
trough serum concentrations. 
Predictive performance and statistical evaluation 
The predictive performance of all models was evaluated by comparing predicted serum 
concentrations 'With measured serum trough concentrations according to the method of 
Sheiner and Beal 16. Bias \.vas calculated as the mean prediction error (J\ffi); the mean 
difference bet\'\reen measured and predicted concentration. This is a measure for the 
systematic component of error. Precision was calculated as the mean squared prediction 
error (lvfSE); the mean of the sum of squared differences between actual and predicted 
serum concentrations. The root mean squared prediction error is the squared root of 
MSE and converts the measure of precision back to concentration units. Relative 
predictive performance was determined by comparing differences and confidence 
intervals of differences of :ME and MSE for models. 
Statistical analysis was performed using SPSS 8. 0 statistical software (SPSS Inc., Chic~oo, 
LSA). Significance for relative predictive performance \.vas defined when the 95% 
confidence inten~al did not include zero. The Wilcoxon signed rank test and Mann-
\Xibitney test '\vere used as non parametric tests. 
RESULTS 
Patient groups 
In the 1-6h group a total of 379 patients had paired 1-6h serum concentrations and 
trough concentrations taken. Serum sampling times were aberrant or incomplete in 32 
patients. An incorrect dose (< 3mg/kg or > 5 mg/kg) \.vas given in 5 patients. In 136 
patients the serum trough concentration '\vas taken outside 1 hour of the GA-related 
intcn~al. Thus a total of 206 patients were evaluated. In the 3-Sh group serum sampling 
group 77 patients \.vere included. Serum sampling time '\vas aberrant or incomplete in 14 
patients. An incorrect dose \.Vas given in 2 patients. T'\vcnty patients had their serum 
trough concentration taken outside 1 hour of the GA-related interval. Forty-one patients 
were evaluated. Table I shO\.VS demographic variables of the 1-6 and 3-8 study group. 
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There arc no significant differences for Gr\, birtll\veight Apgar score or postnatal age 
bet\veen 1-6h and 3-Sh groups. 
Table I: Demographic variables of the 1-6h and 3-8h stud_;' group 
Group1-6h Group3-8h Significance 
(n=206) (n=41) 
Gestational age (weeks) 33.1 (24.4-42.1) 33.3 (25.9-40.3) 0.97 (NS) 
Birrhweight (grams) 2011 (580-4780) 1976 (765-4500) 0.78 (NS) 
APGAR score 5 min 7.5 (1-10) 7.5 (2-10) 0.97 ()JS) 
Postnatal age (days) 0.97 (0-7) 0.93 (0-7) 0.80 (NS) 
Data :lie mcan(rnngc) 
Distribution of obtained serum concentrations 
Table II shows obtained peak serum levels in the 1-6h group. In the 3-8h group no peak 
serum concentrations \vere determined. Peak concentrations ranged from 2.4-14.1 mg/L. 
Table II: Tobra!'1()1cil1 peak senw; concentraiions according to GA-grottp in tbe 1-6h grot;p 
Gestational age groups 
Tobramycin peak 
serum concentration <32 \vccks 32-36 weeks ~37weeks TOTAL 
<5mg/L 14 (14.7) 4 (8.9) 1 (1.5) 19 (9.2) 
5-10 mg/L 79 (83.2) 38 (84.4) 53 (80.3) 170 (82.5) 
> IOmg/L 2 (2.1) 3 (6.7) 12 (18.2) 17 (8.3) 
TOTAL 95 (100) 45 (100) 66 (100) 206 (100) 
Data :l!c number of patients (pcrccnt:tgc of rocl) 
Yrean serum peak concentrations (±SD) for GA-groups are 6.4±1.6. 7.2±1.8 and 
8.2±1.9 mg/L for <32, 32-36 and ~37 '\Veeks, respectively. r\ total of 90.8% of peak 
concentrations '\Vas higher than the lo'\ver limit for presumed optimal efficacy (5 mg/L). 
Only 5 of 19 neonates \vi.th peak concentrations belo'\V 5 mg/L had concentrations bclo'\v 
4mg/L. 
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Table III: TobraJJ!)'cin trottgh serum concentrations according to GA-grottps (both 1-6h and 3-8h group). 
Data in parenthe.res are percentages of total 
Gestational age groups 
Tobramycin trough 
serum concentration <32weeks 32-36 weeks 
< 0.5mg/L 60 (53.6) 17 (28.3) 
0.5-1 111g/L 44 (39.3) 26 (43.3) 
>1 mg/L 8 (7.1) 17 (28.3) 
TOTAL 112 (100) 60 (100) 
Dam arc number of patients (pcrcentlgc of tocl) 
"'37weeks 
12 (16.0) 
y 
-" 
(33.3) 
38 (50.7) 
75 (100) 
TOTAL 
89 (36.0) 
95 (38.5) 
63 (25.5) 
247 (100) 
Table III shows trough serum concentrations for the 1-6h and 3-Sh group. Mean serum 
trough concentrations (±SD) for GA-groups are all higher than the target of 0.5 mg/L. 
Values (±SD) are 0.52 ± 0.33, 0.78 ± 0.46 and 1.07 ± 0.58 mg/L for <32, 32-36 and "'37 
weeks, respectively. Approximately one quarter (25.5%) of patients had serum trough 
concentrations higher than 1 mg/L, the highest percentage (50.7%) in the term group. 
Fourteen neonates had a trough serum concentration < 0.2 mg/L, half of these in the GA 
age group <32 "\veeks. 
Population model 
The results of the NPEM analysis of the three different GA-groups for the 1-6h group 
are sho,vn in table IV. There are substantial differences between V d and K:1 for different 
GA-groups '"i.th a decrease ofVd and an increase ofKe1 in relation to gestational age. I<e1 
increases with 53% and V d decreases '\Vi.th 23% \vhen comparing pretcrms < 32 weeks 
with term infants. 
Table W.· Population phaT!l1acokinetic parameter estimates of the 1-6h groHp 
N ~'(I>') vd (L/kg) 
GA-models G.A < 32weeks 95 0.064 ± 0.034 0.70 ± 0.17 
GA 32-36 weeks 45 0.066 ± 0.022 0.63 ± 0.15 
G.A;::.:. 37 'l.vccks 66 0.098 ± 0.046 0.54 ± 0.11 
G:\ :::::: gestational age, l<c; :::::: elimination rate constant, VJ :::::: volume of distribution. DaL'1 ;uc means :t stmdard 
dcv-i'1tion 
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Predictive performance 
Darn for predictive performance of the investigated models in accurately estimating 
trough concentrations are sho\vn in table V. These data represent all GA-groups. 
Table V· Prediaive peifmJ1ance of models in estimating serttJTJ trough concentration (n=41 ). 
BIAS PRECISON 
Models used lviean error MSE* RootMSE* 
(mg/L) (mg2/L2) (mg/L) 
1\'o TDM model (1-6h group) -0.26 0.34 0.58 
No TDM model (3-8h group) -0.20 0.20 0.45 
)JPEYI: model -0.30 0.21 0.46 
(3-8h semm concentration feedback) 
)JPE::\1: model -0.11 0.20 0.45 
(Jh serum concmtralion feedback) 
NPEMmodel -0.24 0.16 0.42 
(8b semm concentration feedback) 
Linear model -0.39 0.69 0.83 
(1-6h grwp) 
Linear model -0.31 0.23 0.48 
(3-Sh grwp) 
*MSE = mean squared prediction error 
Bias represents the systematic error in the model and was negative in all cases (-0.11 up 
to -0.39 rng/L). Tlus means that all models underpredicted the actual trough serum 
concentration. Linear pharmacokinetic models had a more negative bias than comparable 
NPE~I and no-TDM models. Bias of KPEM models using one serum concentration as 
feedback was lower than "vhen using t'\vO. The measure for precision [root mean squared 
error (rng/L)] differed between 0.42 and 0.83 mg/L. Linear pha.rmacokinetic models had 
a worse precision than comparable :1:'\PEM and no-TDYI models. Precision for NPEM 
models using one or t\VO serum concentrations as feedback did not differ much and \vere 
comparable to precision of the no-TD:\ti model. To investigate whether predictive 
performance '\Vas related to GA, data were also analyzed separately per GA-group (data 
not sho\VTI). Bias and precision for ='JPE~-, linear- as well as no-TDM models in the term 
lnfant group were worse as compared to preterm lnfants < 32 \.veeks. The only exception 
was bias in the 1\iPEYI: 3h model. The model with the best bias and precision was the 
no-TD~ model for preterms < 32 weeks with a bias of -0.02 and a precision of 
0.04 mg/L. 
To determine the relative predictive performance, ratios for bias and precision bet\veen 
the no-TDM model and other models \.vere calculated 16• The predicted trough 
concentration \.Vi.th the no-TDM model was defined as 0.5 mg/L. Table VI shows results 
for this analysis. A positive ratio for bias or precision implies a lower predictive accuracy 
of the TDM model as compared to the no-TDYI: model. 
Table VI: Relative predictive performance of linear and population modeLe compared to vo-TDM models 
in estimating semm trough concentration 
Bias (mg/L) Precision (mg2 /L ") 
Models used Ratio (95% Cl) Ratio (95% Cl) 
1-6h linear 0.12 (0.03,0.22) § 0.34 (0.01.0.70) § 
3-Sh linear 0.11 (0.001,0.22ji 0.02 (-0.08,0.13) 
NPEMmoder" 0.09 ( -0.003,0.19) 0.007 (0.09,0.11) 
(3-8h semm concentration) 
NPEMmodel' -0.09 (-0.24,0.05) ·0.007 (-0.13,0.12) 
(3h senli/J C011CeJJtration) 
NPEMmodcl1 0.04 (·0.07,0.14) ·0.05 (-0.16,0.06) 
(8/J sem111 concentratio11) 
t Rebcive ro 1-6h no IDM model t Relative to 3-Sh no IDM model F p<O.OS 
Predictive performance of the no TDYI: model is significantly better for bills (1-6 and 
3-Sh models) and precision (1-6h model) than the linear model. :\iPE:>f models using 3h 
and/ or Sh Bayesian serum feedback had a predictive performance comparable to the no-
TDM strategy. The NPEM 3h model had a slightly better bias and precision without 
reaching significance. Analysis of linear pharmacokinetic models showed that the 3-Sh 
model had a superior precision (p<0.01) and a comparable bills to the 1-6h model. 
Slnce one of the aims of TD:yf was to predict aberrant trough concentrations, we also 
tested \.vhether the best population model can accurately predict undesirable trough levels 
ill lndivi.dual patients. Undesirable trough serum concentrations were defined as 
<0.2 mg/L or > 1.0 mg/L. 
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Results for thls analysis are shown in table VII. As can be seen the 3h model accurately 
predicted only 3 out of 10 undesirable trough serum concentrations. 
Table VII.· predicted trough serttm concentrations with j'\,TPEM 3h model versus measured serum trough 
concentrations 
Predicted troughs 
Measured trough < 0.2mg/L 0.2-1.0 mg/L 
< 0.2 mg/L 1 
0.2-1.0 mg/L 6 21 
> I.Omg/L 1 5 
TOTAL 7 27 
Data :u:c number of patients 
Covariate analysis 
> 1.0 mg/L TOTAL 
4 
3 
7 
1 
31 
9 
41 
Covariate analysis was performed to study the influence of perinatal asphyxia and 
exposure to other medication on serum trough concentrations. The 5' Apgar score (ASS) 
as a measure of asphyxia showed a negative correlation with trough serum concentration 
for the :0:37 week group (p < 0.01). All term neonates \vith an ASS below 5 had increased 
serum trough concentrations. Serum trough concentration were lower in neonates \.vith a 
GA < 32 weeks who were antenatally exposed to corticosteroids (p<0.01). )Jo correlation 
\.Vi.th antenatal or postnatal exposure to indomethacin \Vas found, though it is important 
to realize that only 14 neonates received postnatal indomethacin before serum sampling. 
Start of therapy was \vi thin 48h from birth in 228 patients and no relation to postnatal age 
could be demonstrated. 
DISCUSSION 
Once daily dosing of amirtoglycosides in adults has become common practice during the 
last decade. Several large studies have shO\.VTI that extended interval dosing has been 
associated "'Wi.th an increase of clinical response rate and a decrease of oto- and 
nephrotoxicity10. 17-20. The need for longer dosing intervals has also been established in 
neonates, though a difference in toxicity bet\veen ODD and :\1DD has not been 
demonstrated yet in thls group9· 12. 13. 21, 22. These extended intervals are GA related. 
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Earlier investigations concerning the pharmacokinetics of aminoglycosides and other 
drugs in neonates have shown that elimination half-lives are longer in neonates, especially 
in preterm infants23-Z7_ This is primarily due to both reduced clearance and the higher 
percentage of body water resulting in a larger volume of distribution28· 29. Extended 
interval dosing has implications for desired serum concentrations and methods of 
aminoglycoside TDM. Monitoring of aminoglycosides is based on the observation that 
outcome is improved with peak serum concentrations of 4-5 mg/L30, 31 and toxicity is 
reduced with trough serum concentrations of< 2 to 4 mg/L32.33_ Combined '\vith the fact 
that peak/:yfiC ratios of 5-10 are essential in preventing emergence of aminoglycoside 
resistant bacteriae, this has led to the common TDM goals of peak and trough serum 
concentrations of 5-10 mg/L and < 2mg/L, respectivelyS, 34. With C.."X:tended interval 
dosing there might be a need for other trough concentration goals. Some authors have 
suggested to maintain the trough standard of 2mg/L in ODD and only reduce dose or 
extend dose intervals when troughs > 2 mg/L are encountered11• 35_ If a trough of 
< 2 mg/L is accepted Mth a ODD rs,ollnen however, exposure to aminoglycosides in 
terms of ADC could be 2.5 rimes as high as that with conventional multiple daily dosing". 
There is clinical evidence that this goal could lead to an increase of nephrotoxicity11· 37. It 
therefore seems more prudent to set trough concentration goals at 0.5 - 1.0 mg/L. In the 
present study we confinned our earlier finding that a dose of 4mg/kg, irrespective of GA 
leads to adequate peak serum concentrations in >90 % of cases9. 
Several methods have been advocated to individualize aminoglycoside treatment in 
relation to these goals. A method being used in adults uses a peak and mid-interval serum 
concentration which allows the calculation of AUC or elimination half-life Mth the use of 
linear pharmacokinetics11. 20,36.38_ These calculated values might then be used for adjusting 
the dose or dosing interval of the administered aminoglycoside. In the present study we 
investigated whether use of early TDM using this approach would :improve prediction of 
individual dose intervals over a model '\vith no TDM from an earlier study 9_ Our data 
show that obtaining lh and 6h serum concentrations after the first dose as advocated by 
Begg 38and using linear kinetics yields a poor prediction of tobramycin trough serum 
concentrations and thus of individualized dose interval. Since some have suggested that 
this might be due to a prolonged distribution phase '\Ve changed sampling rimes to 3 and 
Sh14_ This led to a statistically significant :improvement of precision. However prediction 
based on the original GA-related model, using no TDM, is superior for bias and precision 
to this type of monitoring. For practical purposes linear kinetics are therefore not useful 
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in this setting. A second method uses population pharmacokinetic parameter estimates 39. 
These estimates with Bayesian feedback of one or more serum concentrations have been 
sho\vn to adequately predict aminoglycoside serum concentrations in adults39• 
Individualization of dosing regimens in neonates with Bayesian feedback has been studied 
by some authors13, 40. 41 • Bias and precision in these studies :ranged from -0.11 to 
-0.372 mg/L for bills and 0.359 -0.6 mg/L for precision for gentamicin"· 4D and 
-0.12 mg/L for bias and 3.69 mg/L for precision for amikacin41 • These values are 
comparable to the best Bayesian feedback model in this study, where a bias of -0.11 mg/L 
and a precision of 0.45 mg/L are found (table V). 
The introduction of Bayesilln feedback in this study, using the best model, slightly 
improves bias, but is not statistically superior to the no TDM model. Furthermore use of 
this ='JPEM model only selects 3 out of 9 patients with high trough concentrations and 
thus is not of much practical use in pinpointing individuals at risk for prolonged e::...'Posure 
to tobramycin. Use of the no TDM model leads to a substantial number of relatively high 
trough serum concentrations since approximately 25% of trough concentrations were 
> 1 mg/L. In this study neonates with serum concentrations taken outside the 1h limit of 
the GA-related interval were left out of the analysis. Since it is possible that the difference 
in timing of the inter;ral is related to more extreme phannacokinetic parameters in the 
group not included, we also looked at the total groups of neonates (342 in the 1-6 group, 
61 in the 3-Sh group). :\lo significant differences for bills and precision of both linear and 
KPEM models are found between the study groups and the total groups (data not 
shown). 
Several studies have looked at cova:riates for explaining the large interindivi.dual variation 
of aminoglycosides in neonates. As in other studies this study shows a GA related 
increase in I<ct and decrease ofVd 42-44. 
This study confirms the negative correlation bet\.Veen the ASS and serum trough 
concentration seen before 43, 44. The relation to term neonates can be expected because 
the ASS is a better predictor of hypoxia and concomitant renal failure in term than 
preterm newborns 45 • The decrease of serum trough concentration in preterms with 
prenatal exposure to corticosteroids might be a reflection of increased intra-uterine 
maturation of kidney function 46. In contrast to other studies no relation to P:::--.JA or 
admi.olstration of indomethacin is found 42-44• 47• This is probably due to the fact that 92% 
of neonates received tobramycin within 48h of bird1 in combination \vith the fact that 
indomethacin is often started on day 3. 
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How should these results be translated to dosing and therapeutic drug monitoring of 
aminoglycosides in neonates? 
Since adequate initial peak serum concentrations were found in both this and our earlier 
srudy, routine measurement of peak serum concentrations does not seem to be 
"\varranted9. A direct relation beween serum concentrations and toxicity has not been 
sho\VTI in neonates. Toxicity seems to be related to high trough concentrations and 
duration of therapy in adults19. 4S. The currendy accepted opinion is that aminoglycoside 
induced toxicity does not seem to be associated with short courses of antibiotics (<5 
days). It is possible that a prolonged period of aminoglycoside concentrations below we 
might permit bacterial regrowth. :\ionitoring trough serum concentrations before the 
second dose might allo\v us to prevent potential bacterial regrowth Oow concentrations of 
the aminoglycoside) or toxicity (high concentrations of the aminoglycoside). However it 
remains questionable if this trough concentration has any value in preclicting the amount 
of tobramycin e::-..-posure after the second, third or fourth dose of the aminoglycosidc-26. 
Although we were not able to preclict trough concentrations adequately enough, others 
have inclicated the possibility of preclicring steady state peak and trough concentrations in 
the first week of life, \v'ith a single serum sample taken after the first dose13,4t. Neither of 
these studies looked specifically at trough serum concentrations or compared their 
strategies to not performing TD~. Given the fact that bias and precision in these stuclies 
is comparable to ours it is unlikely that preclictive performance in these stuclies would be 
superior to not using TDM. In conclusion, our results indicate that routine early TDM is 
not useful in neonates in the first week of life. Precliction of individual tobramycin dosing 
intervals can not be Unproved by the use of 1-6h or 3-Sh serum concentrations after the 
first dose. Keonates in the fust week of life should be started on the proposed dosing 
schedule of 4 mg/kg dose with a GA related interval of 24,36 or 48h '· TDM should only 
be performed routinely in neonates receiving tobramycin for longer than 5 days for 
toxicity reasons. Patients "\vith renal failure as well as patients "\Vi.th obvious neonatal 
asphyxia (e.g. ASS < 5) should be monitored more closely. 
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SUMMARY 
Background: Recently the value of vancomycin therapeutic drug monitoring as well as the 
required therapeutic range has been subject of debate, resulting in ne\v recommendations. 
This study was performed to incorporate these new insights in an up-to date dosing 
scheme for neonates of various gestational ages. 
L\J.ethods: A retrospective study \vi.th prospective validation. 108 newborn infants \Vith 
suspected central line related septicemia during the first month of life received 
vancomycin 30 mg/kg/ day div-1.ded into 2 doses regardless of gestational or post-
conceptional age. Trough and peak vancomycin serum concentrations \Vere determined 
before and after the third dose. Vancomycin data \Vere analyzed according to a one-
comparrment open model \vith use of NO:J'(~M population phannacokineric soft\vare. 
~fodel parameters \Vere evaluated and then used to simulate vancomycin dosing for 
different dose and dose interval combinations. Targets were a trough concentration 
berw-een 5 and 15 mg/L and a peak belo"v 40 mg/L. In the prospective study, the optimal 
scheme was tested in 22 patients. 
Results: Of the 108 patients, 34.3% of measured trough- and 17.6% of peak 
concentrations '\Vere outside the desired therapeutic range. The model best fitting the data 
included clearance and volume per kg and was independent of gestational age (GA). 
Simulation of various dosing schemes showed that a dosing schedule of 30 mg/kg/ day, 
irrespective of GA, in three doses was optimal,. and this scheme '.vas prospectively tested. 
Mean trough concentrations before the second dose were 8.2±2.2 mg/L versus a 
predicted trough of 8.9±2.5 mg/L. :\lo peak levels higher than 40 mg/L were found. 
Conclusions: the usc of the proposed schedule leads to adequate vancomycin trough serum 
concentrations and there is no need for routine monitoring of peal( serum concentrations. 
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INTRODUCTION 
The immunologically incompetent premature neonate is especially susceptible to invasive 
Gram-positive infections thxough invasive procedures such as central venous lines. 
Stopf?y!ococctts attrerrs and coagulase-negative staphylococci account for up to 31% of 
nosocomial infections in newborn infants1. Vancomycin is the first-choice antibiotic for 
treatment of these infections in neonates. This glycopeptide antibiotic, \Vhich is 
bactericidal through inhibition of cell wall synthesis, has been used in pediatric patients, 
including neonates, since 19592. Historically, vancomycin dosing has been titrated to 
obtain peak serum concentrations betureen 20-40 rng/L and serum trough concentrations 
of 5-10 mg/L. These therapeutic goals are \vi.dely used in pediatrics and neonatology. 
There are, however, no controlled clinical trials that show a relation bet\veen serum 
concentrations and clinical response. 
Vancomycffi reportedly has potential oto- and nephrotoxic side effects. These side effects 
however are rare, especially after removal of impurities from preparations in the 1960s. 
Ototoxicity is characterized predominandy by transient tinnitus and hearing loss3 and has 
not been described in neonatal patients. ~ephrotoxicity has been reported incidentally4-S, 
especially when given in combination with an aminoglycoside. Recent research sho\ved no 
relation benveen peak serum concentrations > 40 mg/L and nephrotoxicity in neonates9, 
although a relation to very high concentrations over > 60 mg/L is suggestcd8. Therefore 
recent papers have discussed the necessity of therapeutic drug monitoring of 
vancomycin10-13_ In light of these and other papers it seems to be more clinically relevant 
to look at serum trough concentrations as the main determinant of effective therapy14· 15. 
Some studies suggest that minimum trough levels of at least 10 mg/L should be obtained 
for efficient therapy16. As yet no prospective clinical trials have inves~o-ated this 
hypothesis, and no dosing schemes based on target trough concentrations have been 
described in neonates. The aim of our study \vas to retrospectively investigate population 
pharmacokinetics of vancomycin in infants. To that purpose \VC simulated various dosing 
schedules to determine which dosing scheme would be optimal. Finally \Ve prospectively 
evaluated this optimal dosing scheme to determine its value in clinical practice. 
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PATIENTS AND METHODS 
Study design 
Retrospective study '\vith prospective validation. 
Patients 
All neonates "Utith a postnatal age of less than 29 days \vho were treated -with vancomycin~ 
.in the neonatal intensive care unit of the Sophia Children's Hospital bet\veen Al\-:,oust 1992 
and December 1997 \vere eligible for this study. Infants '\Vere only included if their paired 
peak and trough serum vancomycin concentrations \.vere available. 
Parruneters 
All parameters \.Vere abstracted from the patient files. Gestational ages (GAs), 
birthweights and weights at start of antibiotic therapy \.Vcre recorded. GAs '\Vere 
determined on the basis of the mother's menstrual history, confirmed by early ultrasound 
examinations if available, and by physical examination '-Vith d1e use of the criteria of 
Dubo\vitz ct al_17, 
Administration and dosage regimen of vancomycin 
Vancomycin was given as empiric treatment for suspected neonatal sepsis \\tith a line-
related focus, or after confinnation of a positive blood culture \v:i:th coagulase-negative 
staphylococci. Patients '\vith culture proven invasive bacterial infection received at least 7 
days of intravenous therapy. Administration of vancomycin \Vas performed in a 1h i.v. 
infusion with the follov.ing dosing regimen: 30 mg/kg I day divided in 2 doses, 
irrespective of GA. 
All doses and times of administration \Vere recorded routinely. Trough and peak blood 
samples were taken before and 1h after completion of dlC third dose. Dosage adjustJ.nents 
\Vere made according to the outcome, 'W-ith d1e intention to keep trough concentrations 
bet'\veen 5 and 10 mg/L and peak concentrations bet\veen 20 and 40 mg/L. 
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Analytical Techniques 
Concentrations of vancomycin were measured by a Fluorescence Polarization Assay using 
a TDxFLx (Abbott Diagnostic Di·vision, Amstelveen, l"L). The coefficient of variation 
for this test in our laboratory \Vas 5.1% at 7 mg/L and 2.9% at 35 mg/L. 
Data Analysis + Dosage recommendations and simulations 
Vancomycin data were analyzed according to a one-compartment open model, assuming 
the data were attributable to the third dose after birth, using KONN!EM population 
pharmacokinetics sofuvare 0-JO")Jlv.ffiM version V, ~ONlv.ffiM project group, University 
of California, San Francisco, CA) "vith a number of different models; all were one 
compartment models "vith a constant coefficient of variation intra- and inter-individual 
error model. First order conditional estimation (FOCE) \Vas applied in all cases. 
Indiv-i.dual empirical Bayes parameter estimates were generated to examine possible 
covariate relationships. The different models '\vere compared using the minimum value of 
the objective function (likelihood-ratio test). Model parameters (including residual 
variability) were used to simulate vancomycin dosing in 100 subjects for different dose 
and dose interval combinations. The target trough concentration was 5-15 mg/L and 
peak concentrations preferably below 40 mg/L. 
Prospective study 
The predictive performance of the proposed dosing regimen '\Vas evaluated prospectively 
in patients receiving vancomycin according to the dosing recommendation mentioned in 
the results: 30 mg/kg/ day dh~ded in 3 doses. 
Vancomycin trough serum concentration was determined prior to the second dose, to 
ascertain adequate therapy after the first dose. Furthermore peak and trough serum 
concentrations were determined before and 1h after the fifth dose to detect possible 
accumulation of vancomycin. The fifth dose was chosen because in the model as 
described, this \.vas the dose at '\vhich a steady state '\vas reached. 
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RESULTS 
Retrospective study 
Vancomycin trough and peak concentrations were obtained .in 115 neonates. Data for 
seven neonates were indicated as aberrant because results \Vere not identifiable as being 
either peak or trough concentrations and removed from the data set. Results mentioned 
are of the remaining 108 neonates. 
Their GAs and birth weights ranged from 24 to 41 weeks (median age, 28.9 weeks) and 
from 485 to 4625 g (median w~oht 1002 g), respectively. Postnatal age and \veight at start 
of therapy ranged from 3 to 27 days (median age, 14 days) and from 510 to 4410 g 
(median weight, 1045 g), respectively. Figure 1 and 2 summarize the results of 
vancomycin peak and trough concentrations for the various post-conceptional age (PCA) 
groups. 
As sho\VTI, 22.2% of peak concentrations and 34.3% of trough concentrations '\vere 
outside the desired therapeutic range. 17.6% of trough concentrations was below 5 mg/L. 
Population pharmacokinetic analysis was performed \.vith different models in which GA, 
PCA, clearance, volume, clearance per kg and volume per kg were used as parameters. 
The best description of the data was found in the model using clearance per kg and 
volume per kg. In this model empirical Bayes estimates of clearance and volume did not 
correlate \.vi.th weight measures; the r2 (squared correlation coefficient) bct\veen volume 
and gestational and post-conceptional age measures was less than 0.1 indicating that less 
than 10% of the variability could be explained by age. Population pharmacokinetic 
parameters for this model were a clearance of 0.057 ± 0.0018 1/hr/kg ((inter-individual 
variability 31 %) and a volume of distribution (Vd) of 0.43 ± 0.0131/kg ((inter-indi,~dual 
variability 25%). For descriptive purposes an additional model parameterized in terms of 
clearance/kg and half-life was constructed. The population average half-life was 6.0 h 
with a standard error of 0.27 hand a coefficient of variation of 34%. Evaluation of these 
models indicate that vancomycin population pharmacokinetics in neonates is best 
described using clearance per kg and volume per kg. If dosed per kg this means that the 
expected concentration profile is independent of weight or age e.g. \.vith the same Cma.-...;: 
and half-life and therefore the same Cmin. Deviations from this profile are due to inter-
individual differences and not caused by differences in covariates. 
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Fig. 1: Peak concentrations ill the retrospectiv·e study group 
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Using these pharmacokinetic parameters several vancomycin dosing regimens were 
simulated to determine which dosing schedule would be optimal in vic'\v of the target 
trough concentration. Results show that once daily administration of 30 mg/kg would 
lead to an average peak concentration after the first dose of 59.9 mg/L and a trough (at 
24 h) of 3.7 mg/L. Other simulated dose and dose inteD.ral combinations are sho'\vn in 
figure 3 and 4. As can be seen twice daily dosing of 15 mg/kg/ dose leads to an 
unacceptable percentage of undesired trough and peak concentrations, whereas 20 mg/kg 
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t\v:ice daily, results in too much accumulation, indicating that these regimens are not 
optimal. Thrice daily dosing leads to accumulation when giving 12 mg/kg/ dose and to a 
substantial percentage (27%) of ineffective initial trough concentrations "\vhen givi.ng 
Fig. 3: Predicted trough concentrations with tested dose regimem.l:-·..Tumbers are percmtage of predicted 
trough concentrations < 5 mg/ L 
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8 mg/kg/ dose. The best regimen tested was 10 mg/kg/ dose, in which less than 5% of 
predicted trough concentrations is below 5 rog/L and steady state is reached after dose 5. 
Predicted peak concentrations after the 5th dose range from 22.4 to 50.0 mg/L (mean 
34.3 ± 7.7 mg/L). Trough concentrations with this regimen range from 4.3 to 15.0 mg/L 
(mean 8.9 ± 2.5 mg/L) before the second dose and 5.0 to 30.6 mg/L (mean 15.7 ± 
6.3 mg/L) before the 5th dose. 
Prospective study 
The application of the vancomycin 10 mg/kg/Sh regimen was prospectively tested in 22 
patients. Table I sho'\vS the demographic variables for the prospective smdy group in 
relation to the retrospective group. Posmatal age was significantly lower in the 
prospective group (p=0.026), compared to the retrospective group. GA, birth weight, 
weight at start of therapy and PCA \vere not significantly different. 
Table I: demographics if retro.rpectit•e and prospective grottp 
Retrospective group Prospective group p~valuc 
Range (median) Range (median) (one way AN OVA) 
Gestational age (weeks) 24-41 (28) 25-42 (29) 0.488 
Birth\vcight (grams) 485-4625 (1002) 770-3500 (1102) 0.625 
Actual weight (grams) 510-4410 (1045) 730-3420 (1160) 0.469 
Postconccptional age (weeks) 26--42 (31) 27-43 (31) 0.832 
Postnatal age (days) 3-27 (14) 7-21 (11) 0.026 
Table II shows the results of vancomydn serum concentrations. As sho\vn, 95.5% of 
initial trough concentrations \Vas in the desired therapeutic range. Vancomycin trough 
concentrations before the second dose ranged from 3.4 to 12.5 mg/L (mean 8.2± 2.2) 
mg/L). Trough concentrations before the 5th dose ranged from 4.6 to 20.6 mg/L (mean 
12.3 ± 4.1 mg/L). Trough concentrations before the 5th dose were significantly (paired 
saruples T-test, p< 0.001) higher than before the second dose. Both before the second 
and 5th dose only one trough concentration was below 5 mg/L. Vancomycin trough 
serum concentration before the 5th dose was higher than 15 mg/L in four cases, \Vi:th 
serum concentrations of 15.3, 17.8, 20.6 and 20.6 mg/L respectively. 
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Table II: Vancol7!)ci11 serum concentrations (prospedive stttcfy) 
Vancomycin serum 
concentration 
< 5 mg/L 
5-15 mg/L 
> 15 mg/L 
<20mg/L 
20-40 mg/L 
> 40mg/L 
TOTAL 
Trough! 
1 (4.5 %) 
21 (95.5 %) 
0 (0.0 %) 
22 (100 %) 
TroughS 
1 (4.5 %) 
17 (77.3 %) 
4 (18.2 %) 
22 (100 %) 
PeakS 
3 (13.6 %) 
19 (86.4 %) 
0 (0.0 %) 
22 (100 %) 
K umbers :u:e the number of patients with v:mcomycin serum concentrations v,::irh.in specified 
nnge before dose 1 :md 5 and after dose 5. Numbers in parentheses are the percentages of the 
total in the group. 
Peak concentrations after the 5th dose ranged from 16.6 to 34.5 mg/L (mean 25.8 
± 5.0 mg/L). There '\Vas no significant relation bet\veen serum concentrations at any of 
the three sample points and GA, postnatal age (PKA) or post-conceptional age (PCA) 
DISCUSSION 
Historically vancomycin dosing in neonates, similar to aminoglycosides, has been subject 
to therapeutic drug monitoring for N·o reasons: toxicity and clinical effect. 
Apart from the infusion related histamine like reaction (red-man syndrome), due to 
impurities in the earlier preparations of vancomycin in the shties, side-effects are 
relatively rare 10. Proof of vancomycin related nephro- or ototoxicity in adults is 
circumstantial and probably only true for a selected high-risk population 18. Furthermore 
this toxicity was described using the old formulation of vancomycin. Ototoxicity has not 
been described in neonates. Vancomycin-related related nephrotoxicity is rare and no 
relation bet\V·een nephrotoxicity and serum concentrations has been found 9- 19. The few 
neonates \vith nephrotoxicity all had documented very high serum concentrations, so it 
seems prudent to keep peak serum concentrations below an arbitrary threshold of 
40 mg/L, but this in itself is insufficient reason for therapeutic drug monitoring. 
Efficacy of vancomycin related to serum concentrations has been under debate. Several 
mainly in v-itro studies have been performed to determine which pharmacodynamic 
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parameter correlates \.vith efficacy of vancomycin. Serum bactericidal titers of 1:8 or more 
(corresponding to serum concentrations of > 12 mg/L) were associated \Vith clinical 
cures in children 20. In vitro models have sho\.VTI no correlation bet\veen killing rates and 
vancomycin concentrations higher than 2-S mg/L 15. 21 . In animals, outcome of 
endocarditis was related to vancomycin trough serum concentrations 22 .. Although it is not 
possible to draw a definite conclusion as to which pharmacodynamic parameter is best 
correlated to efficacy, these studies indicate that keeping the trough level above the lviiC 
is necessary to obtain clinically good results. Monitoring of vancomycin serum 
concentrations should be focussed mainly on keeping adequate trough concentrations. 
For this study goals '\vere set at trough concentrations of S-15 mg/L and peak 
concentrations preferably belo'\v 40 mg/L. 
Using population pharmacokinetics we first established the parameters that best described 
our retrospective data. In contrast to most other studies 4-23-31, these parameters included 
clearance per kg and volume per kg, but not PCA. Given the fact that each patient only 
contributes two data points, the dependence of for instance Cl/kg on GA would have to 
be strong to be detected by the method used. This strong dependence \.Vas not found; in 
our data there is only a trend towards higher serum concentrations at lower GA. 
Elimination half-life and clearance of most drugs is longer in preterm neonates, partly due 
to a higher percentage of body water. However this factor and the postnatal increase of 
renal function32 change considerably in the first postnatal week, during '\vhich vancomycin 
is seldomly given. Furthermore most (81.8 %) of our patients were antenatally e:xposed to 
intra-uterine corticosteroid administration, which diminishes the GA-dependent 
difference in metabolism of different antibiotics 33. 34. These factors might explain the 
mitigated GA effect in our retrospective data. The independence of PCA was confirmed 
in the prospective study. 
Reported mean clearance, V ss and t-;,~ for neonates and infants ranges from 0.036 to 
0.1 L/kg/hr, 0.44 to 0.97 L/kg and 3.0 to 12.0 hrs, rcspectively19 Clearance and Vd 
found for our model were comparable to the other neonatal population pharmacokinetic 
srudy of Seay et al. 35: CL of 0.057 ± 0.0018 vs O.QJS to 0.059 L/kg/hr, Vd 0.43 ± 0.013 
vs 0.50 L/kg, though in this srudy CL was corrected for GA < 32 weeks and dopamine 
use, explaining the \Vide range. Elimination half-life in our population was quite different: 
t'l=~ 6.0 ± 0.27 hrs compared to 13.4-33.7 hrs, and more in concordance '\vi.th the range 
mentioned in other studies 19. Based on the result of these parameters, and the desired 
therapeutic range mentioned before, we tested several possible vancomycin dosing 
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schemes (table II), of which 10 mg/kg/ dose, three rimes a day led to a minimization of 
undesirable high peak- and especially too low trough serum concentrations. Prospective 
evaluation showed that indeed only 4.5% (1 of 22) of initial trough serum concentrations 
was belo\.v 5 mg/L, assuring effective therapy from the start. Ko potentially toxic peak 
serum concentrations were found. In 4 patients serum trough concentrations before the 
fifth dose were arguably too high, but still not higher than 20.6 mg/L. We did not 
simulate constant rate infusion of vancomycin \Vhich \.vas recently advocated24. Though 
this seems a logical approach to obtain desirable steady state vancomycin serum 
concentration, there are several reasons \vhy we do not consider this a feasible option. 
One of the main treatment modalities for line related infections is removing the central 
venous line. This would make continuous dosing of vancomycin unpractical in this group 
of patients in whom venous access is not always easy. Furthermore drug interactions, 
though not found in this study24, are a potential hazard. Last but not least, the time 
relation bet\veen vancomycin serum concentrations and microbial kill rates does not 
warrant such a cumbersome dosing method. 
In concurrence \.V-1th recent literature and given our results there is no obvious need to 
monitor peak vancomycin serum concentrations in neonates \.'\rithout a strong suspicion 
of renal insufficiency 12. 13.36, though this is contradicted by one author 37. 
In conclusion \Ve have shown that the application of a pharmacokinetic population 
model, built on retrospective data, is useful in determining a practical dosing scheme. 
Prospective validation shows that vancomycin dosing in neonates can be simplified to a 
GA-independent schedule of 10 mg/kg/Sh and leads to adequate vancomycin trough 
serum concentrations before the second dose, \.v-1thout potentially toxic peak serum 
concentrations. Our data indicate a need for routine monitoring of trough, but not of 
peak vancomycin concentrations in neonates. 
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in the newborn period 
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SUMMARY 
Oijectiw: To assess the occurrence of hearing loss in children due to neonatal e::-.:posure to 
long courses of tobramycin and/ or high tobramycin serum concentrations. 
Methods: This \.Vas a pilot case-control study in 3-4 year old children. Data on tobramycin 
administration were abstracted from the patient files of an earlier study. Patients exposed 
in the neonatal period to either long courses (> 7days) or high serum concentrations of 
tobram.ycin constituted the study group. The control group consisted of patients \.vi.thout 
tobramycin exposure. Patients were matched for other risk factor according to criteria of 
the Joint Committee on Infant Hearing. All patients undenvent the follo'\ving 
investigations: otoscopy and pneumatic otoscopy, follo\ved by impedance audiometry, to 
exclude middle ear effusion. Click-evoked oto-acousric emissions ( ce-OAE) as well as 
distortion product oto-acoustic emissions (dp-OAE), tested at f2 frequencies ranging 
from 1-10 kHz, \Vere measured to assess hearing. All patients with abnormal ce-OAE 
results undenvent brainstem electric response audiometry (BERA) as \veil. Since 
aminoglycosidc ototoxicity is usually bilateral, results were compared per patient and not 
per ear. 
Results: A total of 29 patients were tested. Eleven patients \Vere excluded due to middle ear 
effusion. Data for 18 patients \Vere analyzed. In the tobramycin treated group (n=9) both 
ce-OAE and dp-OAE (at all tested frequencies) were not detectable in 6 ears of 3 
patients. All other patients had normal ce-OAE's as \veil as normal dp-OAE's in this 
frequency range. Difference bettveen the tobramycin treated and control group for OAE 
as well as dp-OAE showed a trend (p=O.OS). In all three patients "~th undetectable 
emissions BERt\ confirmed a cochlear loss of 60-70 dB at 3 kHz in both ears. These 
three patients had the longest total exposure to tobramycin: 20-24 days and 84-92 mg/kg, 
respectively. ~o relation to either peak or trough serum concentrations could be detected. 
Conc!Nsion: There was no statistical relation bet\veen hearing los; and tobramycin exposure, 
probably due to sample size. Our results do indicate a need for a case-control follo\v-up 
study of hearing in neonates e::-..1Josed to long courses of arninoglycosides. 
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INTRODUCTION 
Bacterial infections play an important role in the morbidity and mortality of preterm 
nconates1. Arn.lnoglycosides are effective ~o-ainst most gram-negative infections in infants 
and play an important role in the initial empiric treatment of neonatal septicemia. 
The most important specific adverse effects of aminoglycosidcs are nephro- and 
ototoxicity. The incidence of nephrotoxicity is not well kno"Wn, but seems to be 
considerably lo\ver in preterm infants than in adults2 • 
.Aminoglycosides accumulate in the lymphatic fluid of the .inner ear and are potentially 
cochlea- and vesti.bulotoxic. Outer hair: cells, inner hair cells and spiral ganglional neurons 
are damaged in a process of excitotoxic cell death due to enhancement of glutamate 
N-methyl-D-aspartate 0fMDA) receptor activity'. Cochlear hearing loss can be divided in 
acute reversible and chronic irreversible ototoxicity v.;-ith a total reported .incidence of 0 to 
47% in adults4. Hearing loss is mainly bilateral and starts in the high frequency range 
above 5 kHz, but is also found in lower frequencies in serious cases5• Reported 
occurrence of aminoglycoside induced ototoxicity in neonates is low in the range of a fe\v 
percent6- 7. The risk of developing clirllcally significant hearing problems in neonates 
treated shorter than one week seems to be smaJl6, s. 9. Suggested risk factors associated 
v.-ith aminoglycoside induced ototoxicity are elevated peak serum concentrations and 
duration of therapy, but the actual relation is unclear6· 9-11. As in adults, aminoglycoside 
extended dose intervals are recommended for neonatcs12-14. These schedules advise doses 
of 3.5-4 mg/kg with intervals of 24-48h for gentamicin and tobramycin with concomitant 
higher peak serum concentrations and lower troughs. Several studies did not find a 
relation between these ne\v dosing regimens and ototoxicity, but since the incidence is 
low, study size \vas possibly too small to detect a difference12.15.16_ 
There arc many pitfalls in relating neonatal hearing loss to aminoglycoside usc. 
Numerous risk factors for neonatal hearing loss have been identified. Perinatal infections, 
meningitis, prcmaru.rity, hyperbilirubinemia, birthwcight < 1500 grams, asphyxia, 
respiratory distress syndrome, mechanical ventilation, antibiotics, and diuretics have all 
been incriminated9_ Potentiation of aminoglycoside induced hearing loss due to loop 
diuretics has been described17. Furthermore delayed onset of hearing loss, possibly related 
to aminoglycoside use has been described9- ls.-zo. Hence aminoglycoside induced hearing 
loss in neonates should be studied in the light of these concomitant factors. 
The aim of the present pilot study was to assess the occurrence of hearing loss due to 
neonatal high-risk exposure to aminoglycosides, defmed as long courses and/ or high 
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serum concentrations. For this purpose 3-4 year old children, e.~posed .in the neonatal 
period to either long courses (> 7days) or high serum concentrations (peak > 12 mg/L, 
trough > 2 mg/L) of tobramycin were compared to patients '\vi.thout tobramycin 
exposure, but matched for other risk factors of hearing loss. 
PATIENTS AND METHODS 
Study design 
The present study was a pilot case-control study of hearing loss conducted in children of 
3-4 years old admitted to the NICU of the Sophia Children's Hospital during theix the 
neonatal period. 
Patients ·were selected from an earlier study on the emergence of antibiotic resistance due 
to antibiotic use21• In that study (study period December 1996 - December 1997), 
neonates admitted to one ward received initial treatment for suspected septicemia "\Vi.th a 
combination of penicillin-G or flucloxacillin and tobramycin. In the other ward the initial 
treatment consisted of amoxicillin or flucloxacillin with cefota.~e. All other treatment 
protocols for these wards were equal. Patients from that study were divided in two 
groups; those who had received tobramycin during admission (eligible for study group), 
and those who had only received other antibiotics (eligible for control group). 
This study '\vas approved by the institutional revie'\v board and patients '\Vere only .included 
after informed consent from a parent or guardian '\Vas obtained. 
Study group 
All patients whose records indicated that they had received tobramycin were revie'\ved. 
Patients '\vi.th an increased risk of tobramycin related toxicity were identified. Risk factors 
were defined as prolonged exposure (> 7 days), elevated peak serum concentrations 
(> 12 mg/L) or elevated trough serum concentrations (> 2 mg/L). All patients '\vi.th one 
or more of these risk factors '\vhose current address could be traced '\Vere approached and, 
if informed consent was obtained, included. 
The dosage regimen used in the period 1996-1997 was as follows. Tobraruycin (4 mg/kg) 
was administered as a 30-minute intravenous infusion. The initial dosing interval was 24, 
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36 or 48 hours in neonates with a gestational age of <32 weeks, 32-37 weeks and 
:::: 37 weeks, respectively. Therapy adjustments were made at the discretion of the 
attending physician. All doses and times of administration \Vere recorded routinely. 
Tobramycin serum samples were taken as part of routine therapeutic drug monitoring 1 
and 6 hours after the first dose and just before the second dose. 
Control group 
For each patient in the study group matched controls were identified in the non-
tobramycin group. Patients \Vere matched for risk factors for neonatal hearing loss, 
according to criteria of the Joint Committee on Infant Hearing22. These were defined as: 
family history of hereditary childhood sensorineural hearing loss, in utero infections (e.g. 
toxoplasmosis, herpes), craniofacial anomalies and other syndromes related to hearing 
loss, birthweight < 1500 g, hyperbilirubinemia requiring exchange transfusion, bacterial 
meningitis, Apgar scores of 0-4 at 1' or 0-6 at 5', mechanical ventilation for more than 
5 days, use of loop diuretics and usc of vancomycin. The first matched control without 
middle-ear effusion in whom measurement of oto-acoustic emissions was technically 
possible, \Vas included in the study. 
Data collection and audiologic testing 
Risk factors for hearing loss in the intervening period between neonatal admission and 
time of audiologic testing were assessed by interviewing the parents. E:-..-posure to other 
ototoxic drugs, meningitis and head trauma as well as familial hearing loss were excluded. 
Frequency of otitis media \vith or \vi.thout antibiotics, paracentesis or ear operations \Vere 
recorded. 
Investigators were blinded to the antibiotic history of the patient. All patients undet\vent 
the follov,.ing investigations. The tympanum \vas vi.sualized using a binocular Zeiss 
OP.MI-9 microscope. Pneumatic otoscopy was used to assess mobility of the tympanic 
membrane. Test results per ear were labeled as normal (aerated), containing fluid, or a 
diminished mobility. Tympanomctry \Vas performed using a clinical impedance device 
(GSI33, Grason Stadler). Tympanograms were defined as type A, B or C according to 
Jerger, \vhere type A is normal23. 
Otoscopy and tympanogram.s were used to determine the validity of test results of the 
otoacoustic emissions. In cases ·with an abnormal tympanogram. and/ or abnormal 
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otoscopic result the absence of otoacousti.c emissions \.Vas considered as due to a middle 
ear dysfunction. 
Otoacoustic emissions were measured using an IL096 OAE-instrument (OtoDynamics, 
UK). Click-Evoked otoacoustic emissions were recorded, with the standard non-linear 
click sequence stimulation, at a level of 82 dBSPL, \Vi.th the real time lo\v pass filtering 
enabled during recording, and a response pass band filter bet\veen 700 Hz and the 
instruments upper frequency limit (6.25 kHz). Distortion Product Oto Acoustic 
Emissions (dp-OAE) were also recorded at the 2£1 - f2 frequency, "~th primary levels of 
60 and 55 c!BSPL for f1 and f2, respectively. F2 frequencies of 1kHz- 10 kHz were used 
with a resolution of 3 points per octave. Scoring on absence or presence of the ce-OAE's 
and dp-OAE's was done subjectively by an expert judge (author# 2). 
All patients \vi.thout middle ear dysfunction, but \Vi.th abnormal ce-OAE results 
undet\'Vent brainstem electric response audiometry (BERA) as well. 
Statistical analysis 
Statistical analysis was performed using SPSS 8. 0 statistical soft\'vare (SPSS Inc., Chicago, 
USA). Comparison between patients exposed to tobramycin and matched controls \Vas 
performed using a paired samples t-test. 
RESULTS 
A total of 59 patients had received tobramycin for ~ 7 days and/ or were exposed to 
tobramycin serum concentrations outside of the desired therapeutic range. The current 
address of 30 could be traced of whom 12 responded. These t\Velve patients constituted 
the tobramycin group. A total of 17 patients were tested in the control group. Eleven 
patients were excluded of whom three \vere e::-.."Posed to tobramycin . In these 11 patients 
no dependable otoacoustic emissions could be recorded, despite retesting, apparently due 
to middle ear effusion. Eighteen patients were included, 9 patients witl~ exposition to 
tobramycin and 9 patients \Vi.thout. Individual demographic variables for tl~ese patients 
are listed in table 1. All patients were intubated or had a nasopharyngeal tube for more 
than 5 days. )Jo patient had a bilirubin level necessitating exchange transfusion. Patient 1 
and 2 are matched for GA, but not for birtbweight. 
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A total of 33 out of 36 ears were evaluable 'Wjth ce-OAE and dp-OAE. Three patients 
(one Mth tobrarnycin) had middle ear effusion in one ear. 
In the tobramycin treated group both ce-OAE and dp-OAE were not detectable in 6 ears 
of 3 patients. Results for dp-OAE showed no emissions in the range of 1-10 kHz for 
both ears. All other patients had normal ce-OAE's as well as normal dp-OAE's in this 
frequency range. Difference bet\veen the tobramycin treated and control group for ce-
OAE as well as dp-OAE showed a trend (p=O.OS), but did not reach statistical 
significance. In all three patients Mth undetectable emissions, BERA confirmed the 
abnormalities. In all three patients a cochlear loss of 60-70 dB at 3 kHz in both ears was 
found. These three patients had the longest total exposure to tobramycin: 20-24 days and 
84-92 mg/kg, respectively. :::--Jo relation to either peak or trough serum concentrations 
could be detected. 
Patient 5 had a right sided grade III intraventricular hemorrhage. Patients 7 and 9 are 
heterozygote mi.ns. Patient 9 showed bilateral periventricular leucomalacia on cerebral 
sonography. 
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Patient Tobramycin: Tobramycin: Maximum Ma.'Ximum Vancomycin Furosemide Gestational Birth~ AS 54 :;-1 
total exposure peak2 troughl weight "" total exposure exposure exposure age 
"' (days)' (mg/kg) (days) (mg/kg) ("-'eeks) (grams) 
"' \;' 
8 8 7.5 !.6 0 0 31 0/7 995 7 !l., ~. 
2 0 2 31 6/7 2010 9 t 
3 8 8 ll.l 0.3 0 0 28 0/7 950 9 v ~ ~ 
4 0 0 27 6/7 1190 7 ~ , 
5 20 8 9.8 0.7 0 4 27 0/7 1040 5 ~ 
29 4/7 ~ 6 0 0 1235 6 '\\ 
7 22 14 7.7 l.l 13 0 26 1/7 1050 9 ~· 
" 8 6 2 27 0/7 1130 7 ~· 
9 0.6 I 26 1/7 960 
!;-
24 15 7.8 0 7 ~ 
"'-
10 0 2 24 6/7 670 10 ~· 
"'-II 6 6 14.8 0.9 0 0 37 5/7 3155 9 ~ ~ 
12 0 37 0/7 " 0 
3800 9 ~ 
13 16 12 9.7 0.6 0 2 25 5/7 1130 7 
14 0 0 29 3/7 1450 8 
15 16 9 8.2 l.l 22 22 37 0/7 2840 lO 
16 30 30 39 6/7 4000 lO 
17 14 7 14.0 2.3 4 4 28 1/7 860 8 
18 I I 28 1/7 1140 8 
1 Longest consecutive treatment (days), 2 .Maximu peak serum concentration, J ~laximum trough serum concentration,-+ 5' Apgar score 
'D 
'-'. 
~ I'" u, ~;, 
'"' 
DISCUSSION 
The relation benveen adm.inisttation of aminoglycosides and ototoxicity has been under 
discussion since early reports ID 194524• Studies in adults have suggested an influence of 
absence of sufficiendy low trough concentrations for adequate periods, but there is little 
evidence for a relation bertveen peak or trough serum concentrations and 
ototoxicityS, 11· 25· 26. In adults as \Veil as neonates a relation bet\veen ototoxicity and total 
dose and duration of therapy is postulatedS-to. Treatment for longer than 10 days is 
considered to be a risk factorS, s. Reported aminoglycoside ototoxicity in neonates is low, 
also \vith present day extended interval dosing7, 12. 16. 27. ~o relation bettveen serum 
concentrations of aminoglycosides and ototoxicity has been demonstrated. Also, hearing 
screening in neonates did not show an increase in occurrence of hearing loss in 
aminoglycoside exposed patients2S-3l_ These studies did not however look specifically at 
serum concentrations. On the other hand several authors have demonstrated that, mainly 
reversible, abnormalities on BERA can be seen early on in aminoglycoside treated infants, 
indicating alteration of the central transmission of auditory brainstem responses1D. 1s. 32. 33. 
Furthermore it has been demonstrated in adults and suggested in neonates that 
aminoglycoside related ototoxicity can occur \.Veeks to months after discontinuation of 
treatment5· 18·2D. In the study by Ka\.vashiro et al., all patients \.vi.th this type of hearing loss 
were exposed to 7-14 days of treatment with gentamicin and/ or amikacin, next to other 
risk factors19. To capture the possibility of delayed hearing disturbance we investigated the 
patient group most at risk for aminoglycoside related ototoxicity at the age of 3-4 years. 
Since aminoglycoside ototoxicity is mosdy bilateral '.ve chose not to compare patients to 
matched controls per car but per patient. Although no statistical significance was found, 
possibly due to the small number of patients, it is worrisome that three patients in this 
high-risk group had moderate to severe cochlear hearing loss. No relation to either peak 
or trough serum concentration could be detected. Also hearing loss, which if induced by 
aminoglycosides \vas expected to be mainly in the higher frequency range, was apparent at 
all frequencies in our patients. This could imply that these \.Vere more severe cases of 
aminoglycoside induced hearing loss, where damage has progressed beyond the basal turn 
of the cochlea. There \vas a striking relation to total exposure; the three patients with 
hearing loss had the highest overall e:A'Posure to tobramycin (duration as well as in mg/kg) 
of the 9 patients studied. This result is in concordance '.vi.th several other studiesS-10_ 
Borradori and co-workers performed a case-control study in S neonates \vi.th 
sensorineural hearing loss, all exposed to more than 10 days of aminoglycoside treatment 
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and found a significant relation to cumulative dose and total treatment duration of 
aminoglycosides9• In the study by Chayasirisobhon et al., neonates treated '\vi.th 
gentamicin for 2: 10 days \vere at a significant greater risk of having abnormalities on 
BERA than neonates exposed to < 10 days of treatments. Patients in both studies were 
not matched for all other risk factors. Therefore abnormalities might have been related to 
underlying co-morbidity. An earlier study also found a correlation bertveen \vave V 
latencies on BERA \Vi.th the total dose of aminoglycosides adm.i.nisteredlO. Hearing \Vas 
evaluated \.vi.thin 2 days of end of treatment. Therefore abnormalities might have been 
reversible. 
Since nvo of our patients \vi.th hearing loss \.vere nvins, familial hearing abnormalities, 
possibly of mitochondrial origin could be the cause'4 • Family history for hearing loss was 
negative and permission for mitochondrial D~A analysis was refused. 
How should \Ve perceive the seemingly conflicting ev-idence of aminoglycoside related 
ototoxicity in newborns? On the one hand screening programs found no relation bet\veen 
e:-."Posure to aminoglycosides and hearing loss2S·31• Also, \vith the present extended dose 
intenrals, aminoglycoside related ototoxicity is rare 12. 16. On the other hand several studies 
in relatively few patients, including this one, found a relation to duration of therapy. In 
most of these studies neonates had been exposed to more than 10 days of aminoglycoside 
treatments-1o. Furthermore, there are reports \vhere delayed onset of hearing loss in 
infants is described9- 18-20. It is possible that hearing screening performed in infants before 
discharge might be too early to detect this type of hearing loss. A second reason might be 
that aminoglycoside induced hearing loss starts at higher frequencies ·which are not 
detected by routine hearing screening methods. These factors imply that aminoglycoside 
related hearing loss could be underreported. The main limitation of this pilot study is the 
small number of patients included. Our results do indicate a need for a case-control 
follow-up study in neonates exposed to aminoglycosides for longer than 10 days 
compared with patients matched for other risk factors related to hearing loss. 
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Newborn hearing screening: tobramycin 
and vancomycin as risk factors for 
hearing loss 
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SUMMARY 
0/jectiz:e: to investigate the chance of detecting hearing loss '\vith neonatal hearing 
screening in relation to exposure to tobramycin and vancomycin expressed in terms of 
duration of therapy and serum concentrations. 
Methods: Automated Auditory Brainstem Response (A-ABR) hearing screening \vas 
performed in all neonates with at least one risk factor as defined by the Joint Committee 
on Infant hearing. Data on administration of tobramycin, vancomycin and furosemide as 
well as available serum concentrations were abstracted from patient files of neonates who 
undenvent hearing screening bet\veen :I:"ovember 1998 and November 2000. Exposure to 
these drugs was quantitated in terms of total dose, duration of therapy and, where 
possible, serum concentrations and related to the result of hearing screening using logistic 
regression. In patients failing hearing screening, exposure to ototoxic medication was 
assessed in the light of other risk factors for hearing loss. 
Results: A total of 625 patients \.Vere analyzed. Forty-five neonates failed hearing 
screening. Tobramycin, vancomycin and furosemide were used in 508, 130 and 174 
patients, respectively. 
E::...-posure to vancomycin and tobramycin in terms of treatment duration, total dose or 
serum concentrations \.vas not related to failure to pass A-ABR screening. Exposure to 
both antibiotics in the same patient, as well as combination -..v-ith furosemide treatment, 
\.Vas also not related to a failure to pass hearing screening. In none of the patients \.vith 
serum concentrations outside the therapeutic range, exposure to ototoxic medication was 
the most likely risk factor for hearing loss. 
Co!lc!Jtsion: )Jo quantitative or qualitative relation berureen exposure to tobramycin or 
vancomycin and a failure to pass hearing screening \.Vas found. Routine TDM of 
vancomycin and tobramycin in neonates for ototoxicity reasons is not helpful in detecting 
patients at risk for clinically important hearing loss. 
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INTRODUCTION 
Congenital neonatal hearing loss has a reported prevalence of 0.1-0.3%1. 2. ;\Jconates 
admitted to a neonatal intensive care unit (:'JICU) have a higher risk of developing 
sensorinew:al hearing loss of approximately one in every hundred3. Late recognition leads 
to impaired acquisition of language and speech~. Therefore, early detection of impaired 
infant hearing is important, and consequently many neonatal hearing screening programs 
have been developed. The methods most often used are Oro-Acoustic Emissions (OAE) 
and Automated Auditory Brainstem Response (A-ABR)5. A-ABR is a very reliable 
screening method with a reponed sensitivity of 100o/o and specificity of over 95% 6•8. 
Screening programs in the NICU follo\.V one of t\\70 strategies. Screening is either 
performed in all neonates6. 9 admitted to a NICU or in neonates "Wi.th certain risk factors 
previously described3. Risk factors are among others: family history of hearing loss, 
perinatal infections, meningitis, birthweight < 1500 gms, hyperbilirubinemia, asphyxia, 
respiratory distress syndrome, mechanical vemihtion, diuretics and antibiotics, especi2.lly 
aminoglycosides and vancomycin10. These potentially vestibulo- and cochleotoxic 
antibiotics are frequently used for early (aminoglycoside) and late onset (vancomycin) 
neonatal septicemia. Vestibulotoxicity is difficult to determine in neonates, so reports on 
ototoxicity are limited to hearing loss. Vancomycin reported ototoxicity, mainly based on 
case reports, is < 2°/o in adults. Data from the current literature do not show a relation 
benveen vancomycin related ototoxicity and serum concentrations, and it is not clear 
\vhether ototoxicity should be attributed to vancomycin or other confounding factorsll. 
Little is known about vancomycin ototoxicity in neonates. The fC\v studies addressing this 
issue did not f111d ototoxicity12.13. 
Aminoglycoside induced ototoxicity in adults usually occurs in patients \vho have received 
either long, or repeated, courses of aminoglycosides14. A relation bet\veen high serum 
concentrations and toxicity has been suggested, but not demonstrated. There are still 
many gaps in our knowledge on the relation bet\veen aminoglycoside use and hearing loss 
during infancy. Even though some studies show a relation to administration of 
aminoglycosides, it remains difficult to separate the effect of aminoglycoside use from 
other confounding factors 15-17. Ko clear relation was found to peak and trough 
concentrations and most of these studies did not correct for concomitant risk factors. 
Concurrent treatment \vi.th furosemide and vancomycin was associated "\vith hearing 
loss1S. 19. Furthermore these studies were performed in neonates receiving 
aminoglycosides several rimes daily, \Vhile over the last few years dosing intervals, similar 
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to dosing regimens in adults, have been extended20· 21• Ototoxicity should be studied in 
the light of these ne\.v regimens. It is also clear that this toxicity has to be seen ~oainst the 
background of other risk factors. Although several recent screening studies in neonates 
have not shown aminoglycoside administration to be an important risk factor, no study 
has looked specifically at serum concentrations and duration of therapy1. 22-2+. The aim of 
the present study \.vas to explore the risk of detecting hearing loss "vi.th neonatal hearing 
screening in relation to exposure to tobramycin and vancomycin expressed in terms of 
duration of therapy and serum concentrations. 
PATIENTS AND METHODS 
Study design 
The present study was conducted in neonates admitted to the NICU of the Sophia 
Children's Hospital from November 1998 to ~ovembcr 2000. 
Inclusion criteria 
.All neonates \.vho undenvent A-ABR screening were included in this study. A-ABR 
screening \.vas performed in neonates \.Vi.th the follo\.vi.ng risk factors, as noted on a chart 
by the attending physician: positive family history for hearing loss, positive serology for 
toxoplasmosis, rubella, cytomegalo virus or herpes virus, craniofacial abnormalities, 
bird1.weight below 1500 grams, hyperbilirubinemia necessitating exchange transfusion, 
cerebral complications, a 1' APGAR score below 5 or a 5' APGAR score below 7, 
mechanical ventilation longer than 5 days, syndromal abnormalities. 
Data collection 
ParaUJeters 
Gestational age (GA), birthweight, indication(s) for A-ABR screening, test date and result 
were abstracted from A-ABR case record forms. Apgar scores \.Vere abstracted from the 
patient files. Information on administration of potential ototoxic medication (tobramycin, 
vancomycin and furosemide) \.Vas abstracted from the computerized hospital medication 
ordering system by t\Vo independent inves~o-ators and cross-checked. 
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Administration and dosage regil7lel1 of tobraJJ()Icil1_, v·anCOJJ()'ci!l and Jirrosel7lide 
Administration of tobramycin was performed in a 30-minute i.v. infusion in a dose of 
4 mg/k.g. The initial dosing interval was 24, 36 or 48 hours in neonates \vi.th a GA of 
<32 weeks, 32-36 weeks and 2: 37 weeks, respectively. Tobramycin serum samples were 
taken as part of routine therapeutic drug monitoring 1 and 6 hours (October 1998-
February 2000) or 3 and 8 hours (from March 2000 onwards) after the first dose and just 
before the second dose (all), at the discretion of the attending physician. Thus tobramycin 
peak concentrations were only available for the first period. Vancomycin was 
administered in a dose of 10 mg/kg in a 1h infusion \vith an intenral of Sh irrespective of 
GA. Trough and peak serum sampling \Vas performed around the fourth dose, \vith the 
trough just before and the peak 1h after completion of the infusion. Therapy adjustments 
were made at the discretion of the attending physician. AJl doses and times of 
administration were recorded routinely. Duration of therapy and ma:illnum peak and 
trough concentrations were noted for vancomycin. 
Exposure to furosemide in mg/kg was also noted. 
A;rdi!O!]' te.rtt'ng 
Hearing screening was performed with an automated auditory brain stem response device 
(ALGO-l E, Natus Medical Inc., California, l.:"SA) by specialized nurses. This device 
measures responses to a monoaural 35 dBnHL click stimulus. Artefact rejection for 
ambient noise and myogenic acti'vity is automatic. ALG0-1 E displays a pass when the 
internal algorithm reaches a likelihood ratio ~ 160 in discriminating between response + 
noise, noise and no response5 . The algorithm criteria were defined by comparison "'W-ith 
conventional ABR Sensitiv·ity for this test (compared to conventional ABR as the gold 
standard) is 100%, specificity ranges from 96 to 98.7% 8.25-27_ 
Patients \Vi.th refers from A-ABR testing ·were scheduled for a retest and a further retest 
on second failure to pass. All patients failing this sequence of testing were referred for 
further conventional testing. 
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Statistical analysis 
Statistical analysis was performed using SPSS 8. 0 statistical software (SPSS Inc., Chicago, 
t:SA). 
The \Vilcoxon signed rank test and ~nn-\Vbitney test were used as nonparametric tests. 
All variables were entered as single covariates for logistic regression. For the purpose of 
analysis certain continuous variables \vere categorized, to enable valid inclusion of non-
exposed patients. Tobramycin: exposure as longest consecutive duration of treatment 
(days): 0, 1-5, >5; total exposure (mg/kg): 0, S 20 mg/kg, > 20 mg/kg; peak serum 
concentrations: 0 (no e.:-."Posure), :S 12 mg/L, > 12 mg/L; trough serum concentrations 0 
(no exposure), :S 2, > 2 mg/L. Vancomycin: exposition in days of treatment: 0, 1-7 and 
> 7 days; peak serum concentrations: 0 (no exposure), :S 40 mg/L, > 40 mg/L; trough 
serum concentrations 0 (no e::..."Posure), :.S 15 mg/L, > 15 mg/L Furosemide exposition: 
0, 1-10 and >10 mg/kg. If a relation bet\veen serum concentrations and ototoxicity exists, 
this is expected \vith higher exposure. For this reason, univariate logistic regression \Vi.th 
serum concentrations as continuous variable '\vas also performed in a subgroup of 
patients with serum tobramycin and vancomycin peak and trough concentrations 
exceeding arbitrary limits: tobramycin 8 mg/L and 1 mg/L, respectively and vancomycin 
30 mg/L and 10 mg/L, respectively. 
Multiple logistic regression was performed on combination therapy of tobramycin, 
vancomycin and furosemide. 
RESULTS 
Patient characteristics 
During the study period a total of 1197 patients were admitted to the NICC. A total of 
669 patients \vere eligible for ALGO screening. In 44 patients complete A-ABR screening 
was not performed; 28 patients died before screening, 11 parents refused cooperation in 
screening and in 2 repeat A-ABR screening has not been performed. In three patients 
A-ABR screening failed for technical reasons. All dtree undenvenr conventional ABR and 
tested as normal. Data for 625 patients were analyzed. 
Demographic parameters are sho\Vn in table 1. There \Vere no differences in GA and 
bird~weight bet\veen patients passing or failing A-ABR screening. There is a significant 
difference in age at final A-ABR screening betv.reen neonates who pass or fail hearing 
screening, inherent to the method of screening. 
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Tab!e1: Demographics for stllcj)i grot~p. l\Tttmbers are medians and ranges 
p-value 
Total Pass Refer (Mann-
(n=625) (n=580) (n=45) Whitney) 
Gestational age (weeks) 32.0 (24-43) 31.9 (25.3-43.0) 32.1 (24--41.9) 0.56 
Birth-..veight (grams) 1480 (520-5800) 1478 (520-5800) 1550 (545- 4050) 0.89 
Age at A-_A.BR (days) 19 (0-286) 18 (0-286) 47 (1-255) <0.001 
Statistical relations between ototoxicity and risk factors 
Figure 1 shmvs the distribution of number of risk factors per patient. Thlrteen neonates 
had no indication, but were tested by request of the parent, because they \.Vere part of a 
t\\rin pregnancy of '\vhlch the orher half had to be screened. There \.vas one indication for 
testing in 377 neonates, t\vo indications in 178 neonates and 3 or more indications in 
57 neonates. 
Fig.1: Ri.rk of foiling A-/fER screening in relation Jlt1111ber of iJJdicutiom:for screeJJing 
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Number of indiations 
In univariate analysis, the number of indications per patient for testing '\vas the single 
most important risk factor (p=0.0007). This is also illustrated by %oure 1. Given the 
influence of the number of indications as well as the significant difference in postnatal age 
at final screening, univariate analysis of orher variables was corrected for these t\vo 
factors. Table 2 shows all inclusion criteria for A-ABR screening and the relative risk for 
failure of this screening. These numbers are only valid in a population \.Vith at least one 
risk factor. The presence of craniofacial abnormalities \.Vas the most imponant single risk 
factor in failing A-ABR screening. No other single risk factor attained significance. 
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Table 2: Distribution of risk factors in ilifants Jl!ith normal and abnormal A-ABR scremi;tg. P-ml11es 
are from tmil/an"ate ana!Jsis> corrected for number of indicatiom and age at A-ABR screeniJ7g 
A-ABR normal A-ABRrefer Odds ratio 
Risk factor (n=580) (n=45) P-value (95% CI) 
Family history 12 2.1% 3 6.7% 0.18 2.5 (0.6-9.9) 
TORCH* 8 1.4% 1 2.2% 0.81 1.3 (0.2-11.0) 
Craniofacial 10 1.7% 5 11.1% 0.0014 6.9 (2.1-22.6) 
Birthwcight<1500 304 52.4% 22 48.9% 0.04 0.5 (0.2-1.0) 
Hyperbilirubinemia 17 2.9% 3 6.7% 0.19 2.4 (0.6-9.2) 
Cerebral complications 63 10.9% 8 17.8% 0.84 1.1 (0.4-2.8) 
Apgar score 1 '<5/5'<7 223 3.8% 17 37.8% 0.62 0.8 (0.4-1.7) 
Mechanical ventilarion>S days 172 29.7% 19 42.2°/o 0.65 0.8 (0.4-1.8) 
Syndrome 23 4.0% 4 8.9% 0.24 2.0 (0.6-6.2) 
" Positive serology for toxoplasmosis, rubella, cytomegaly virus or herpes. 
Table 3 sho\VS details on exposure to ototoxic medication in the study group. As can be 
seen 508 patients received tobramycin, 130 patients vancomycin and 174 patients 
furosemide. Total exposure to tobramycin was 15.3 ± 11.1 and 20 ± 19.6 mg/kg for 
neonates passing and failing hearing screening, respectively. For vancomycin, total 
exposure \vas 234 ± 159 and 375 ± 273 mg/kg respectively for groups of neonates \vho 
passed or failed hearing screening. These data were not statistically different bet\veen both 
groups. Table 3 also shows ototoxic medication as risk factor for failure of A-ABR 
screening. Potential ototoxic medication, defined in terms of duration of treatment, total 
exposure and aberrant peak and trough serum concentrations \Vas analyzed using logistic 
regression. As can be seen exposure to vancomycin and tobramycin in terms of treatment 
duration and total dose was not significantly related to failure to pass A-ABR screening. 
Exposure to both antibiotics in the same patient, as well as combination \Vith furosemide 
treatment, was also not related to hearing loss. Peak and trough serum concentrations of 
both vancomycin and tobramycin were not associated \vith an increased risk of failing A-
ABR screening. In the subgroup of patients \.vi.th l,jgher peak- or trough serum 
concentrations of vancomycin or tobramycin, entered as continuous variable in logistic 
regression, no relation to failing A-ABR screening \vas detected (p-valuc ranging from 
0.13- 0.67). 
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Table 3: Unh·miale ana!J:.ris rj ototoxic nJedication a.r: n:r:k factor for Jaihtre o/ A-ABR .r:creming. P-valtres and 
oddr ratio.r are corrected for nJtmber of indications and age at A-ABR screening 
Total Pass Refer n p--value Odds ratio 
(95% CI) 
Tobramycin 508 473 35 625 0.19 0.6 (0.3-1.3) 
Total cposJtre (mg/ kg)> 20 mg/ kg 102 93 9 6?" -0 0.28 0.8 (0.4-1.3) 
Longe.r:t seqJtentia!treatment > 5 dqy 135 125 10 6?" -0 0.18 0.7 (0.4-1.2) 
Peak concentration> 12 mg/L 6 5 1 449 0.23 0.6 (0.3-1.4) 
Tro11gh concenlrotion > 2mg/L 9 8 1 393 0.55 0.8 (0.4-1.7) 
Vancomycin 130 119 11 625 0.52 0.8 (0.4-1.7) 
Vancoi?(Jcin ex:po.mre > 7 dqys 54 8 62 625 0.89 1.0 (0.6-1.5) 
Peak concentration> 40 mg/L 4 3 1 593 0.45 0.7 (0.3-1.7) 
Tro11gh concentration> 15 mg/L 26 25 604 0.22 0.7 (0.3-1.3) 
Furosemide 174 158 16 625 0.49 0.3 (0.4-1.6) 
Total e:;. .. pomre > 10 mg/ kg 25 21 4 625 0.90 1.0 (0.5-1.7) 
Tobramycin +vancomycin 122 111 11 6?" -0 0.67 0.8 (0.4-1.8) 
Tobramycin +furosemide 154 140 14 625 0.44 0.7 (0.4-1.6) 
T obramycin + vancomycin + 66 59 7 625 0.73 0.8 (0.3-2.1) 
furosemide 
n = number of patients included in analysis 
Relation of ototoxicity to antibiotic use in individual patients 
Tobranrycin 
Patients \V·ith potential ototoxic serum concentrations failing A-ABR screerung were 
analyzed. Only one of the si.x patients Vlith a peak tobramycin concentration > 12 mg/L 
failed hearing screening and conventioool ABR showed bilateral hearing loss of 50-60 dB 
Vlith a cochlear component at follow-up. This patient was born a premature (GA 26 
weeks) and had low Apgar scores (6/7) as well as periventticnlar leucomalacia. 
Furthermore he also received vancomycin for 35 days Vlith normal serum concentrations . 
Only one out of three peak serum concentrations of tobramycin in this patient was 
> 12 mg/L. 
Nine patients had trough serum concentrations > 2 mg/L. One of these nine patients 
failed A-ABR screening. This patient had bilateral hearing loss with a cochlear 
component of 50-60 dB. This patient received only 2 doses of tobramycin however and 
also had neonatal asphyxia and delayed motor development. Since there is evidence that 
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trough concentration goals should be set to 0.5-1.0 mg/L \.vith extended interval dosing 
of aminoglycosides, '\Ve also looked at the 56 patients ""l.th trough serum concentrations 
exceeding 1.0 mg/L2S. 29. In this group, three neonates failed hearing screening. One 
patient, "vl.th a trough > 2 mg/L, is described above. Of the t\VO others, the first patient, 
'\vho had severe perinatal asphyxia, '\Vas exposed to only one dose of aminoglycosides. The 
second patient, exposed to 7 doses (2 courses, longest consecutive treatment 7 days), had 
severe bilateral hearing loss ""l.thout a clear cause. 
Eleven patients received tobramycin for 2: 10 consecutive days; t\.vo failed A-ABR 
screening. The first patient had slight cochlear loss (20-25 dB) in one car and '\Vas also 
exposed to 12 days of vancomycin treatment. The second patient had severe bilateral 
hearing loss with no reproducible responses on ABR pointing at auditory neuropathy 
and/ or severe loss of ear sensitivity to sound. This patient '\vas not exposed to 
vancomycin, but had 3 other risk factors; birthweight <1500 grams, 1' Apgar score of 5 
and abnormalities on cerebral ultrasound. 
Vanco!J(Jcin 
Four patients had peak vancomycin concentrations > 40 mg/L. One of these patients 
(peak 42.3 mg/L) had bilateral severe hearing loss. This patient, who had a grade III 
intraventricular hemorrhage and sepsis/meningitis, died later. 
One of 26 patients '\vl.th vancomycin trough concentrations exceeding 15 mg/L failed 
hearing screening. This patient (trough 17.7 mg/L), who had neonatal septicemia and 
periventricular leucomalacia, was exposed to 12 days of vancomycin and 27 days of 
tobramycin. He had mild (20-25 dB) cochlear loss in one ear. There was a rise in serum 
creati.nin to 112 f.liDol/L prior to this serum trough concentration. 
Si.xteen patients were e::-.."Posed to vancomycin for more than 14 days, "\Vl.th 3 failures on 
hearing screening. One patient had grade III intraventricular hemorrhage as well as 
abnormalities on YIR1 compatible Mth kernicterus. The second and third patient received 
3 doses of tobramycin as \.veil, Mth normal serum concentrations for both antibiotics. 
The second patient had 5 indications for A-ABR screening, including bilateral grade III 
IVH and posthemorrhagic hydrocephalus. The third patient, with neonatal periventricular 
leucomalacia and hydrocephalus, had bilateral cochlear hearing loss (50 dB). 
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DISCUSSION 
The relation bet\veen use of tobramycin or vancomycin and neonatal hearing loss is not 
'\veil defined. In this study \Ve investigated the effect of e::-.."Posure to tobramycin and 
vancomycin, both commonly used in the ~ICU, on failing hearing screening. Ototoxicity 
has been related to usc of both antibiotics and therapeutic drug monitoring (TD~ has 
been advocated. Commonly accepted TD.YI goals for tobramycin are peak and trough 
serum concentrations of 5-12 mg/L and < 2mg/L, respectively. A clear relation of serum 
concentrations of arninoglycosides to ototoxicity has not been demonstrated in adults or 
neonates'O. 14-lrJ. 30. Possible reduction of nephro- and ototoxicity \v-ith extended interval 
dosing of arninoglycosides \vas a major reason for implementation of this regimen in 
adults and neonates during the last decade. A definite reduction in the number of patients 
\vith aminoglycoside related ototoxicity has not been demonstrated ho\vever31, 32, These 
new extended dosing interval regimens have implications for therapeutic drug monitoring. 
To prevent prolonged exposure, it has been suggested that trough concentration goals 
should be reduced to 0.5-1 mg/L in adults with once daily dosing'"·"· In this study we 
evaluated the effect of our extended interval dosing regimen on occurrence rate of failure 
to pass A-ABR screening. As in several other screening studies, \ve could not detect an 
overall difference of prevalence in hearing loss bet\veen patients exposed or not 
exposed to aminoglycoside treatment.!. 22- 24· 33 . Kone of these studies sho\ved detailed 
information on admirllstration regimens and/ or serum concentrations, \vhich might be 
important since other studies in neonates suggest that ototoxicity might be related to 
total duration of therapy and high peak and/ or trough serum concentrations to. 15.16.34. No 
relation to any of these determinants was found in the present study. Several studies have 
demonstrated that extended interval dosing in neonates is relatively safe16, 21. 35. These 
studies have focussed on screening neonates exposed to aminoglycosides \\r.ithout 
matching for concomitant risk factors. Borradori et al. found a relation between hearing 
loss and aminoglycoside treatment .in a matched control study .in 8 children -with hearing 
loss10. Their study found a relation bet\veen cumulative dose and treatment days, but not 
\vith serum concentrations. Ho\vever, patients \Vere not matched for all risk factors 
(e.g. hyperbilirubinemia, days on ventilatory support). In this study, there was no patient 
exposed to tobramycin in \Vhom aberrant tobramycin serum concentrations \Vhere the 
most likely cause of hearing loss. 
TDM goals for vancomycin are peak and trough concentrations of 20-40 mg/L and 
< 15 mg/L, respectively. There is circumstantial evidence relating high peak 
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concentrations to ototoxicity, but a relation between v'"2ncomycin related ototoxicity and 
serum concentrations has not been demonstrated in adultsll, 36. Information in neonates 
is very scarce but did not demonstrate vancomycin related hearing loss13. 37• 
In this srudy no relation was found bet\veen e::-.-posure to vancomycin and hearing loss. 
Only one patient \vith peak concentrations exceeding 40 mg/L failed A-ABR screening, 
but as described before, this patient had sever neurologic deficit including meningitis and 
IVH which have been shown to induce hearing loss38. 39. All three patients \vith high 
trough vancomycin concentrations and failure to pass A-ABR screening had central 
nerv-ous system abnormalities (e.g. IVH, hydrocephalus) associated urith hearing loss38. 40. 
Incidence of ototoxicity is said to be higher in patients receiv--ing both arninoglycosides 
and vancomycin18- l9,3G. The present study, however showed no relation between failure to 
pass A-ABR screening and concomitant usc of tobramycin and vancomycin. Several 
authors have indicated that the potential ototoxic effect of arninoglycosides is potentiated 
by loop diuretics and/ or vancomycin10. 41 • 42• In the present study we did not find this 
association, not even when the patient group with highest exposure to both furosemide 
and tobramycin was compared to the rest (data not shown). 
There are three limitations to this study. First, this study describes hearing screening in an 
at risk population, '.Vi.th at least one risk factor for hearing loss. One has to be careful to 
translate results to the total group of ne\vboms admitted to a ~ICU. However a high 
percentage of all patients admitted to the NICU and e:<posed to either tobramycin (60%) 
or vancomycin (84%) were included in this study. Second, click-evoked A-ABR screening 
detects hearing loss in the 2-4 kHz frequency range, which is clinically important for 
speech and language development. Aminoglycoside related hearing loss starts in the 
higher frequency ranges, above 8 kHz, but is also found in lower frequencies in serious 
cases43. It is possible that some neonates in tllls study had hearing loss in this range, 
which can not be investigated \Vi.th current routine techniques in this age group. Because 
cochlear damage induced by arninoglycoside use is stationary over the years, the long-
term clinical importance of this high-frequency hearing loss is doubtful. 
Third, delayed onset of hearing loss in infants has been described10• 44. In the present 
study, 77% of patients exposed to tobramydn for more than 10 days undenvent hearing 
screening at least t\vo weeks after cessation of therapy. It is conceivable ho\vever, that 
hearing screening was performed too early in some patients to detect hearing loss and it 
might be necessary to reassess hearing in neonates \Vi.th prolonged exposure to 
aminoglycosides. 
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O:o:oxiciiJ' 
Given these limitations, this study still has important implications for TDM. Aberrant 
serum concentrations for tobramycin and vancomycin in the present study were not 
associated "With failing hearing screening, and adherence to TD.M goals did not preclude 
hearing loss. There was no patient in this study in whom aberrant serum concentrations 
were a likely cause of hearing loss. This leads us to conclude that routine TD:yf of 
vancomycin and tobramycin in neonates is not helpful in detecting patients at risk for 
clinically important hearing loss. 
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INTRODUCTION 
Keonatal sepsis remains one of the main causes of mortality and morbidity of newborn 
infants admitted to a neonatal intensive care unitl. Sepsis in this age group can be divided 
in early onset, defined as \vi.thin the first 3-4 days of life and late-onset, occurring after 
4 days1. 
Group B streptococcus and gram negative organisms such as Escherichia coli and 
Haemophi!tts ilifluenza are the most common causative organisms for early-onset scpsis2. 
Especially in the United States an increase of gram-negative neonatal infections has been 
noted due to prenatal administration of anribiotics3• Late onset neonatal sepsis is related 
to the increased use of invasive procedures such as central venous lines and includes as 
major pathogens gram-positive organisms from the skin: S. epidermidis and S. aureu.f+, 5• The 
spectrum of pathogens .in these t\vO different age groups has led to conunonly accepted 
empiric antibiotic strategies. Early onset sepsis is treated "\Vith a combination of a 
penic.illin '-Vith either a third generation cephalosporin or an aminoglycoside. Empiric 
treat:nlent of late onset sepsis often starts \vith a combination of flucloxacillin and either a 
third generation cephalosporin or an aminoglycoside, with a switch made to vancomycin 
when culture results and resistance patterns indicate a need for change4.6. 7. 
Treatment with vancomycin as well as aminoglycosides has historically been subject to 
therapeutic drug monitoring (TD:\1), and many dosing regimens in neonates have been 
constructed, \vi.th the aim to adhere to currendy accepted therapeutic ranges. 
Several interconnecting aspects surrounding dosing of these antibiotics in newborns have 
to be taken into account to optimize the therapeutic effect of these drugs. Goals for 
TDM have to be determined based on the relation between serum concentrations and 
efficacy/toxicity. On the basis of target concentrations and pharmacokinetic behavior of 
these drugs in neonates a dosing regimen must be developed. During trearment efficacy 
and toxicity have to be monitored. Monitoring can not be limited to taking well timed 
serum concentrations. 
In the follo"\Ving sections the different aspects ofTDNC, dosing and monitoring of efficacy 
and toxicity 'Wi.ll be discussed in detail. 
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THERAPEUTIC DRUG MONITORING: WHEN AND WHY? 
In general, routine TD~ is only rational when the use of the drug has the follo'.ving 
characteristics: 
1. Availability of an assay for the drug v.ith an adequate assay error. 
2. Clinical effect or toxicity of the drug is difficult to determine or has a delayed 
presentation. 
3. A large interindividual variation in pharmacokinetic behavior bet\veen patients. 
4. A good correlation bet\veen serum concentrations and effect or toxicity. 
5. Lise of TDM should appropriately predict subsequent serum concentrations in the 
same patient. 
Aminoglycoside and vancomycin use in newborns fulfill several of these prerequisites. 
Good quality serum assays for both tobramycin and vancomycin exist. The most widely 
used routine method, Fluorescence Polarization Assay, has adequate performance 
characteristics. In both drugs clinical effect as well as toxicity are difficult to determine. 
Toxicity, especially ototoxicity, can have a delayed presentation, as will be discussed later. 
As described in chapter 1, iliere are large interindividual differences in the 
pharmacokinetics of vancomycin and am.inoglycosides (including tobramycin) in 
newborns. Of the points mentioned above, two remain unclear. There is still a lot of 
uncertainty on both a good correlation between serum concentrations and effect or 
toxicity and the usefulness of TDM to predict subsequent serum concentrations in the 
same patient. These issues \\.7ill be discussed in the following paragraphs. 
TDM of aminoglycosides: correlation between serum concentrations and effect 
Since arninoglycosides have a narrow therapeutic \\I-indow, any discussion regarding the 
dosing regimens of these drugs should take into account both efficacy and toxicity. Given 
the differences between individual aminoglycosides, this implies that concentrations and 
dose recommendations discussed in the follo\ving sections are valid for gentamicin, 
tobramycin and netilmicin. Because of the pharmacokinetic and pharmacodynamic 
characteristics of amikacin values regarding this drug have to be multiplied by three. 
Efficacy of aminoglycosides is related to both peak serum concentration to minimal 
inhibitory concentration (.N.llC) ratio (Peak/WC) and area under the time versus 
concentration curve (AUC/WC) in clinical and experimental stucliesS--10. It seems that 
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peak/MIC ratio's of 5-10 are desirable for clinical efficacy. Given the sensitivity of gram-
negative organisms in our KICU, this ratio translates to desirable peak serum 
concentrations of 2: 5 mg/L for our setting. The study presented in chapter 3.1 shows 
that this goal is reached in more than 90% of patients 'iNi.th the proposed dosing regimen. 
Based on desirable ratio's and pharmacokinetic behavior of aminoglycosides in neonates, 
higher doses at longer intenrals (24h for adults, 24-48h in neonates) have been advocated 
over the last 10 years. Studies in adults as well as neonates have failed to detect an 
increase of efficacy '.Vi.th this strategy11-16. The studies in chapter 3 have sho'WTI the need 
for extending dose interval up to 4Sh for premature neonates. However, no conclusion 
on resulting efficacy can be dra•wn from our studies. 
TDM of aminoglycosides: correlation between serum concentrations and toxicity 
J\'ephrotoxicity of aminoglycosides is related to the quantity of aminoglycosides stored in 
the proxlmal tubular cell17• Since aminoglycosides show drug satu.table uptake into these 
cells, nephrotoxicity can occur when the time period of low trough concentrations is too 
short to prevent accumulation 18• Although aminoglycoside induced nephrotoxicity has 
been related to high serum trough concentrations in studies in humans, exact information 
on the relation to serum concentrations is lacking. Aminoglycoside induced 
nephrotoxicity in neonates is rare, especially if the treatment period docs not exceed 
7 days. Ko relation bet\'veen serum concentrations and glomerular filtration rate (GFR) 
distu.tbanccs has been demonstrated in newboms15, 16· 19• However, reversible tubular 
dysfunction, resulting in a decreased capacity to form concentrated urine as well as 
electrolyte loss, is seen more often20. 21. 
Mainly based on toxicity characteristics, extended intenral dosing has been advocated for 
adults and neonates. Extended intenral dosing has .implications for TDM goals. Although 
desired peak serum concentrations of circa 5 mg/L \vould still suffice, trough 
concentration goals should be lower. Aiming at a trough concentration of 2 mg/L \vould 
lead to a 2.3 times higher total exposure (AUC) 22• Trough concentration goals of 
0.5-1 mg/L seem to be more appropriate. For amikacin these goals should be multiplied 
by three. :,Y[ost studies, ho\vever, are still using trough concentration goals associated \vith 
multiple daily dosing (2 mg/L). Several clinical and meta-analysis srudies in adults have 
sho\vn nephrotoxicity to be equal or less \vith single daily dosing as compared to multiple 
daily dosing11-14• In neonates no difference in nephro- or ototoxicity bet\veen once-daily 
dosing and multiple daily dosing has been demonstrated15. 16. This suggests that 
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nephrotoxicity in newborns is either infrequent and a clifference is therefore undetected in 
the relatively small stuclies or that maturational dependent clifferences in nephrotoxicity 
exist. 
Ototoxicity of aminoglycosides in man has been related to total dose and duration of 
therapy v.i.th no clear relation to high serum concentrarions23• A causal relation bet\V"een 
ototoxicity and eA"Posure to aminoglycosides in neonates has not been proven. Most 
stuclies comparing aminoglycoside treated infants to non-treated patients clid not detect 
permanent hearing loss24-26. Routine hearing screening in infants exposed to 
aminoglycosides has failed to detect a significant relation to hearing loss27. 28. These 
stuclies clid not quantify· exposure in terms of serum concentration and/ or duration of 
therapy. In chapter 5.2 we studied 625 neonates undergoing routine neonatal hearing 
screening and could not demonstrate a relation to e.'(posure to tobramycin. :!'\either 
duration of therapy, nor high serum concentrations or simultaneous treatment v.i.th other 
ototoxic drugs was found to be a significant risk factor. Also, in patients failing A-ABR 
screening, aberrant serum concentrations were not found to be the most likely 
explanation for hearing loss. There are reports however which describe delayed-onset 
hearing loss \vi.th a possible association to prolonged (>7-10 days) exposure to 
aminoglycosides29-31. This hearing loss could be missed by routine hearing screening, 
which is often performed shortly after discontinuation of the drug. In chapter 5.1 we also 
studied possible late effects of aminoglycoside eAJ'Osure on hearing in a matched case-
control study, by examining 3-4 year old children who had been treated with tobramycin 
as neonates. Although no statistical significance was found, possibly due to the small 
sample size, the finding of three infants v.i.th moderate to severe hearing loss, all of them 
exposed to > 14 days of aminoglycoside is worrisome. ~ing exposure to tobramycin 
in terms of duration of therapy should be the aim. 
Our studies thus show that aberrant tobramycin serum concentrations do not detect 
patients at risk for hearing loss, and adherence to IDM goals does not preclude hearing 
loss. From that point of view, the fourth point mentioned above as a prerequisite to 
perform TDM, is not fulfilled. 
In summary, efficacy is related to peak concentration to ~C ratio's, but improvement of 
efficacy \Vi.th extended interval dosing has not been demonstrated. Clinically important 
nephro- an ototoxicity are rare in neonates in courses shorter than 7 days, and there is no 
clear relation to serum concentrations. The importance of routine TDM in the first \Veek 
of life for efficacy and toxicity reasons is questionable. 
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TDM of aminoglycosides: predictive performance 
Predictive performance of TDM of aminoglycosides in newborns needs careful attention. 
Routine TDM for aminoglycosides is normally performed around the third or fourth 
dose, and is based on the assumption that steady state is more or less attained. For 
several reasons this assumption is not valid in neonates in the first week of life. Antibiotic 
courses in neonates are often discontinued after a few days when blood cultures and other 
tests remain negative. Since extended interval (24-48h depending on GA) dosing of 
aminoglycosides is now general practice, steady state \vould not be reached before 
discontinuation of the drug, and TDM would therefore not be performed in rime to be of 
use. One solution to this problem is to predict initial individual dosing interval using 
population pharmacokinetic parameters v..i.th Bayesian feedback of early serum 
concentrations. In this thesis (chapter 3.2) we hypothesized that, given the large .inter~ 
individual pharmacokinetic differences within GA-groups, early TDM, directly after the 
first dose, may improve these predictions for the individual. A prerequisite is ho\vever 
that a model incorporating early TDM data is superior in predicting subsequent serum 
concentrations to a model based on the population parameters alone. Data in adults have 
sho\\rn that population estimates -wi.th Bayesian feedback of one or more serum 
concentrations can adequately predict aminoglycoside serum concentrations32• In 
neonates this is not so clear. Two studies in neonates showed that serum concentrations 
can be predicted from an early sample using a population approach with Bayesian 
feedback33, 34. ~either study looked specifically at predicting trough serum concentrations, 
which is necessary to individualize dose interval. Also, they did not compare their 
feedback model to a strategy -wi.thout TDM 33, 34• We investigated the Bayesian approach 
as well, looking solely at predicting trough serum concentrations, and found a predictive 
performance comparable to the other t\vo studies. We could not however detect an 
increase of predictive performance of this method over our original population based, 
gestational age related dose advice \Vi.thout using TDM. Patients at risk for prolonged 
exposure to aminoglycosides in our study were not detected by this method. Hence, the 
results of our study indicate that routine early therapeutic drug monitoring does not 
improve the model based prediction of initial tobramycin dosing intervals in neonates in 
the first week of life. 
In conclusion, routine early TDM of aminoglycosidcs in newborns in the first week of life 
does not seem to be very useful from the viewpoint of toxicity. Furthermore early TDM 
does not adequately predict subsequent trough serum concentrations. \Vc therefore 
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propose that routine TDM of aminoglycosides is not needed in the first 7 days of life. An 
exception should be made for patients \vi.th renal failure, patients \Vi.th obvious neonatal 
asphyxia (e.g. 5' Apgar score < 5), and patients exposed to drugs or situations which are 
known to significantly alter pharmacokinetic beha;~or (e.g. indomethacin, ECMO). 
In these difficult to manage patients use of a population model Mth feedback of repeated 
serum concentrations as well as serum creatinin might be useful in guiding therapy. 
TDM of vancomycin 
TDM of vancomycin: correlation between serum concentrations and effect 
For vancomycin the correlation bet\veen serum concentrations and efficacy or toxicity is 
not clearly defined. Several, mainly in vitro, studies have sho\VTI no relation bet\veen 
killing rates of bacteria and increasing vancomycin concentrations above the :MIC35, 36. In 
animals, outcome of endocarditis was related to vancomycm trough serum 
concentrations37• Clinical studies in neonates have shown a \Vide range of serum 
concentrations associated \vi.th resolution of infection, but causal relation was not 
studied3s, 39. i\.lthough it is not possible to draw a definite conclusion, these studies 
indicate that keeping the trough level above the we is necessary to obtain clinically good 
results. This implies minimal serum concentrations are needed of approximately 
4-5 mg/L, when considering MIC's and protein binding. These findings are not reflected 
in currently accepted TDYI goals however, where peak and trough serum concentrations 
of 20-40 mg/L and 5-10 mg/L respectively, are generally accepted. 
TDM of vancomycin: correlation between serum concentrations and toxicity 
Vancomycin can cause reversible nephrotoxicity in humans. Toxicity has been related to 
trough concentrations > 10 mg/L, but it remains unclear whether elevated serum 
concentrations are the cause or consequence of renal dysfunction. Ototoxicity has been 
described in incidental cases where patients were exposed to high peak serum 
concentrations, but a relation benveen vancomycin induced ototoxicity and serum 
concentrations can not be ascertained from available literature. Although there arc studies 
relating both nephro- and ototoxicity to vancomycin in combination with an 
aminoglycoside, there is little evidence for vancomycin alone. In neonates, data are limited 
even more and very scarce. Several hearing screening studies did not detect vancomycin 
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related ototoxicityn2B. In the study presented in chapter 5.2, we investigated the effect of 
qualitative and quantitative e.'{posure to vancomycin on hearing screening in infants. This 
was the first study to relate serum concentrations of vancomycin to hearing screening. \YJe 
could not detect ·a significant relation ·of any denominator _of vancomycin use to hearing 
loss-found-'\vith neonatal hearing screening~ 
From the above, it can be concluded that there is no clear relationship between serum 
concentrations and toxicity, and TDM for toxicity reasons is not substantiated by current 
literature or studies presented in this thesis. TDM might be warranted for efficacy and 
should focus on adequate serum trough concentrations. 
TDM of vancomycin: predictive performance 
Adequate predictive performance for TDM of vancomyc1n in neonates has been 
established. In contrast to aminoglycosides, subsequent vancomycin serum concentrations 
can be reasonably well predicted \vith use of 2 serum samples in a Bayesian feedback 
modeJ40. Additional feedback concentrations are needed approximately every 14 days40. 
In conclusion, TDM requirement criteria for vancomycin are doubtful. Neither efficacy 
nor toxicity sho\v a clear relation to serum concentrations; the relation of efficacy to 
trough serum concentrations does not seem to exist above concentrations exceeding the 
~C. Although there are substantial inter-individual differences in pharmacokinetic 
behavior they are not important in the context of pharmacokinetic-phannacodyna.m.ic 
relations. In the light of these factors routine TDM of vancomycin, \vith both peak and 
trough concentrations, is not \v"atranted for either efficacy or toxicity reasons. A case can 
be made for routine monitoring of serum trough concentrations for efficacy reasons. 
Intensified TDM should only be performed in patients in whom an alteration of 
pharmacokinetic behavior (e.g. renal failure) is likely. 
DOSING REGIMEN: HOW MUCH AND HOW OFTEN? 
Although TDM goals, as discussed above, for both vancomycin (trough > 5 mg/L) and 
aminoglycosides (peak 5-12 mg/L, trough < 1 mg/L) are disputable, they have 
implications for drug dosing in neonates. \'Yhen designing a dosing regimen, these goals 
together \Vi.th pharmacokinetic characteristics have to be taken into account. 
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Aminoglycoside dosing 
Pharmacokinetics of aminoglycoside antibiotics .in neonates, as other drugs, are 
gestational age related. Premarure neonates have a larger volume of distribution and lower 
clearance. As in adults once daily dosing has been advocated in neonates. Based on these 
considerations several dosing regimens have been suggested and tested for 
neonates15.33. 41 . 42. The dose recommendation of our study presented in chapter 3.1 
(4 mg/kg) is simihr to these studies, where dose advice ranges from 2.5-5 mg/kg for 
neonates of varying gestational ages, mostly with an interval of 24h. Some of these studies 
however vary dose to keep the dosing interval the same, which is counterproductive in 
the face of efficacy15. 42. Lower doses in these studies led to subtherapeutic peak 
concentrations in 15-47% of patients15- 33. Our studies in chapter 3 have shown that 
dosing tobramycin at 4.0 mg/kg for neonates of all GA's in the first week of life leads to 
peak serum concentrations > 5 mg/L for more than 90% of patients. The need for 
dosing intervals exceeding 24h in preterm. infants has been established, but not evaluated 
by others15,42. Results from our studies have indicated a need for extending dose illtervals 
up to 48h in neonates \Vi.th a GA< 32 weeks. Use of our GA related dose interval showed 
that in pretenns< 32 weeks, mean trough serum concentrations were still 0.52 mg/L after 
48h. Results from recent studies, including ours, clearly indicate that aminoglycoside 
doses of approximately 4 mg/kg 'N"ith a GA-related interval are warranted. There is no 
need for a loading dose "'Wi.th this regimen. 
Vancomycin dosing 
The pharmacokineti.c profile of vancomycin in neonates is mainly determined by 
postconceptional age (PCA) and renal function, although a relation to other factors like 
birthweight and gestational age (GA) is described. 
As 'With aminoglycosides, dose adv-ises in most studies so far try to adhere to traditional 
monitoring goals. Studies based on PCA and/ or serum creatinin have shov.n to achieve 
serum concentrations within that therapeutic range43-46. Dose recommendations range 
from 10-20 mg/kg with an interval of 8-36h. In contrast to others we showed in chapter 
4.1 that, if serum goals are set at trough concentrations > 5mg/L, vancomycin can be 
dosed at 10 mg/kg every Shin all neonates in the first month of life, irrespective ofPCA. 
This regimen leads to >95% of trough serum concentrations above 5 mg/L. The lack of 
association to PCA in our study is partly explained by two factors_. First, very few patients 
received vancomycin in the first week of life, the period ·where volume of distribution, 
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clearance and renal function show the largest change. Second, the majority of our 
patients (81.8 %) were antenatally exposed to corticosteroids, which has been shown to 
d.itn1nish the GA-dependent difference in renal clearance of other antibiotics47. The 
dosing advise presented in this thesis, namely 10 mg/kg every 8h for all neonates in the 
first month of life, has the practical advantage of be.ing simple. Since dosing errors are 
frequently seen in infants, this practical dosing scheme might be important in the clinical 
setting4S. 
Finally, therapy with both tobramycin and vancomycin should be seen in rehtion with 
disease and immunological status of the patient. Although extended dose intervals are 
generally desirable, diseases in which microbiological rehtion to serum concentration or 
pharmacokinetic behavior are very different (e.g. endocarditis, renal failure, eA--posure to 
indomethacin, ECMO) or in immunologically compromised patients, treatment should be 
individualized, as will be described in the following parag<aph. 
MONITORING OF EFFICACY AND TOXICITY 
:y_{onitoring efficacy of antibiotic treatment in the first week of life is difficult. Culrure 
proven early onset sepsis occurs in approximately 2% of VLBW infants, but there are 
limitations to blood cultures in neonates and single blood culrures can be false 
negative2· 49. so. Furthermore increasing prenatal treatment of mothers \Ni.th antibiotics 
obscures culrure results in newborns. In our study population culrure proven early-onset 
sepsis was approximately 3°/o, in other words, for every patient \Vi.th a positive blood 
culture, 30 others were treated as well. Early detection of neonatal sepsis remains difficult. 
Laboratory tests are unspecific and clinical signs can be ambiguous. Neonatal sepsis is 
suspected in many VLB\V-infants on clinical grounds and antibiotic treatment is 
frequently started and discontinued after 48-72h '-Vhen blood cultures and results of other 
tests remain negativel. Given the infrequent occurrence of positive blood cultures, these 
can not be used as marker for antibiotic efficacy. Laboratory data, including C-reactive 
protein, complete blood count and ratio of immature to total neutrophils hck sufficient 
sensitivity to detect neonatal sepsis, and can therefore not be used to evaluate efficacy51• 
The same counts for clinical features (e.g. respiratory rate, skin color) which can either 
not be quantified or lack a clearly defined relation betw"een predictor and outcome. 
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Monitoring efficacy in late-onset sepsis is slightly bener. l..:p to 31% of VLBW infants 
have late onset culture proven sepsis5• In our series, 30% of neonates treated "vi.th 
vancomycin had positive blood cultures. Even though this number is lllgher, it still is 
difficult to monitor efficacy this \.vay. Treatment of central line asSociated ··sepsis often 
includes--remOval of·-the~ intravascular catheter· and· it is hard· to separate the ·antibiotic· 
effect from other treatment modalities used. Again traditional clinical and laboratory 
parameters are not useful. It is dear from the point of view of efficacy that there is a need 
for a more evidence-based approach of suspected neonatal sepsis. .YI:arkers like 
interleukin-1 receptor antagonist, interleukin-6 and interleukin-8 have shovm promising 
results in the early detection of neonatal sepsis52. 53. It is clear that a reduction in 
unnecessary treatment of neonatal suspected sepsis 1s needed before the question of 
antibiotic efficacy can be addressed. 
Toxicity is another matter. As discussed in the section on TDM, monitoring serum 
concentrations alone \.Vill not prevent aminoglycoside and vancomycin associated nephro-
and ototoxicity. Since TD:y£ is not enough, the obvious way to augment monitoring 
nephrotoxicity for aminoglycosides as "\veil as vancomycin is assessing renal function. 
Both antibiotics are almost totally renally excreted and a decrease of renal function is 
directly reflected in accumulation of the drug . ..1\Jthough glomerular function in neonates 
in the first \.Veek of life can not be reliably predicted from a single serum creatinin 
concentration, repeated measurements are indicative of renal function54. In neonates at 
risk for, or witb overt renal failnre (e.g. asphyxia), clinically detectable by oliguria and/ or a 
rise of serum creatinin, administration of aminoglycosides should be seriously 
reconsidered. If no good antibiotic alternatives for aminoglycosides are available, dose 
interval should be extended on the basis of repeated serum drug monitoring. 
Results from hearing screening studies in ne\.vboms have indicated that aminoglycoside 
and/ or vancomycin ototoxicity has not been proven, especially in the face of short 
courses of treatment. The Achilles heel of this conclusion is the reports on delayed onset 
hearing loss associated with prolonged exposure to aminoglycosides, as several studies 
including ours indicate29-31. Although routine follow-up of hearing screening in infants 
treated 'Wi.th aminoglycosides and/ or vancomycin is not necessary, a case can be made for 
retesting infants exposed to more than 10-14 days of therapy of aminoglycosides. 
In conclusion, based on current literature and the findings of this thesis, we propose the 
follo"\vi.ng simplified strategy for dosing and monitoring tobramycin and vancomycin in 
neonates (Fig. 1 and 2). 
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Fig. 1: Dosing and TOM strategy fortobramycin in newborns in the first week of life 
Renal dysfunction/severe asphyxia ? 
Exposure to indomethacin ? 
ECMO? 
Other special clinical considerations ? 
Tobramycin: 
,---------'1>1 4 mg/kg 
Alternative for 
Tobramycin: 
4 mg/kg 
Other antibiotic 
therapy 
GA < 32 weeks: GA 32-37 weeks: GA ;::: 37 weeks: 
Initial interval 48h Initial interval 36h Initial interval 24h 
yes 
1 Before the next dose. 
Suspicion of renal failure ? 
Exposure to indomethacin ? 
ECMO? 
Other special considerations? 
2 Evaluate necessity of continuing tobramycin. 
3 Individualize treatment, preferably on the basis of a 
population model with serum concentrations and renal 
function as feedback. 
Perform TOM 1 with 2 serum 
samples (8h and trough 
concentration) 
Individualize treatment3 
Treatment 2: 10 days 
Perform hearing screening and arrange 
foJJow-up of hearing 
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Fzg. 2: Dosing and TDM strategy for vanco»rycin in the first month of lift 
Renal dysfunction/severe asphyxia ? 
Exposure to indomethacin? 
ECMO? 
Other special clinical considerations? 
Vancomycin: 
10 mg/kg q 8h 
PNA <?days 
Suspicion of renal failure 
Exposure to indomethacin ? 
ECMO? 
Other special considerations? 
Measure serum trough 
yes concentration at steady state 
(repeat every 14 days) 
1 Early is before the next dose. 
2 lndividualize treatment, preferably on the basis of a 
population model with serum concentrations and renal 
function as feedback. 
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yes 
yes 
yes 
Vancomycin: 
10 mg/kg 
Perform early TDM1 with 
2 serum samples {peak 
and trough) 
Individualize treatmenf 
Limitations of the studies 
Results from our studies have important implications for dosing and therapeutic drug 
monitoring of tobramycin and vancomycin in neonates. It is necessary to judge these 
results in the light of certain limitations of our studies. 
The major limitation of our studies analyzing pharmacokinetics of vancomycin and 
tobramycin is the retrospective nature. The TDM data used in our studies were taken 
from a large section of patients exposed to these drugs in everyday NICU practice. 
Results therefore depict the total spectrum of inter-individual variability encountered in 
this population. Implicitly, conclusions of these studies can be used in the same 
heterogeneous group. However, although only patients were included .in whom timing of 
drug administration as well as serum sampling was recorded, these data may not have the 
same precision as when prospectively recorded. Furthermore a general limitation to 
srudies in neonates is the acrual amount of drug given. In newborns, for aminoglycosides, 
this can be up to 20% lower than the prescribed dose, due to dilution and other processes 
involved in administrationss. This might lead to an overestimation of inter-individual 
phannacokinetic differences. Since )JQNJ\ffiM accounts for unexplained variability of 
both these issues, this is not a major drawback '"rith population modeling56. Also, it must 
be stressed that both proposed dosing regimens have been prospectively validated in the 
srudies presented in this thesis. 
In the srudy describing predictive performance of TD11:, only patients were selected in 
whom trough serum sampling was performed at the GA-related interval, to facilitate a 
comparison '.Vi.th a regimen 'W-ithout TDM. This might have led to a selection bias; 
patients not included in the analysis might have had more extreme pharmacokllietic 
parameters. We investl.:,oated this assumption by analyzing the total srudy group. Predictive 
performance in the total group was not significantly different from the srudy group. 
There are three limitations to our hearing screening study. First:, this study describes 
hearing screening in an at risk population, 'W-ith at least one risk factor for hearing loss. 
One has to be careful to translate results to the total group of newborns admitted to a 
NICU. However a hlgh percentage of all patients admitted to the NICU and C).:posed to 
either tobramycin (60%) or vancomycin (84%) were included in this study. Only one 
patient not included in this study was exposed to more than 7 days of tobramycin 
treatment. Second, click-evoked A-ABR screening detects hearing loss in the 2-4 kHz 
frequency range, \vhich is clinically important for speech and language development. 
Aminoglycoside related hearing loss starts above 8 kHz and it is thus possible that some 
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neonates .in this study had hearing loss in this high-frequency range. Because cochlear 
damage induced by aminoglycoside use is stationary over the years, the long-term clinical 
importance of this high-frequency hearing loss is doubtful. Third, delayed onset of 
hearing loss in infants has been described. In the study in chapter 5.2 a large percentage 
of patients e::...-posed to tobramycin for more than 10 days underv.rent hearing screening at 
least t\Vo weeks after cessation of therapy. It is conceivable however, that hearing 
screening was performed too early in some patients to detect hearing loss and it might be 
necessary to reassess hearing in neonates "\Vi.th prolonged e::..."Posure to aminoglycosides. 
The main limitation of our matched case-control study in 3-4 year old children exposed 
to tobramycin as neonates is the relatively small number of patients included. All patients 
whose address was traceable were approached, of \vhom approximately half responded. 
Also a few patients were not measurable due to chrocic middle ear effusion. 
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Future perspectives 
Although this thesis addresses several features of tobramycin and vancomycin use in 
neonates, further research into selected issues is needed. 
• Efficacy of aminoglycosides in neonates can not be addressed effectively as long as 
more than 95% of treated neonates have negative blood cultures. Research into 
clinical, biochemical and other markers that can adequately select patients at risk for 
invasive bacterial infections is needed. 
• For vancomycin, studies relating clinical efficacy to serum concentrations as well as 
MIC's will have to be performed. 
• Although the safety of extended interval dosing of aminoglycosides in newborns is 
comparable to that of multiple daily dosing, a clinical advantage has not been 
conclusively sho\VTI. These advantages are mainly extrapolated from adult and animal 
studies. Further prospective double blind studies in large numbers of neonates are 
needed to assess this theoretical advantage. 
• Ototoxicity related to aminoglycoside use in newborns has not been proven for short 
courses. The alarming case reportS of delayed onset hearing loss in neonates \Vith 
prolonged e.•,:posw::e to amlnoglycosides warrants further investigation. 
• Since mitochondrial point mutations are associated 'N'ith amlnoglycoside related 
ototoxicity, genetic studies in infants \Vi.th une.~plained hearing loss and exposw::e to 
amlnoglycosides \\.-ill have to be performed. 
• This thesis describes amlnoglycoside use in the first week of life. There is a lack of 
data on the change of aminoglycoside pharmacokinetics in the period between one 
week and one month. This gap will have to be filled, especially for VLB\'V' -infants, to 
determine dosing intervals in this period. 
• The role ofTDM of vancomycin and aminoglycosides, preferably in conjunction 'N'ith 
Bayesian feedback, will have to be redefined in the light of changing serum 
concentration goals. 
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SUMMARY 
Tbis thesis describes pharmacokineric and pharmacodynamic aspects of tobramycin and 
vancomycin in the neonatal intensive care unit. 
Chapter 1 provides an overvie\"~l of current knowledge on use of both antibiotics in the 
neonatal setting, and describes the aims of the stuclies. 
Chapter 1 a describes the use of the four main aminoglycosides (gentamicin, tobramycin, 
netilmicin and amikacin) in neonates. Special attention is given to the influence of 
gestational age and patient-related factors, such as e::..-posure to EC:yiO, indomethacin and 
corticosteroids. The recent shift towards longer dosing intervals of aminoglycosides .in 
adults, which has also been noted in neonates has implications for dosing and TD::YI of 
these drugs in neonates. 
Chapter 1 b sumrnar:izes the literature on use of vancomycin in the :::-.II CU. The relation 
berw-een phannacokineric behavior and PNA as well as renal function is described in 
detail. The recent discussion regarding the validity of current therapeutic range targets as 
well as necessity of routine determination of peak serum concentrations in adults are put 
in a neonatal conte:-;:t. The implications for drug dosing as \Veil as TDM in newborns are 
discussed. 
Chapter 1 c denotes the objectives of the studies presented in this thesis: 
1. E:: .. :plore the use of parametric and non parametric population modeling of tobramyc.in 
in the setting of routine therapeutic drug monitoring in a ~1CC". 
2. Determine a gestational age related e:-;:tended interval dosing of tobramycin in 
neonates. 
3. Investigate the potential of inclividualbing drug therapy by way role of early TDM of 
tobramyc.in in neonates. 
4. Determine the need for gestational age or postconceptional age related dosing of 
vancomycin in the :1:'\ICU. 
5. Evaluate the occurence of hearing loss caused by neonatal exposition to vancomycin 
and/ or tobramyc.in. 
In chapter 2 we compared t\VO population modeling methods, nonlinear mi"Xed effect 
modeling (:\JOKMEYI) and nonparametric tc'Cpectation maximization (NPE""l), using 
routinely obtained therapeutic drug monitoring data of tobramyc.in in neonates. 
KO:\IMEM and NPEM were found to be dissimilar in population estimates. The source 
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of these differences \.Vas investigated by creating models in which the error algorithm used 
by NQ)\JjY.(EM emulates that of~PEM and vice versa. \YJe determined that differences in 
range estimates of pharmacokinetic parameters bet\veen l"Q)\J1ffiM and NPEM are 
largely deter.mlned by _the method of incorpo:ra:ting·crror patterns_ in both programs. Use 
of both modeling ·techniques are ·synergistic- ·in--· adequately- ~describing population 
pharmacokinetics. 
Chapter 3 describes the development of a neonatal dosing regimen of tobramycin and 
the place of early TD~ in individualizing treatment in neonates in the first \.veek of life. 
In chapter 3.1 a tobramycin dosing schedule was established for neonates of various 
gestational ages, with use of a population pharmacokinetic method. In a study in 470 
newborns in the flrst week of life, paired peak and trough serum concentrations were 
analyzed according to a one-compartment open model using NOl":YIEYI population 
pharmacokinetic software. Using population estimates the follo\.ving dosing regimen was 
recommended: GA belo\.v 32 \.veeks: 4 mg/kg/ 48 hours, GA bet\\reen 32 and 36 \.Veeks: 
4 mg/kg/36 hours, GA above 36 weeks: 4 mg/kg/24 hours. This dosing advice was 
prospectively tested in a group of 26 patients. Measured concentrations \.Vere \.V-ithin the 
desired therapeutic range for more than 90% of patients. This study taught us that dose 
intervals in newborns in the first week of life are GA-related and should be longer than 
generally recommended. 
In chapter 3.2 we looked at the possibility of refining individual treatment as recommended 
in chapte:r 3.1 by way of linear pharmacokinetics or a population model v.--i.th Bayesian 
feedback. Tobramycin concentrations of 206 patients were used to obtain gestational age 
dependent population models 'vith NPEYr software. A second group of 41 patients with 
different sampling rimes was studied as well. Serum trough concentrations were predicted 
using linear pharmacokinetics in both groups and by using the population models with 
Bayesian feedback of one or t\.V·o serum concentrations in the second group. These 
predicted concentrations were compared to actual serum trough concentrations. The 
predictive performance of these models was compared to the GA-related model in 
chapter 3.1 "'ithout TD:YL 
None of the evaluated models yielded a significant hnprovemcnt of predictive 
performance over the model '\vithout TDM. This study sho\.ved us that early therapeutic 
drug monitoring does not hnprove the model based prediction of initial tobramycin 
dosing intervals in neonates in the first week of life. 
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In chapter 4 we performed a study on vancomycin pharmacokinetics in neonates in the 
first month of life. In the same way as in the study on robramycin, routinely sampled peak 
and trough serum concentrations in steady state of 108 newborns \Vere analyzed with 
NON11EM, according to a one-comparrment open model. The model best fitting the 
data included clearance and volume per kg and \vas independent of GA. Simulation of 
various- doslng-schemes-showed-that a dosing-schedule of-30--mg/kg/-day,-irrespective· of 
GA, in three doses \Vas optimal, and this scheme was prospectively tested in 22 patients. 
Mean trough concentrations \vere comparable to predicted trough concentrations. ~o 
peak levels higher than 40 mg/L \Vere found. The conclusion of our study \Vas that the 
proposed dosing regllnen leads to adequate vancomycin trough serum concentrations. 
There is no need for routine monitoring of peak: serum concentrations. 
Chapter 5 describes ototoxicity in relation to administration of tobramycin and/ or 
vancomycin. 
In chapter 5.1 we tested the effect of neonatal tobramycin use on hearing loss in 3-4 year 
old children. This study was a pilot case-control study \vhere neonates who had received 
tobramycin during their admission where compared to newborns who had only received 
other antibiotics. Nine KICC graduates with a high risk profile for aminoglycoside 
induced hearing loss (prolonged exposition to tobramycin and/ or high serum 
concentrations) were matched for other potential risk factors for hearing loss with nine 
control infants. Hearing \Vas evaluated by means of oto-acoustic emissions and, if 
necessary, brainstem evoked response audiometry. r\lthough there was no statistical 
difference, three of nine tobramycin treated children had moderate to severe cochlear 
hearing loss compatible \Vi.th aminoglycoside ototoxicity. These three infants were all 
exposed to tobramycin for longer than 14 day--s and there was no relation to high serum 
concentrations. All control patients had normal hearing. Our results suggest that 
tobramycin ototoxicity is related to duration of therapy rather than serum concentrations. 
Hearing screening of infants with prolonged exposure to tobramycin is warranted. 
In chapter 5.2 we investigated the effect of administration of vancomycin, tobramycin and 
furosemide on hearing in 625 neonates. This group of newborns unde:Nrent routine 
automated auditory brainstem response screening as part of neonatal follow-up on the 
basis of previously described risk factors. The relation bet\V·ecn administration of the 
aforementioned ototoxic drugs and a failure to pass hearing screening was investigated. 
)Jo statistical relation of hearing loss to e::...--position to these drugs, described in terms of 
total exposure as well as aberrant serum concentrations, was found. In individuals failing 
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to pass hearing screening, a causal relation bet\"lleen e::-..-posure to ototoxic medication and 
hearing loss could not be demonstrated. The results of our study indicated that 
aminoglycoside- and vancomycin related ototoxicity is rare. TDM of these drugs was not 
helpful in detecting newborns at risk for hearing loss. 
Chapter 6 described the results of our studies in context \.vith the literature. We discussed 
the implications of our finclings for dosing regimens and TDM of tobramycin and 
vancomycin in neonates. We provided a flow-chart for management of these t\V"o drugs in 
the ~ICU setting. Limitations of our studies were pointed out and directions for future 
research were given. 
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SAMENVATTING 
Dit proefschrift beschrijft farmacokinetische en farmacodynamische aspecten van het 
gebruik van tobramycine en vancomycine in de neonatale intensive care unit (NICU). 
Hoofdstuk 1 geeft een oveoJcht van de huidige kennis op het gebied van her gebruik van 
beide antibioti.ca in de neonatale setting en beschrijft de doelstellingen van de studies. 
Hoofdstuk I a beschrijft het gebruik van de 4 belangrijkste aminoglycosiden (gentamicine, 
tobramycine, netilrnicine en amikacine) bij pasgeborenen. Hierbij wordt speciale aandacht 
gegeven aan de invloed van Z\vange:rschapsduur en patientgerelateerde factoren zoals 
blootstelling aan extracorporele membraan m ... ygenatie, indomethacine en 
corricosterolden. De recente vexschuiving naar langere doseringsintenrallen van 
aminoglycosiden bij volwassenen, die ook bij neonaten gezien wordt, heeft itnplicaties 
voor dosering en therapeutische monitoring van deze geneesm.iddelen bij pasgeborenen. 
Hoqfdstuk 1 b vat de literatuur op het gebied van het gebruik van vancomycine bij 
pasgeborenen samen. De relatie tussen farmacokinetisch gedrag en postnatale leeftijd 
alsook nierfunctie wordt in detail beschreven. De recente discussie in de volwassen 
literatuur aangaande de validiteit van de huiclige doelen voor therapeutische vancomycine 
spiegels, alsmede de noodzaak van het routinemarig meten van pick serumconcentraties, 
\vordt besproken in de neonatale context. De gevolgen voor dosering en 
spiegelbepalingen worden bediscussieerd. 
Hoqfdstuk 1 c geeft de doelstellingen weer van de studies in dit proefschrift: 
1. Onderzoek het gebruik van parametrisch en non-parametrisch populatiemodelleren 
van tobramycine tegen de achtergrond van het routinemarig monitoren van dit 
geneesrniddel op een NICU. 
2. Bepaal een Z\Vangerschapsduur afhankelijk dose.ringsinte.nral voor tobramycine bij 
pasgeborenen. 
3. Onderzoek de mogelijkheden van het individualiseren van de neonatale behandeling 
met tobramycine door middel van vroege bepaling van geneesmiddel spiegels. 
4. Bepaal de noodzaak tot het hanteren van een Z\vangerschapsduur of 
postconceptioneel gerelateerde dosering van vancomycine bij pasgeborenen op een 
NICU. 
5. Evalueer het v66rkomen van gehoorverlies veroorzaakt door neonatale blootstelling 
aan vancomycine en/ of tobramycine. 
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In hoofdstuk 2 is met gebruik van routinemarig verkregen geneesmiddelspiegels van 
tobramycine bij neonaten een vergelijking gemaakt tussen t\vee methodes voor het 
modelleren van populaties; nonlinear mi'>:ed effect modeling ~O::':J.jyffii\1) en 
nonparametric expectation ma:ilinization (NPEM). ~O~MEM en ~PEYf bleken te 
verschillen in populatie schatti.ngen. De bron van deze verschillen werd onderzocht door 
modellen te creeren waarin NOK:MEM het fouten algoritme d3.t gebruikt \.vordt door 
KPEM simuleert en vice-versa. Wij stelden vast dat de verschillen in schatti.ngen van de 
spreiding van farmacokinetische parameters met name bepaald worden door de marrier 
\.V--a.a.top beide progranuna's fouten algorirmen inbouwen. Gebruik van beidc populatie-
modellen is synergistisch in het adequaat beschrijven van populatie farmacokinetiek. 
Hoofdstuk 3 bcschrijft de ont\Vikkeling van een neonataal doserings schema van 
tobramycine. Tevens \.vordt de plaats bepaald van het vroeg bepalen van serumspiegels bij 
neonaten in de eerste levensweek ten behoeve van individualisering van de behandeling. 
In hoofdstuk 3.1 wordt met behulp van een populatie farmacokinetisch model een 
doseringsschema vastgesteld voor neonatcn met een verschillende zwangerschapsduur. 
De gepaarde pick- en dalconcentraties van 470 neonaten in de eerste levensweek werden 
geanalyscerd met gebruikmaking van een 1-compartiments model in 1'0~1\ffiM. Met 
behulp van de populatieschatti.ngen werd het volgende doseringsschema geadviseerd: 
zv.rangerschapsduur < 32 \.veken: 4 mg/kg/ 48 uur, zwangerschapsduur tussen 32 en 36 
weken: 4 mg/kg/36 uur, zwangerschapsduur 2: 37 weken: 4 mg/kg/24 uur. Dit 
doseringsadvies werd prospectief getest in een groep van 26 patienten. Gemeten serum 
concentraries lagen binnen het ge\.venste therapeutische bereik bij meer dan 90% van de 
patiCnten. Deze studie leerde ons dat doseringsintervallen van pasgeborcnen in de eerste 
levensweek Z\vangerschapsduurafhankelijk zijn en langer dienen te zijn dan algemcen 
aangenomen. 
In hoofdstttk 3.2 hebben we gekeken naar de mogelijkheid van het verfijnen van de 
individuele bebandeling, zoals aanbevolen in hoofdstuk 3.1, door ntiddel van het gebruik 
van lineaire farmacokinetiek of een populaticmodel met Bayesiaanse terugkoppeling. De 
tobramycine concentratics van 206 patiCnten werden gebruikt ID ='JPE:y£ om 
zwangerschapsduur afuankelijke populatiemodellen te verkrijgen. Een t\veede groep van 
41 patienten met andere afname tijdstippen van serumconcentraties wcrd eveneens 
bestudeerd. De dalspiegels werden voorspeld met behulp van l.ineaire farmacokinetiek in 
beide groepen en met de populatiemodcllen met Bayesiaanse terugkoppeling van CCn of 
n.vee serumspiegels in de t\Veede grocp. Deze voorspelde concentraties werden vcrgeleken 
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met de gemeten dalconcentrati.es. De voorspellende waarde van deze modellen wcrd 
vergeleken met het mrangerschapsduur afhankelijke doseringsschema van hoofdstuk 3.1 
zonder gebruik van serum concentrati.es. Geen van de onderzochte modellen gaf een 
significante verbetering van de voorspellende waarde boven het model van hoofdstuk 3.1, 
waarbij geen gebruik \.Vordt gemaakt van serumconcentrati.es. Deze studie liet ons zien dat 
routinematig v-roege bepaling van scmmconcentraties geen toegevoegde '.V'aarde heeft 
voor het voorspellen van de initiele tobramycine doseringsinte!\rallen van pasgeborenen 
in de eerste levens\veek. 
In hoofdstuk 4 verrichtten "\Vi.j een studie naar de farmacokineri.ek van vancomycine bij 
pasgeborenen in de eerste levensmaand. Zoals bij de studie naar tobramycine, \verden 
routinematig verkregen steady-state top- en dalspiegels van 108 neonaten geanalyseerd 
met KON:y(E.:\1, volgens een CCn-compartimentsmodel. Het best passende model 
bevatte klaring en volume per kilogram en was onafhankelijk van de zwangerschapsduur. 
Simulati.e van verschillende doseringsschema's liet zien dat een dosering van 
30 mg/kg/ dag, verdeeld over 3 doses, onafhankelijk van de zwangerschapsduur, oprimaal 
was. Dit schema werd prospecti.ef onderzocht bij 22 pati.Cnten. De gerniddelde dalspiegels 
waren vergelijkbaar met de voorspelde waarden. Er weren geen piekspiegels boven de 
40 mg/L gevonden. De conclusie van onze studic was dat het voorgestclde 
doseringsschema leidt tot adequate vancomycine dalspiegels. Er is geen noodzaak tot 
routinemarig bepalen van vancomycine piekspiegels. 
Hoofdstuk 5 beschrijft ototoxiciteit in relatie tot de toediening van tobramycine en/ of 
vancomyane. 
In hoifdstttk 5.1 testten we het effect van het gebruik van tobramycine in de neonatale 
periode op het v66rkomen van gehoorverlies bij 3-4 jaar oude kinderen. Deze studie \vas 
een pilot case-control studie waarin neonaten die tobramycine hadden gekregen 
gedurende hun opname werden vergeleken met pasgeborenen die aileen andere 
antibiorica hadden gekregen. Kegen ex-neonaten met cen hoog risico profiel voor 
aminoglycoside gerelateerd gehoorverlies Oangdurige blootstelling aan tobramycine en/ of 
hoge serum spiegels) \.verden gematched met negen controle pari.Cnten voor andere 
potenti.Cle risicofactoren voor gehoorverlies. Het gehoor \Verd geevalueerd met oto-
acoustische ernissies en, zonodig, hersenstam respons audiometric. Alhoe\vel er geen 
statistisch significant verschil was, hadden 3 van de 9 kinderen die behandeld \varen met 
aminoglycosiden een matig tot emsti.g cochleair gehoorverlies, compatibel met 
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aminoglycoside ototoxiciteit. Deze drie kinderen waren allen langer dan 14 dagen 
blootgesteld aan tobramycine en er was geen relatie met serumspiegels. Aile 
controlepatienten hadden een normaal gehoor. Onze resultaten suggereren dat 
tobramycine ototoxiciteit sterker gerelateerd is aan de duur van de behandeling dan aan 
serumspiegels. Gehooronderzoek van neonaten met langdurige blootstelling aan 
tobramycine is noodzakelijk. 
In hoofdsfttk 5.2 onderzochten '\Vij het effect van toediening van vancomycine, tobramycine 
en furosemide op het gehoor bij 625 neonaten. Deze groep kinderen ondergjng 
routinematige gehoorsscreening met de geautomatiseerde auditieve hersenstam respons 
methode (A-ABR) als onderdeel van neonatal follow-up op basis van eerder beschreven 
risicofactoren. De relatie tussen toediening van de hiervoor genoemde ototoxischc 
geneesrniddelen en het "niet slagen" voor de gehoorsscreening werd onderzocht. Er werd 
geen statistische relatie gevonden met blootstelling aan deze geneesrniddelen, uitgedrukt 
in termen van totale blootstelling alsmede af\.vijkende serumspiegels. Ook kon bij 
indiv'iduele patienten geen causaal verband worden aangetoond tussen blootstelling aan 
deze ototoxische medicamenten en het "niet slagen" voor de gehoorsscreening. 
De resultaten van deze studie gaven aan dat aminoglycoside- en vancomycine gerelateerde 
gehoorsschade zeldzaam is. Routinematig bepalen van serumspiegels hielp niet bij het 
detecteren van pasgeborenen met een verhoogd risico op gehoonrerlies. 
Hoofdstuk 6 beschrijft de resultaten van onze studies in samenhang met de Jiteraruur. De 
implicaties van onze bevindlngen ten aanzien van doser:ingsschema's en routinematig 
bepalen van serumspiegels van tobramycine en vancomycine bij pasgeborenen werden 
bediscussieerd. Er \.verd een stroomdiagram gepresenteerd voor het praktisch hanteren 
van deze t\.vee geneesrniddelen in de neonatale setting. De beperkingen van onze studies 
werden beschreven en suggesties voor toekomstig onderzoek werden gedaan. 
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